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ABSTRACT
Since its discovery in 2000, an increasing body of evidence has demonstrated the importance of 
the transient receptor potential vanilloid 4 (TRPV4) ion channel in regulating two critical 
components of endothelial function, namely the control of vascular tone and permeability. 
However, our understanding of both mechanisms is incomplete. TRPV4 modulates vascular tone 
by activating endothelial nitric oxide and endothelial-derived hyperpolarization factor pathways. 
In this thesis, evidence is provided linking TRPV4 activation to the release of vasoactive 
prostaglandins. Pharmacological TRPV4 activation elicited a striking release of prostaglandins 
both in vivo, in rats and in vitro from human umbilical vein endothelial cells (HUVECs). 
Prostaglandin release in vivo in rats contributed to the noted blood pressure reducing effect 
associated with the TRPV4 activator GSK1016790A. Moreover, TRPV4-mediated prostanoid 
release in rats also appeared to counteract the lung permeability increase , assessed by lung wet 
weight, also associated with this agent. In subsequent experiments, the mechanism by which 
TRPV4 mediates increases in vascular permeability were explored in vitro, using a HUVEC 
detachment assay. The results obtained demonstrate that two selective, structurally distinct 
TRPV4 activators, GSK1016790A and GSK634775, elicit divergent endothelial detachment 
responses in vitro, whereby both increase intracellular calcium levels but only GSK1016790A 
induced detachment. Surprisingly, the mechanism of GSK1016790A-mediated detachment was 
found to be independent of intracellular calcium or cytoskeletal modulation, but was mediated in 
part by activation of PKC and disruption of the plasma membrane. These findings demonstrate 
that TRPV4 couples to prostaglandin-generating pathways in endothelial cells. The release of 
these prostanoids may play a role in modulating blood pressure and endothelial permeability, 
which may be of relevance in hypertensive states. In addition, these studies also highlight an 
intriguing differential coupling of TRPV4 channels in isolated endothelial cells in response to 
structurally distinct agonists.
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Chapter 1
Introduction
1.1 Overview of calcium signaling and TRP channels
Transient receptor potential (or TRP) channels comprise a large and diverse family of ligand- 
gated cation channels that play critical roles in regulating intracellular calcium [Ca^^ji 
homeostasis in various tissues (Clapham et al., 2001). Ca^ "^  ions are crucial intracellular 
messengers that regulate a multitude of cellular responses. These responses can be temporally 
distinct and range from transient (contraction, secretion, transcription) to longer lasting 
(proliferation, differentiation) to ultimately ‘terminal’ effects (apoptosis) (Berridge et al., 
2000). Two critical mechanisms have evolved that facilitate the elevation of intracellular 
calcium levels: the first involves release from endoplasmic reticulum stores; the second 
involves extracellular calcium influx via membrane permeable ion channels. This latter mode 
can be further subdivided, based on the mechanism of channel activation, into voltage-gated 
and non-voltage-gated (or ligand-gated) ion channels. The importance of calcium is no more 
apparent than in the vasculature, where it regulates key physiological fimctions including 
vascular tone, angiogenesis and vascular permeability. Importantly, TRP channels have been 
shown to regulate a number of these critical functions (Nilius et al., 2003; Troidl et al., 2010; 
van Nieuw Amerongen & van Hinsbergh, 2002). Consequently, aberrant TRP channel 
function may play an important role in vascular disease (Jian et al., 2008; Yin et al., 2008; 
Gao et al., 2009; Everaerts et al., 2010; Gao & Wang, 2010a; Thomeloe et al., 2012). 
Therefore, a better appreciation of the intricate roles these channels play in the vasculature 
will not only enhance our understanding of physiological and pathophysiological processes 
but potentially lead to the development of novel therapeutic agents. A brief introduction to 
TRP channels will now be provided followed by an overview of transient receptor potential 
vanilloid family member 4 (TRPV4) literature, culminating with a synopsis of the role of this 
specific channel in vascular function.
1.2 The transient receptor potential (TRP) family and Drosophila melanogaster
In 1969, Cosens and Manning were investigating the visual transduction cascade in the fruit 
fly Drosophila melanogaster, when they noticed a peculiar behavioral phenotype in a highly 
inbred mutant strain (Cosens & Manning, 1969). They noted: “We are working with a mutant 
strain of D. melanogaster which, though behaving phototactically positive in a T-maze under 
low ambient light, is visually impaired and behaves as though blind in a simple optomotor 
apparatus”. The impaired visual behavior under sustained bright light was further 
characterized phenotypically using an electroretinogram (ERG) -  a technique which 
measures the change in potential due to extracellular current flow in the eye in response to 
light; analogous to the electrocardiogram in the heart. The ERG in both wild-type and mutant 
flies displayed an initial increase in receptor potential (depolarization), which was proceeded 
by a rapid decrease in receptor potential (repolarization) in the mutant, in contrast to the slow 
repolarization observed in the wild-type. The response of the mutant flies to subsequent light 
stimulation was also abnormal. Wild-type flies displayed an ERG response regardless of the 
time-interval between light exposures, whereas mutant flies require a prolonged period (1 
minute) of dark adaptation before regaining responsiveness.
The term ‘transient receptor potential, or trp for short, was coined in 1975 to describe the 
mutant ERG response to intense light stimulation (Minke et al., 1975). Using stationary 
fluctuation analysis, Minke and colleagues demonstrated that the short-lived receptor 
potential in the trp mutant under bright light conditions was attributable to a reduction in the 
number of electrical responses to individual photons (decreased excitation efficiency) as 
opposed to a diminished amplitude of response (i.e. strong adaptation). Moreover it was also 
demonstrated that during illumination the photo-pigment levels were indistinguishable
between wild-type and trp flies, thereby eliminating this as a potential mechanism 
responsible for the trp phenotype (Minke et ah, 1975; Minke, 1982).
1.2.1 Identification of the trp gene
In 1989, 20 years after the initial discovery of the Drosophila trp mutant, came the molecular 
characterization of the trp gene (Montell & Rubin, 1989). However, two notable prior studies 
paved the way for this landmark finding. Firstly, comparative screening of Drosophila 
mRNA transcripts revealed 20 cloned sequences that were more abundantly expressed in the 
adult head than the body (Levy et ah, 1982). Of these clones, 1559 was mapped 
cytogenetically, by in situ hybridization, to the tip of the third chromosome -  the location of 
the trp gene (Cosens & Manning, 1969). Secondly, the temporal expression pattern and 
localization of 1559 revealed it to be restricted to the retinula cells (the specialized 
phototransduction cells in arthropods) of the photocapable adult (Montell et ah, 1985). 
Moreover, germline transformation of the 1559 coding region into trp mutants, completely 
rescued the trp phenotype, resulting in ERG responses that were indistinguishable between 
the mutant and wild-type flies (Montell et ah, 1985). Thus ensued the complete molecular 
characterization of the Drosophila trp gene by Montell and Rubin in their aformentioned 
1989 publication, trp mRNA consisted of a 4.1.kilobyte sequence encoding a 1275 amino 
acid protein, which hitherto showed no homology to any known proteins. Amino acid 
sequence analysis revealed that trp contained 8 putative transmembrane segments, similar to 
other known integral membrane proteins. By combining the structural analysis with the 
prevailing electrophysiological understanding of trp in phototransduction, Montell proposed 
that trp was either a membrane transporter or an ion channel that modulated calcium levels. 
Using immunoblotting it was also demonstrated that the protein encoded by trp was absent in 
the mutant, implying that the mutant phenotype arises from the absence of the protein rather
than a defective gene product. Montell’s findings were independently verified, shortly after, 
by Wong and colleagues (Wong et al., 1989).
1.2.2 Functional characterization of trp
Attempts to decipher the functional role of trp followed the sequencing of the trp gene 
product. Electrophysiological studies in the blowfly (Calliphora erythrocephala) and 
subsequently in Drosophila revealed that application of lanthanum (La^^), a non-selective 
calcium channel blocker, was able to mimic the trp phenotype (Hochstrate, 1989; Suss-Toby 
et al., 1991). These studies strongly suggested that TRP provided a means for calcium to enter 
photoreceptor cells from the extracellular space, analogous to known ion channels. 
Compelling evidence that trp encoded a light-sensitive Ca^^-permeable channel resulted 
following the development of whole cell patch-clamping from dissociated Drosophila 
photoreceptors (Hardie, 1991). Using this technology, Hardie and Minke demonstrated that 
light-induced calcium permeability was profoundly reduced (> 10-fold) in the trp mutant. 
The effect was recapitulated in wild-type photoreceptors pharmacologically with La^^ 
(Hochstrate, 1989; Suss-Toby et al., 1991). Importantly, the whole cell recordings revealed 
that the wild-type ERG response in Drosophila was derived from a combination of at least 
two light-sensitive calcium channels: a major calcium permeable channel -  encoded by trp, 
and a second, unknown, less calcium permeable channel responsible for the residual ERG 
response in trp mutants (Hardie & Minke, 1992).
1.2.3 Identification of trp homologues in Drosophila
In a screen to identify calmodulin binding proteins in Drosophila, a 1124-amino acid protein 
was identified (Phillips et al., 1992). The amino acid sequence showed greatest homology 
(40%) with TRP, resulting in the gene being designated Transient Receptor Potential-Like
(TRP-like or TRPL). Importantly, comparison of both TRP and TRPL sequences 
demonstrated a high degree of similarity with known Ca^^ channels, which led the authors to 
propose that the products of trp and trpl were likely to encode individual subunits of a Ca^  ^
channel; the functional channel being derived from four monomeric units, thus producing a 
tetrameric structure analogous to other Ca^^ channels (Tanabe et al., 1987; Hui et al., 1991). 
The absence of basic amino acid residues at key locations along the amino acid sequence 
suggested that TRP and TRPL were not gated by membrane potential, and likely belonged to 
a class of non-voltage-gated ion channels (Phillips et al., 1992). The advent of null trpl 
mutants facilitated the exploration of their role in Drosophila phototransduction. 
Surprisingly, whole-cell currents in trpl knockout photoreceptors were indistinguishable from 
wild-type controls (Niemeyer et al., 1996). However, the trp'Jrpl double knockout resulted in 
a complete loss of conductance, rendering the flies completely blind. The lack of a phenotype 
in trpl mutants was believed to be due to the presence of functional TRP channels - the major 
light-activated conductance channel (Hardie & Minke, 1992) - masking its requirement. This 
and subsequent studies demonstrated that Drosophila phototransduction required the 
activation of two Ca^  ^channels, TRP and TRPL (Niemeyer et al., 1996; Reuss et al., 1997; 
Scott et al., 1997). Moreover, the functional characterization of TRPL finally explained the 
reason for the partial ERG response in the trp mutant (Cosens & Manning, 1969; Minke et 
al., 1975).
1.2.4 Drosophila phototransduction
The studies detailed above, in conjunction with other mechanistic studies, contributed 
significantly to the current working model of Drosophila phototransduction. In this pathway, 
light activates rhodopsin, leading to the activation of a heterotrimeric G protein (dGq). This 
in turn activates phospholipase C which catalyses the hydrolysis of phosphatidylinositol 4,5-
bisphosphate (PIP2) into the soluble inositol-1,4,5-trisphosphate (InsPs) and the membrane 
bound diacylglycerol (DAG). InsPg binds InsPg receptors on the endoplasmic reticulum 
resulting in a rapid release of stored Ca^ .^ Depletion of intracellular Ca^  ^stores results in the 
opening of plasma membrane TRP and TRPL channels. This pathway commonly referred to 
as ^store-operated Ca^  ^entry (SOCE), sustains intracellular Ca^  ^levels, thereby maintaining 
the depolarizing membrane potential (for review see Minke & Cook, 2002).
1.2.5 The discovery of mammalian TRPs
The discovery that Drosophila TRPs functioned as SOCE channels led to the search for 
mammalian homologues. Polymerase chain reaction (PCR) cloning, using TRP fragments 
from the conserved transmembrane region of Drosophila trp, revealed homologous sequences 
in mouse brain and Xenopus oocytes (Petersen et al., 1995). Subsequent studies, using full 
length trp cDNA, identified homologous human sequences (Wes et al., 1995; Zhu et al., 
1995). Human trp homologues displayed 40% overall sequence identity with the Drosophila 
proteins and were originally designated human trp-1 or Htrp-1 (Zhu et al., 1995), and 
transient receptor potential channel-related protein 1 or TRPCl (Wes et al., 1995). Following 
the adoption of the unified TRP nomenclature, TRP-Canonical or TRPC, became the 
preferred designation (Montell et al., 2002). The remaining TRPCs, TRPC2-7, were 
subsequently identified using bioinformatic approaches (reviewed in Harteneck et al., 2000).
The identification of mammalian TRP homologues heralded an explosion of research, leading 
to the discovery of 28 cation channels. Based on amino acid homologies, the mammalian 
TRP channel superfamily can be divided into 6 families; TRPC (‘Canonical’), TRPV 
(‘Vanilloid’), TRPM (‘Melastatin’), TRPA (‘Ankyrin’), TRPP (‘Polycystin’) and TRPML 
(‘Mucolipin’) (Wu et al., 2010). A seventh family, designated TRPN (‘no mechanoreceptor
potential C’, or ‘NOMPC’), has been characterized in Caenorhabditis elegans. Drosophila 
and zebrafish but not in mammals (Sidi et al., 2003).
1.3 TRP Vanilloid channels
1.3.1 Vanilloid overview
The TRPV family is named after its founding member, Vanilloid Receptor 1 (VRl, now 
TRPVl, Montell & Birnbaumer, 2002). TRPVl was identified in an expression cloning study 
using mRNA from rodent sensory neurons; the primary aim of this study was to decipher the 
molecule target of the vanilloid-containing compound capsaicin (the molecular entity that 
gives hot chili peppers their pungency) in order to enhance the understanding of its role in 
nociceptive pathways (Caterina et al., 1997). In addition to gating by vanilloid-containing 
compounds, this study also revealed that TRPVl was activated by heat (>43°C) and 
sensitized, to ligand stimulation, by protons. Subsequent investigations -  also using 
expression cloning strategies -  identified two additional TRPVl homologues. These 
channels, designated Epithelial Calcium Channel (ECaC, now TRPV5) and Calcium 
Transport protein (CaTl, now TRPV6) were found to be responsible for mediating calcium 
reabsorption in the kidney and the intestine, respectively (Hoenderop, 1999; Peng, 1999). The 
remaining members of the vanilloid subfamily (TRPV2-4) were identified using 
bioinformatics searches designed to identify TRPVl homologues (Caterina et al., 1999; 
Delany et al., 2001; Liedtke et al., 2000; Peier et al., 2002; Strotmann et al., 2000; 
Wissenbach et al., 2000).
The six members of the mammalian TRPV family can be divided into two groups, based on 
sequence homology and functional similarity (Nilius et al., 2004). TRPVl, 2, 3 and 4, 
constitute Group 1 and TRPV5 and 6 constitute Group 2. Group 1 members are non-selective
cation channels with modest calcium permeability ratios {PcJPm between 1 and 10); 
whereas, Group 2 members are the most calcium selective {PcJP^a > 100) TRP channels in 
existence (Pedersen et al., 2005). Like TRPVl, all other Group 1 vanilloid subfamily 
members display temperature-dependent activation; however, each channel has a different 
thermal threshold for activation: TRPV2 (>52‘^ C); TRPV3 (>33 °C); TRPV4 (>25‘’C) 
(Caterina et al., 1999; Güler et al., 2002; Peier et al., 2002; Watanabe et al., 2002). Neither 
TRPV5 or TRPV6 are activated by heat (Nilius et al., 2004).
In addition to temperature, the TRPV subfamily is gated by a variety of diverse stimuli. 
TRPVl is activated by allicin and piperine, compounds derived from garlic and black pepper, 
respectively (Macpherson et al., 2005; McNamara et al., 2005). TRPV2 is activated by 
insulin-like growth factor 1 (Kanzaki et al., 1999). TRPV3 is activated by thymol and 
camphor, compounds derived from thyme and the bark of the evergreen tree camphor laurel, 
respectively (Moqrich et al., 2005; Xu et al., 2006). TRPV4 is activated by 
bisandrographolide, an extract from the Chinese herbal plant Andrographis paniculata (Smith 
et al., 2006) and dimethylallyl pyrophosphate, an intermediate on the mevalonic acid 
generation pathway (Bang et al. 2012). Interestingly, only TRPVl, in the vanilloid subfamily, 
is activated in response to vanilloid-containing compounds.
Non-mammalian orthologs of TRPV channels exist in both Drosophila melanogaster 
{Nanchung) and the nematode worm Caenorhabditis elegans (Osmotic avoidance abnormal 
family member 9, OSM-9) highlighting a conservation of these channels throughout 
evolution (Colbert et al., 1997; Kim et al., 2003).
1.4. Discovery of TRPV4
TRPV4 was identified in late 2000 by four independent groups attempting to identify 
homologues of TRPVl, TRPV2 and the C elegans isoform OSM-9 using expressed sequence 
tag database searches (Liedtke et al., 2000; Strotmann et al., 2000; Wissenbach et al., 2000; 
Delany et al., 2001). Each group identified a novel TRP isoform that was abundantly 
expressed in the kidney (in addition to a variety of other tissues) and was activated in 
response to changes in osmolality, specifically hypoosmotic stimulation (Liedtke et al., 2000; 
Strotmann et al., 2000; Wissenbach et al., 2000; Delany et al., 2001). Although, this channel 
is now designated TRPV4, it was known by a variety of alternative names following its 
discovery including: Osm-9-like TRP channel 4 (OTRPC4, Strotmann et al., 2000), vanilloid 
receptor-related osmotically activated channel (VR-OAC, Liedtke et al., 2000), TRP 12 
(Wissenbach et al., 2000) and vanilloid receptor-like channel 2 (VRL-2, Delany et al., 2001). 
Further details pertaining to the structure, function and physiological role of TRPV4 will be 
discussed in the subsequent sections.
1.5 TRPV4 structure
The human TRPV4 gene is located on chromosome 12q23-q24.1 and consists of 16 exons 
(NCBI Reference sequence: NM 021625.4). Five splice variants have been reported (Arniges 
et al., 2006). The full length form is designated TRPV4-A. The alternatively spliced variants 
include: TRPV4-B, which lacks exon 7 (A384-444 aa); TRPV4-C, which lacks exon 5 (A237- 
284 aa); TRPV4-D which contains a short deletion within exon 2 (A27-61 aa); and TRPV4-E, 
which lacks exons 5 and 7 (A237-284 and A384-444 aa). Of the splice variants, TRPV4-A 
and TRPV4-D are correctly processed by the endoplasmic reticulum and subsequently 
inserted into the plasma membrane where they form functional channels. The other variants
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are retained in the endoplasmie retieulum, thus highlighting the importanee of the N-terminus 
for ehannel assembly and traffieking (Amiges et ah, 2006).
The full length TRPV4 protein eonsists of 871 amino aeids (NCBI Referenee sequence: 
NP_067638.3) and contains six transmembrane segments with cytoplasmic N- and C-termini 
that are comprised of multiple domains (Figure 1.1). The N-terminal region contains six 
ankyrin (ANK) repeats that are specifically located between amino aeids 132-383. Each ANK 
motif eonsists of 33 amino acid residues which form two antiparallel a-heliees followed by a 
long (3-hairpin or “finger” loop projecting outward from the helices at a 90° angle (Landouré 
et ah, 2010). The ANK-repeat domains mediate a number of protein-protein interactions and 
also facilitate the multimerization of the TRPV4 channel (Amiges et ah, 2006). A proline- 
rieh domain (PRD), which is absent in other TRPV family members, is located downstream 
of the first ANK-repeat (D’hoedt et ah, 2008; Everaerts et ah, 2010). The PRD is involved in 
the transduction of mechanical stimuli (D’hoedt et ah, 2008).
The six transmembrane domains (designated S1-S6), which are the most highly conserved 
structures amongst all TRP channels, are located between amino acids 469-717. Each 
transmembrane segment consists of 19-25 amino acid residues connected to the next by 
alternating intracellular and extracellular loops of varying length (Plant & Strotmann, 2007). 
Like many TRP channels a putative cation-permeating pore is found within the intracellular 
loop between transmembrane regions S5 and S6 (Everaerts et ah, 2010). The S3-S4 domains 
regulate channel activity by forming a putative ligand binding domain (Vriens et ah, 2007). 
In contrast to the voltage-gated potassium channels, which also assume a six transmembrane 
topology, TRPV4 displays a paucity of positively charged arginines in the S4 domain, 
indicative of weak voltage sensitivity (Clapham, 2003). It is postulated that the cytoplasmic
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end of the S6 transmembrane region forms a gating structure that modulates cation entry into 
the channel (Owsianik et al., 2006).
WtSÉ
Extracellular
um
In tracellu lar
A1MK6
ANK5
ANK4
7 ^"" "t-^ ANKS
CaM dom ain
COOH
AÎMK2 
S^A N K l
Figure 1.1: Schematic representation of TRPV4 monomer structure. The TRPV4 protein is 
composed of a long intracellular N-terminal region, which contains a proline rich domain (PRD) and 
6 ankyrin repeats designated ANK1-ANK6. The transmembrane domains are designated S I-86. The 
pore region is located between the 5* and 6* transmembrane domains. The C-terminal region contains 
a TRP-box (TRP, red box) immediately upstream of the 6* transmembrane region, a calmodulin 
binding domain (CaM, green box) and a PDZ-like binding motif (PDZ, purple box). Locations of 
structural components are approximate.
The C-terminal region of TRPV4 consists of 154 amino acids and is located between amino 
acids 718 and 871. Like the N-terminal, the C-terminal also contains a variety of domains. 
Immediately upstream of the 6^ ’^ transmembrane segment (S6) lies a block of -25
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hydrophobic residues that forms the TRP-domain. The TRP-domain was postulated to be a 
signature sequence amongst mammalian TRP families (TRPC, TRPV, TRPM); however, its 
absence in the TRPP, TRPML, TRPA and TRPN subfamilies has meant that this view has 
recently been revised (Owsianik et al., 2006). The TRP-domain encompasses a 6-amino acid 
sequence -  called the TRP-box -  that is highly conserved in TRPC channels (EWKFAR 
motif) yet has a much lower conservation in the TRPV and TRPM subfamilies (TRPV4: 
IWKLQW). The functional role of the TRP-domain remains uncertain, although it has been 
demonstrated to play a role in the tetramerization of the TRPVl ehannel (Gareia-Sanz et al., 
2004); a comparable function may be played by this structure in the TRPV4 channel. 
Upstream of the TRP-domain, between amino aeids 812 and 831, lies a calmodulin (CaM) 
binding site. Calmodulin -  a calcium binding protein -  is an important regulator of various 
types of ion ehannel; with respect to TRPV4, the CaM-binding domain appears to potentiate 
channel activity in response to various stimuli, in a calcium dependent manner (Strotmann, 
Schultz, & Plant, 2003; Strotmann et al., 2010). The last four amino aeids of the C-terminus 
(DAPL) comprise the PDZ-binding motif (PDZ is an acronym combining the first letters of 
the three proteins in which this motif was first described: post-synaptie density protein, disc- 
large tumor suppressor and zonula oceludens-1 (Ranganathan & Ross, 1997). Mutational 
analysis revealed that deletion of the PDZ-binding domain (TRP V4-AD APE) did not affect 
ehannel activity (Garcia-Elias et al., 2008). As such, the fimctional significance of this 
domain is unclear. However, PDZ-containing scaffolds are known to permit the assembly of 
proteins into large molecular complexes, suggesting that this domain may be important in 
tetramerization of the TRPV4 channel (Owsianik et al., 2006).
The functional TRPV4 channel consists of four monomeric subunits that complex to form a 
tetramer -  each subunit contributes to a shared selectivity filter and ion-eonducting pore.
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similar to that seen in many channels (Lepage & Boulay, 2007). It was assumed for many 
years that TRPV4 was homomultimerie i.e. comprised of four TRPV4 monomeric units 
(Plant & Strotmann, 2007). However, a recent set of reports has contested this dogma by 
demonstrating that TRPV4 can eo-assemble with other TRP family members including 
TRPP2 (Kottgen et al., 2008) and TRPCl (Ma et al., 2010a; 2010b; Ma et al., 2011) to form 
functional heterotetramers. Although heterotetramers have been shown to exist within the 
TRP superfamily previously, they mainly occurred within the same subfamilies e.g. TRPCl 
and TRPC4 and/or TRPC5 heterotetramers (for review see Wu et al., 2010). Of the three 
known exceptions (i.e. TRP subfamily cross-multimerization) two involve TRPV4 
heterotetramers (Bai et al., 2008; Kottgen et al., 2008; Ma et al., 2010a) the other involves 
TRPP2 and TRPCl (Kobori et al., 2009). The physiological function of TRPV4 
heterotetramers remains to be established; although TRPV4-TRPC1 heterotetramers were 
found to permit calcium influx in response to ligand application in native endothelial cells, 
suggesting a potential role in vascular function (Ma et al., 2010a; 2010b). The extent of 
subfamily heteromultimerisation still remains to be determined, however, the existence of 
heterotetramers vastly increases the complexity and functional diversity not only of the 
TRPV subfamily, but of the TRP superfamily as a whole.
1.6 TRPV4 Expression and function
TRPV4 displays an extensive tissue expression pattern in the adult, which may indicate a 
potentially broad physiological role of this channel within the body.
1.6.1 TRPV4 in development
In postnatal life, TRPV4 is expressed in a wide variety of cells and tissues derived from the
three embryonic germ layers (endoderm, mesoderm and ectoderm); however, the precise
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pattern of expression and role of TRPV4 during embryogenesis and subsequent stages of 
mammalian development is not elear. It is noteworthy that TRPV4 deficient miee are viable, 
therefore suggesting that TRPV4 is not indispensable for development (Liedtke & Friedman, 
2003; Mizuno et al., 2003). Studies in the zebrafish have demonstrated that TRPV4 is 
expressed in 4-eell embryos and subsequently in developing organs ineluding the brain, heart 
(endocardium restricted) and kidney (distal nephron) -  suggesting that TRPV4 may be an 
important player in the organogenesis of the central nervous system (CNS) and cardiorenal 
systems (Mangos et al., 2007). Consistent with these findings, TRPV4 is also abundantly 
expressed in various regions of the post-natal mammalian brain as well as the vascular and 
renal systems (Plant & Strotmann, 2007), in addition to a number of other tissues and organs 
that will be discussed in more depth below.
1.6.2 Cardiovascular system
1.6.2.1 Vascular system
TRPV4 is abundantly expressed in both endothelial cells and vascular smooth muscle cells 
where it has been demonstrated to modulate vascular tone and permeability (for a set of 
excellent reviews see: Cioffi et al. 2009; Earley 2011; Filosa et al. 2013; Zhang & Gutterman, 
2011). A more in-depth overview of the role of TRPV4 in the vascular system is provided 
below (see 1.10.1).
1.6.2.2 Heart
Although TRPV4 mRNA is expressed in whole heart specimens (Strotmann et al., 2000) 
there is little evidence to suggest that it is expressed in eardiomyoeytes. Indeed, Willette et al, 
demonstrated that TRPV4 immunoreaetivity was undetectable in any extravaseular structures 
in the heart (Willette et al., 2008). Recent studies have demonstrated that cardiac fibroblasts
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cultured ex vivo express functional TRPV4 channels (Hatano et ah, 2009; Adapala et ah, 
2013); however, the absence of TRPV4 expression in these cells in vivo may suggest the 
expression in isolated cells is an artifact of tissue culture.
1.6.3 Respiratory system
TRPV4 was discovered as a channel that was highly expressed in whole lung samples 
(Liedtke et ah, 2000). Further analysis demonstrated that TRPV4 was predominantly 
localized to epithelial and endothelial cells throughout the airways (Willette et ah, 2008). 
Within the bronchial epithelium TRPV4 seems to be important for regulation of the ciliary 
beating frequency and mucociliary transport (Lorenzo et ah, 2008). Within the endothelium 
TRPV4 is abundantly expressed on micro vascular endothelium and, to a lesser extent, in the 
extra-alveolar endothelium (Alvarez et ah, 2006). Accumulating evidence suggests an 
important functional role for (alveolar) endothelial TRPV4 in regulating permeability 
responses; however, TRPV4 expressed on alveolar type I epithelial cells and alveolar 
macrophages has also been implicated in this permeability response (Hamanaka et ah, 2007; 
Alvarez et ah, 2006; Hamanaka et ah, 2010; Femandez-Femandez et ah, 2008). Finally, 
TRPV4 is also expressed on bronchial smooth muscle cells -  possibly regulating airway tone 
in response to osmotic stimuli (Jia et ah, 2004).
1.6.4 Urogenital system
1.6.4.1 Kidney
Reports describing the discovery of TRPV4 highlighted it to be abundantly expressed in the 
epithelia of the mammalian kidney, specifically in cells comprising the distal tubule (Delany 
et ah, 2001; Liedtke et ah, 2000; Strotmann et ah, 2000). Subsequent studies pinpointed more 
precisely the anatomical location of TRPV4 to nephron segments that are constitutively (i.e..
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ascending thin limb, thiek ascending limb, and distal eonvoluted tubule) or eonditionally (i.e., 
collecting duct) water impermeant. In all positive segments, TRPV4 expression is 
concentrated at the basolateral membrane (Tian et al., 2004). The water-permeant regions of 
the kidney including cells of the maeula densa, the glomeruli, the proximal tubule and the 
descending thin limb do not express TRPV4 (Tian et al., 2004; Willette et al., 2008).
1.6.4.2 Bladder
Downstream of the kidney, TRPV4 is expressed in a variety of structures including the renal 
pelvis, ureter, urinary bladder and the urethra (Birder et al., 2007). Within the bladder, 
TRPV4 is highly expressed in the urothelium, with a comparatively lower (20-fold) 
abundance in the underlying smooth muscle layer (Birder et al., 2007; Thomeloe et al., 
2008). A recent study has confirmed the existence of TRPV4 in human urothelial tissue, 
where it has been localized more specifically to adherence junctions (Janssen et al., 2011). 
Activation of urothelial TRPV4 mediates the release of adenosine triphosphate (ATP; Birder 
et al., 2007; Gevaert et al., 2007; Mochizuki et al., 2009; Thomeloe et al., 2008) and 
prostaglandin E2 (PGE2; Xu et al., 2009) which are postulated to activate their respective 
receptors on afferent neurons thus mediating bladder contraction.
1.6.4.3 Reproductive system
TRPV4 is expressed in the gonadal tissue of both the male (testis) and female (oviduct) 
reproductive organs (Liedtke et al., 2000; Strotmann et al., 2000; Teilmann et al., 2005). 
Within the female reproductive system, TRPV4 localizes to a sub-population of motile cilia 
on the epithelial cells of the ampulla and isthmus within the oviducts. Here it is postulated to 
play a role in oocyte transport following ovulation (Teilmann et al., 2005). The physiological 
role of TRPV4 in the male reproductive system remains elusive.
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1.6.5 Immune system
In circulating human leukocytes TRPV4 mRNA -  along with the transcripts for other Group 
1 vanilloid family members, TRPV 1-3 -  is detectable by quantitative Real Time PCR (qRT- 
PCR). The rank order of mRNA abundance appears to be TRPV2 »  TRPVl > TRPV4 > 
TRPV3; however, the precise cell population harboring TRPV4 is unknown (Spinsanti et ah, 
2008). Based on reports demonstrating a functional role for TRPV4 in tissue-resident 
macrophage populations it is possible that circulating monocytes might harbor TRPV4 
mRNA (Alvarez et al., 2006; Masuyama et al., 2008; Hamanaka et al., 2010). Related to this, 
TRPV4 is also expressed on granulocytes within the kidney (Delany et al., 2001). These 
findings therefore highlight that TRPV4 is expressed on a variety of hematopoietic cells of 
myeloid origin. Interestingly, no reports have demonstrated TRPV4 expression in 
lymphocytes, suggesting that TRPV4 may not play a role in adaptive immune responses. The 
precise physiological role of TRPV4 on immune cells requires further investigation. 
Preliminary studies in macrophages suggest that TRPV4 may regulate: 1) osteoclast 
differentiation, which influences bone density (discussed below); and 2 ) blood vessel 
permeability in the lung, as discussed above (Masuyama et al., 2008; Hamanaka et al., 2010).
1.6.6 Digestive system
TRPV4 is expressed along the entire length of the gastrointestinal tract, from the salivary 
glands in the mouth to sensory neurons in the colon (Plant & Strotmann 2007; Cenac et al., 
2008; Delany et al., 2001). The role of TRPV4 in the upper gastrointestinal tract remains 
largely undetermined; however, it has been reported to form a nociceptive sensor in the oral 
mucosa (Nakatsuka & Iwai, 2009). In the lower gastrointestinal tract TRPV4 is primarily 
expressed in the ileal and colonic tissue epithelia, dorsal root ganglia neurons, and fine nerve 
fibers associated with blood vessels in the submucosa and serosa, yet it is absent in the
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circular and longitudinal smooth muscle cells (Brierley et al., 2008; Cenae et al., 2008; 
Willette et al., 2008; D’Aldebert et al., 2011). In addition, TRPV4 is also found in the 
hepatobiliary tract in ciliated eholangiocytes, where is it has been demonstrated to serve a 
mechano- and osmosensory role (Gradilone et al., 2007; Gradilone et al., 2010).
1.6.7 Skeletomuscular system
TRPV4 is expressed in three of the major cell types within skeletal bone, i.e. osteoblasts, 
osteoclasts and chondrocytes, as well as in the cells of the epiphyseal plate that mediate bone 
development (Muramatsu et al., 2007; Masuyama et al., 2008). In vitro studies demonstrate 
an important role for TRPV4 in regulating chondrogenesis via a mechanism involving 
calcium-dependent activation of S0X9 (sex determining region Y-box 9, Muramatsu et al., 
2007). Moreover, TRPV4 activation has also been demonstrated to play an important role in 
maintaining articular cartilage integrity, according to a recent report involving a naturally 
occurring human TRPV4 mutant (see section 1.8 and Lamandé et al., 2011).
Osteoclasts represent the resident macrophage population in bone. Functionally, TRPV4 
activation in these cells sustains intracellular calcium levels which permits the terminal 
differentiation of osteoclasts via a nuclear factor of activated T-eells, cytoplasmic, 
calcineurin-dependent 1 (NFATcl)-dependent mechanism. Interestingly, this cellular 
mechanism correlates with an increased bone density in the TRPV4 null mice (Masuyama et 
a l, 2008).
Finally, recent evidence also demonstrates that TRPV4 is expressed in skeletal muscle where 
it regulates calcium homeostasis and is implicated in regulating muscle fatigue (Ho et a l, 
2012; Krüger et a l, 2008; Pritsehow et al, 2011).
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1.6.8 Skin
Within the dermal and epidermal layers of the skin, TRPV4 is expressed on keratinoeytes, 
sweat glands, and sensory nerve terminals, where it has been demonstrated to play important 
structural and sensory roles (Chung et ah, 2003; Delany et ah, 2001; Sokabe et ah, 2010; 
Suzuki et al., 2003). TRPV4 expressed on both sensory neurons and keratinoeytes mediates 
warmth perception as well as cutaneous thermoregulation (Chung et al., 2003; Chung et al., 
2004); whereas, its expression on dorsal root ganglionic nerves (innervating the skin) has 
been implicated in pressure sensation (Suzuki et al., 2003c).
More recently, TRPV4 has been found to regulate skin barrier function by enhancing cell-cell 
junction development and formation of the tight barrier between skin keratinoeytes (Kida et 
al., 2012; Sokabe et al., 2010). Consistent with these finding TRPV4-defieient miee display 
an impaired skin barrier function (Sokabe et al., 2010). These studies highlight that TRPV4 
may play a role in preventing excessive water loss through the skin.
1.6.9 Sensory systems
In the inner ear, TRPV4 is expressed in a variety of structures within the cochlea including: 
the inner and outer hair cells of the organ of Corti; hair cells in the eristae of the semicircular 
canals and in the utricular macula; the large cell bodies of the auditory ganglion; the marginal 
cells of the stria vascularis and the epithelial cells of the endolymphatic sac (Liedtke et al., 
2000; Shen et al., 2006; Takumida et al., 2005). It is postulated that TRPV4 may engage 
osmosensory and mechanosensory pathways within the cochlea that facilitates both hearing 
and fluid homeostasis in the inner ear (Takumida et al., 2005; Shen et al., 2006).
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TRPV4 is also expressed in structures both on the surface of the eye and within the eye itself, 
including the cornea (epithelial and endothelial cells), retina (ganglionic cells, Müller glia), 
and the epithelia of the conjunctiva and the lens (Mergler et ah, 201 la; Mergler et ah, 201 lb; 
Mergler et ah, 2012; Pan et ah, 2008; Ryskamp et ah, 2011; Shahidullah et ah, 2012). 
Comeal epithelial TRPV4 is thought to play a sensory role in protecting the eye surface from 
mechano- and thermo-insults (Mergler et ah, 201 la; Pan et ah, 2008). Similarly, activation of 
lens epithelial TRPV4 may enable these cells to sense and respond to hyposmotie stress 
(Shahidullah et ah, 2012). In retinal cells, TRPV4 activation by membrane stretch facilitates 
calcium-induced excitation. However, excessive calcium influx through TRPV4 can mediate 
neuronal apoptosis, which is hypothesized to play a role in pathological conditions arising 
from elevated intraocular pressure (Ryskamp et ah, 2011). The role of TRPV4 in both comeal 
endothelial cells and conjunctival epithelial remains to be established (Mergler et ah, 2011b; 
Mergler et ah, 2012).
1.6.10 Neural tissue
TRPV4 is expressed in a variety of brain regions including the eireumventricular organs, the 
vascular organ of the lamina terminalis and subfornical organ, in the median preoptie area, 
the hippocampus, dopaminergic neurons in the nigra and in ependymal cells of the choroid 
plexus (in the lateral ventricles) (Delany et ah, 2001; Guatteo et ah, 2005; Liedtke et ah, 
2000; Strotmann et ah, 2000; Wissenbach et ah, 2000). In the cortex TRPV4 is localized to 
glial cells (astrocytes) where it is postulated to mediate communication between astrocytes 
and neurons (Benfenati et ah, 2007). More peripherally, TRPV4 is expressed in autonomic 
ganglia, in parasympathetic and sympathetic nerve endings as well as in dorsal root and 
trigeminal ganglia neurons (Grant et ah, 2007). Within these brain regions and peripheral
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neurons, TRPV4 predominantly facilitates the perception of sensory input including osmo-, 
thermo- and mechano-stimuli as well as nociception.
1.7 TRPV4 knockout phenotypes
The physiological function of TRPV4 has been greatly aided by studies conducted in mice 
where the TRPV4 gene has been deleted. This section will focus on phenotypes identified 
from in vivo studies, whilst limiting the mention of reports where TRPV4 knockout mice 
{trpv4'^') have been used as a means to isolate primary cells for mechanistic studies in lieu of 
using a pharmacological inhibitor.
Miee lacking TRPV4 are viable and display normal physical attributes including appearance, 
growth and overall size. Moreover, these mice are fertile and devoid of behavioral 
abnormalities (Liedtke & Friedman, 2003; Mizuno et al., 2003). Consequently, the 
phenotypic manifestations of TRPV4 deletion tend to be subtle and generally require the 
animal to be ‘challenged’ before they become evident.
Given TRPV4’s discovery as a channel gated by hypotonicity and its expression in both the 
kidney and the eireumventricular area of the brain -  a region that plays an important role in 
sensing systemic osmolality -  initial reports utilizing trpv4'^' mice explored its role in 
osmoregulation (Liedtke et al., 2000; Liedtke & Friedman, 2003; Mizuno et al., 2003). Under 
basal conditions trpv4'^' mice consumed less water and exhibited increased blood osmolality, 
compared to wild type littermates. Following hyperosmotic challenge trpv4'^' miee showed 
impaired serum osmotic counter-regulation (i.e. serum hypertonieity is sustained) and 
secreted less antidiuretic hormone (ADH). In response to hypoosmotic challenge trpv4'^' mice 
became hypotonic, whereas wild-type littermates remained normotonie. Interestingly, and
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somewhat eounter-intuitively, hypotonieally ehallenged trpv4'^' mice consumed more water 
than wild type counterparts (Liedtke & Friedman, 2003). Contrary to these findings, a 
separate study found basal serum osmolarity and water consumption were similar between 
genotypes; however, hypertonic challenge resulted in an augmented ADH release in trpv4'^' 
miee, compared to wild-type littermates (Mizuno et al., 2003). This latter finding is curious as 
it suggests that TRPV4 negatively regulates ADH release when activated by hypertonic 
stimuli which is at odds with the hypotonic gating of TRPV4 as described by others (Liedtke 
et al., 2000; Strotmann et al., 2000; Wissenbach et al., 2000; Delany et al., 2001). The precise 
reasons for the discrepancies between these studies is unclear; however, it may relate to 
differences in the method for generating TRPV4 null mice -  i.e. deletion of the C-terminus 
(exon 12, Liedtke & Friedman, 2003), or disruption of the N-terminus (exon 4) of the TRPV4 
gene (Mizuno et al., 2003). Interestingly, chronic inhibition of TRPV4, using two structurally 
distinct pharmacological agents, demonstrated no effect on water intake or osmoregulation in 
wild type miee, under basal conditions or following hypertonic and hypotonic challenges 
(Thorneloe et al., 2012; Everaerts et al., 2010). In aggregate, these studies highlight the fact 
that the role of TRPV4 in osmoregulation is complicated. Gene knockout studies suggest a 
role for TRPV4 in osmoregulation, whereas studies with pharmacological inhibitors do not. 
These divergent findings may relate to issues associated with gene ablation which include the 
induction of compensatory processes (i.e. upregulation of other genes/pathways) and/or 
altered development, both of which can contribute to the observed phenotypes.
At the cellular level, hypoosmotic stimulation can be considered a mechanical stimulus, 
because hypotonic solutions cause increases in cell volume which increases membrane 
tension and distortion. Consistent with this, trpv4'^' mice show impaired responses to 
mechanical stimulation such as noxious pressure application to the hind paw or tail (Liedtke
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& Friedman, 2003; Suzuki et al., 2003). Related to this, trpv4'^' miee exhibit diminished 
sensitivity to bladder distension, resulting in an increased micturition threshold and a larger 
bladder capacity (Gevaert et al., 2007; Thomeloe et al., 2008). However, responses to 
innocuous (low-threshold) mechanical stimulation e.g. von Frey hairs (i.e. touch) are similar 
between genotypes (Suzuki et al., 2003e). Finally, the mechanosensitivity of TRPV4 coupled 
with its expression in various structures within the inner ear have made it a candidate 
transducer of auditory stimuli (Liedtke et al., 2000; Shen et al., 2006; Takumida et al., 2005). 
trpv4''' miee display normal inner ear development and morphology; however, they are more 
vulnerable to acoustic injury culminating in delayed-onset hearing loss. Although the precise 
mechanism mediating hearing loss is unclear, this study highlights a potential protective 
function of TRPV4 in the auditory system (Tabuchi et al., 2005). In contrast, no differences 
in hearing were observed between wild-type and trpv4''' in a pre-stimulus startle model of 
auditory function, despite miee being subjected to a wide range of decibels and frequencies 
(Thomeloe et al., unpublished data). The different outcomes from these studies may suggest 
that the role of TRPV4 in hearing is complicated and requires additional investigation, or 
alternatively, it may be a feature of the auditory examination models utilized.
As mentioned previously, TRPV4 displays temperature-dependent activation in heterologous 
systems (see section 1.9.1 for more detail). Basal body temperatures as well as thermal 
circadian rhythms are indistinguishable between trpv4'^' mice and wild type littermates (Lee 
et al., 2005; Liedtke & Friedman, 2003). Moreover, trpv4'''~ mice and wild type littermates 
respond similarly to cold stress (4°C, 150 minutes) or noxious warmth (>47°C) (Lee et al., 
2005; Liedtke & Friedman, 2003; Suzuki et al., 2003). However, trpv4'^'m\cQ exhibit specific 
thermosensitivity behaviors such as preferring floor temperatures set at 34°C (versus 30°C) 
whereas wild type miee do not discriminate (Lee et al., 2005). In addition, trpv4'^~ mice
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display a longer latency for tail withdrawal in response to a moderately hot stimulus (45- 
46°C) compared to wild type controls (Lee et ah, 2005). In thermal hyperalgesia models 
involving earrageenan or capsaicin injection into the hind paw, trpv4'^' miee display longer 
latencies for escaping a hot plate (Todaka et ah, 2004); whereas latency times are similar 
between genotypes in the absence of thermal hyperalgesia (Liedtke & Friedman, 2003). 
Collectively these studies highlight that TRPV4 acts as a thermosenor and is important in 
detecting warm, but not hot, temperatures.
A number of skeletal phenotypes have been observed in trpv4''' miee including a mild 
osteopetrosis (increased bone mass) due to a defect in the terminal differentiation of bone 
resorbing osteoclasts (Masuyama et ah, 2008). Moreover, trpv4'''rmct spontaneously develop 
age-dependent osteoarthritis (Clark et ah, 2010), and are more susceptible to obesity-induced 
osteoarthritis (O’Conor et ah, 2012), thus highlighting the importance of TRPV4 in 
maintaining joint health.
Other notable phenotypes in trpv4''' miee include a significant thickening of the eomified 
layer in the skin. Yet, despite this hyperplasia, trpv4''' miee exhibit defective barrier 
functionality which is believed to be due to aberrant eell-cell junction development between 
skin keratinoeytes (Sokabe et ah, 2010). Finally, in response to high fat feeding (60% kcal 
fi-om fat) trpv4''' miee gain significantly more weight that wild type controls and exhibit 
reduced locomotor activity. Moreover, adipocytes in trpv4''' mice are hypertrophic (compared 
to wild type) in the absence of high-fat feeding, suggesting that TRPV4 may play an 
important role in energy metabolism (O’Conor et ah, 2012).
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1.8 TRPV4 channelopathies
Diseases attributed to aberrant ion ehannel function are termed ‘ehannelopathies’ (Nilius & 
Owsianik, 2010). Recently a number of spontaneously occurring mutations in the TRPV4 
gene have been identified that result in a spectrum of diseases that ean be broadly labeled 
neuromuscular disorders. Sueh diseases ineluding the peripheral neuropathies: congenital 
spinal muscular atrophies (SMA); scapuloperoneal SMA; and hereditary motor and sensory 
neuropathy type IIC (or Chareot-Marie-Tooth Disease type 2C; Deng et al., 2010; Landouré 
et al., 2010; Auer-Grumbach et al., 2010; Fawcett et al., 2012). In addition to a family of 
skeletal dysplasias that include (in order of decreasing severity): metatrophic dysplasia, 
parastremmatie dysplasia, spondyloepiphyseal dysplasia Maroteaux type, 
spondylometaphyseal dysplasia Kozlowski type (SMDK), autosomal dominant brachyolmia 
and familial digital arthropathy with brachydactyly (Rock et al., 2008; Krakow et al., 2009; 
Camacho et al., 2010; Nishimura et al., 2010; Nishimura et al., 2012).
The clinical manifestations of peripheral neuropathies derive from progressive axonal 
degeneration and include muscle weakness, muscular atrophy, sensory abnormalities, 
arthrogryposis and even bone abnormalities (Deng et al., 2010; Landouré et al., 2010; Auer- 
Grumbach et al., 2010; Faweett et al., 2012). However, skeletal dysplasias arise from 
abnormal bone formation and development -  these cover a more dramatic phenotypic range 
encompassing shortened phalanges to neonatal lethality due to thoracic hypoplasia and 
resultant respiratory failure (Nishimura et al., 2012).
Since 2008, fifty eight mutations in the human TRPV4 gene have been identified (Faweett et 
al., 2012; Nishimura et al., 2012; Rock et al., 2008). The vast majority of these mutations are 
attributable to single amino-aeid substitutions, or missense mutations, although five
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exceptions have been reported whereby the mutation is attributed to either a deletion, a 
duplication, a ffameshift or a non-sense mutation (Camacho et al, 2010; Dai et a l, 2010; 
Nishimura et a l, 2010; Andreucei et a l, 2011). TRPV4 mutations are distributed across the 
entire length of the gene (Figure 1.2). In general, many of the reported peripheral neuropathy 
mutations are found within the ARDs of TRPV4 (Faweett et al, 2012). In contrast, no 
appreciable pattern exists within the skeletal dysplasia family of mutations; although, two 
mutation “hot spots” comprising codons encoding R594 and P799 have been identified 
(Nishimura et a l, 2012). Interestingly, the missense mutations G78W, K276E, and T740I 
(fetal hypokinesia phenotypes) and A217S, E278K, R315W, S542Y and P799R (late onset 
neurodegenerative disease) result in phenotypes that constitute both skeletal dysplasias and 
peripheral neuropathies, thus highlighting that the pathologies affecting these two broad 
systems (i.e. skeletal and neuronal) are not mutually exclusive (Chen et al, 2010; Cho et a l, 
2012; Unger et a l, 2011).
The molecular mechanisms contributing to the disease phenotypes are not completely 
established. Functional studies involving some TRPY4-mutants have aided our understanding 
of disease pathology but not all mutants have been characterized in this way. With respect to 
peripheral neuropathies, a dichotomy in mutant channel function is clearly evident. Auer- 
Grumbaeh and colleagues demonstrated that expression of mutant TRPV4 constructs in HeLa 
cells caused a reduction in stimulus-dependent TRPV4 activation due to reduced plasma 
membrane expression of mutant channels (Auer-Grumbaeh et al, 2010). In stark contrast, 
two other groups showed gain-of-funetion mutations with the same mutant constructs in both 
HEK293 and Xenopus laevis oocytes, with no apparent difference in the level of membrane 
expression versus wild-type (Landouré et a l, 2010; Deng et al, 2010). The most likely 
explanation for these discrepancies is the choice of different heterologous systems; however,
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these differences also offer the intriguing possibility that the same mutation may elicit 
contrary functional effects, i.e. gain- vs. loss-of-funetion, in cells from different anatomical 
locations -  which could conceivable result in different diseases being derived from the same 
mutant. As such, characterization of mutant function in the correct physiological context may 
be optimal e.g. neurons for peripheral neuropathies. Skeletal dysplasias generally result from 
gain-of-function mutations (Rock et al., 2008; Krakow et al., 2009; Camacho et al., 2010); 
however, exceptions exist (Krakow et al., 2009; Lamandé et al., 2011). Clearly, more 
research is required to fully decipher the precise disease mechanisms.
Although the pathologies discussed above comprise monogenetie inherited disorders, it is 
likely given the broad tissue expression of TRPV4 that other diseases exist. Indeed, 
polymorphisms in the TPRV4 gene have been associated with chronic obstructive pulmonary 
disease (COPD), thus highlighting that TRPV4 also plays a role in polygenetic diseases (Zhu 
et al., 2009).
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Figure 1.2: Diagram of the TRPV4 molecule highlighting location o f skeletal dysplasia (top) and 
peripheral neuropathy (bottom) mutations. Missense mutations are designated with a letter prefix, 
followed by a number indicating the location o f the amino acid, followed by a letter suffix (e.g. 
G78W). 1 = deletion, insertion; 2 = deletion; 3 = duplication; 4 = ffameshift mutation. ARD, ankyrin 
repeat domain; CaM-binding, calmodulin binding domain; metatrophic dysplasia; BO, autosomal 
dominant brachyolmia; FDAB, familial digital arthropathy with brachydactyly; PD, paratremmatic 
dysplasia; PRD, proline rich domain; SI, transmembrane domain 1; SEMD, spondyloepiphyseal 
dysplasia Maroteaux type; SMA, spinal muscular atrophy; HMSN2C, hereditary motor and sensory 
neuropathy type IIC (or Charcot-Marie-Tooth Disease type 2C); SMDK, spondylometaphyseal 
dysplasia Kozlowski type. Figure adapted from Dai et al. (2010).
1.9 TRPV4 modes of activation
TRPV4 demonstrates a remarkable diversity in its modes of activation, ranging from physical 
stimuli (e.g. heat, osmolality, shear stress) to a variety of structurally distinct chemical 
ligands (e.g. endocannabinoids, phorbol esters, PLA2-metabolites). This promiscuity of 
gating mechanisms has led to the suggestion that TRPV4 may function as a polymodal
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integrator of disparate stimuli (Everaerts et al., 2010). The specifics of these gating modalities 
will be outlined below.
1.9.1 Thermo-gating
Like other members of the Group 1 vanilloid family, TRPV4 is activated in response to 
thermal stimulation. Although most ion channels demonstrate some degree of temperature 
dependenee in gating, TRPV4 (as well as other thermosensative TRP ehannels) differs from 
non-thermosensitive ion ehannels in the magnitude of the increase in ehannel activity with 
temperature. Thermal sensitivity is typieally eharacterized by the 10°C temperature 
coeffieient, or Qio. Non-thermosensative ion channels typically demonstrate Qio values of 2 - 
4, whereas TRPV4 surpasses these with Qio values of 10-20 (Giiler et al., 2002; Watanabe, 
Vriens, et al., 2002). The threshold for TRPV4 thermal aetivation lies between 25-32®C 
depending on the cellular background; however, current densities are typieally modest at 
temperatures below 30°C (Chung et al., 2004; Giiler et al., 2002; Watanabe et al., 2002a). 
Temperatures >38°C result in diminished TRPV4-mediated eurrents (Güler et al., 2002; 
Chung et al., 2004), although others have reported no apparent saturation at temperatures up 
to 43°C (Watanabe et al., 2002). The reasons for this apparent disparity are unelear. 
Prolonged thermal stimulation results in a reduction in TRPV4 current, although this 
desensitization is incomplete as the ehannel remains responsive to subsequent thermal 
challenges (Chung et al., 2004; Güler et al., 2002; Watanabe et al., 2002a).
The molecular mechanism(s) that mediate thermal activation of TRPV4 have only been 
partially elueidated. Site-direeted mutagenesis studies have provided important elues into the 
eritical regions of the TRPV4 moleeule that impart thermo-sensitivity. Three amino aeids, 
distributed between the 3"^  ^and 4^  ^transmembrane segments of the TRPV4 moleeule, appear
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to be crucial for thermo-gating. These residues inelude: a tyrosine at position 556 (Tyr^^^); a 
leueine at position 584 (Leu^ "^^ ) and a tryptophan at position 586 (Tpr^^^). In the case of 
Tyr^^ ,^ thermo-sensitivity is dependent on the presence of an aromatie amino acid. Mutating 
tyrosine to alanine (non-aromatic) abates thermo-aetivation, whereas, mutation to 
phenylalanine (aromatie) has no effeet (Vriens et al., 2007). Importantly, mutation of these 
residues does not affect channel aetivation to hypotonic stimuli (discussed below), suggesting 
that some degree of independenee exists in the meehanisms of gating in response to thermal 
and osmotie stimuli (Vriens et al., 2007). In addition to the and 4‘^  transmembrane 
segments, deletion of the N-terminal ankyrin-repeat domains also ablates thermal activation 
(Watanabe et al., 2002). It is hypothesized that the ankyrin repeats may stabilize a channel 
eonformation that is permissive to thermal-aetivation; however, further investigation is 
needed to substantiate these claims. Finally, heat-evoked eurrents are absent in eell-free 
inside-out patches (Watanabe et al., 2002a). This finding suggests that thermal aetivation of 
TRPV4 is: 1) indirect, in contrast to TRPVl (Tominaga et al., 1998); and 2) requires an intaet 
eytoplasm. With respeet to this latter point, it is hypothesized that heat evokes the generation 
of an, as yet, unidentified TRPV4 activating ligand, which cannot be generated in cell-fi-ee 
patches (Watanabe et al., 2002a). Although speeulative, this ligand -  if it exists -  may 
bind/interact with the key residues (Tyr^^ ,^ Leu^ "^^  and Tpr^^ )^ found within the 3^  ^ and 4^  ^
transmembrane segments of TRPV4.
Thermal gating of TRPV4 is sensitive to osmolality: low osmolality augments, and high 
osmolality ablates, TRPV4 eurrents (Giiler et al., 2002; Chung et al., 2004). In addition, 
hypotonic activation of TRPV4, as well as agonist-induced aetivation, is augmented at higher 
temperatures. This suggests that heat may be an important potentiator of other (aetivating) 
stimuli, in addition to gating TRPV4 itself (Liedtke et al., 2000; Gao et al., 2003).
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1.9.2 Mechano-gating
As already noted, TRPV4 is sensitive to ehanges in extraeellular osmolality. In fact, TRPV4 
demonstrates bi-directional modulation in response to osmolality, inasmuch as it is activated 
by decreases in extracellular osmolality (hypotonie solutions) but inhibited by inereases in 
extracellular osmolality (hypertonie solutions, Liedtke et al., 2000; Strotmann et al., 2000). 
The response to hypotonieity is graded and exquisitely sensitive; osmotic fluctuations as little 
as 1% are readily deteetable by the ehannel (Liedtke et al., 2000; Strotmann et al., 2000). The 
dynamic range for osmotie sensitivity ranges from 330 mosmol/L to 200 mosmol/L, with the 
osmotie set-point being -295 mosmol/L, in mammals (Liedtke, 2005; Strotmann et al., 2000).
At the cellular level, application of a hypotonic solution induces cell swelling whieh is 
followed by a delayed increase in eellular current (Vriens et al., 2004). The delayed current 
indicates that the effect of osmolality is indirect. Indeed, hypoosmotic activation is attenuated 
by inhibition of eicosanoid signaling, speeifically inhibition of the enzymes PLA2 and 
cytoehrome P450 epoxygenase (Vriens et al., 2004). The temporal sequence of events leading 
to TRPV4 aetivation in response to hypotonicity is as follows: cell swelling activates PLA2, 
whieh liberates membranous araehidonie acid that is metabolized by cytochrome P450 
epoxygenase to generate epoxyeicostrienoic aeid (LET) species (Vriens et al., 2004; 
Watanabe et al., 2003; Figure 1.3). To date, all EET regioisomers (5,6-EET, 8,9-EET, 11,12- 
EET and 14,15-EET) have been demonstrated to activate TRPV4 (Watanabe et al. 2003; 
Alvarez et al. 2006; Earley et al. 2009). The effect of 5,6-EET is preserved in cell-free inside- 
out patehes highlighting that this molecule acts in a membrane delimited, and likely direct, 
manner (Watanabe et al., 2003). Importantly, exogenous applieation of 5,6-EET, as well as 
araehidonie acid, induces TRPV4 currents indistinguishable from those induced by 
hypotonicity (Vriens et al., 2004; Watanabe et al., 2003).
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Figure 1.3: Mechanism of TRPV4 osmotic activation. Application of a hypoosmotic solution lowers 
extracellular osmolality resulting in cell swelling. Increased cell size activates PLA 2 , facilitating 
araehidonie acid liberation from membrane phospholipids. Araehidonie acid is subsequently 
metabolized to EET species by cytochrome P450 epoxygenase. EET regioisomers, including 5,6-EET, 
8,9-EET, 11,12-EET and 14,15-EET activate TRPV4. EET, epoxyeicostrienoic acids; PLA2 , 
phospholipase A2. Adapted from Plant & Strotmann (2007).
Similar to thermo-gating, the 4^  ^ transmembrane portion of the TRPV4 molecule is also 
involved in osmotic gating. Mutagenesis studies have demonstrated that a positively charged 
arginine residue at position 594 (Arg^ "^^ ) is crucial for mediating hypotonic activation (Vriens 
et ah, 2007). Whether 5,6-EET binds to or interacts with this critical residue has not been 
determined but it remains an intriguing possibility. Osmo-sensitivity is also impaired 
following deletion of the N-terminal ankyrin repeat domains. However, unlike thermal 
aetivation, deletion of the ankyrin-repeat domains does not completely eliminate osmotie 
gating. Instead, the magnitude and kinetics of the response are reduced. The precise reason 
for the impairment have not been established; ankyrin may connect TRPV4 to the
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cytoskeleton which facilitates both a rapid, and complete response to hypoosmotic stimuli 
(Liedtke et al., 2000).
The osm-9 gene in C. elegans is the invertebrate homologue of the mammalian TRPV4 gene. 
A variety of osm-9 mutants display abnormal avoidance behaviors to odorant, osmotic, and 
mechanical (nose touch) cues (Colbert et al., 1997). Transgenic expression of mammalian 
TRPV4 in osm-9 mutants rescues the response to osmotic and mechanical stimuli, thus 
highlighting the evolutionarily conserved role this channel plays in osmo- and mechano­
sensitivity (Liedtke et al., 2003b).
Hypotonicity-induced cell swelling increases tension in the plasma membrane, tantamount to 
a mechanical stimulus. Although, Stotmann et al. (2000) did not note any channel activation 
in response to membrane stretch in their paper describing the discovery of TRPV4, 
subsequent reports (Fan et al., 2009; Mochizuki et al., 2009) have consistently demonstrated 
activation in response to mechanical stimuli of various guises. The lack of mechano-response 
reported by Strotmann et al. likely reflects the use of ambient temperature over physiological 
temperature in that study, eompared to subsequent studies. Gao et al. (2003) neatly 
demonstrated the importance of temperature in facilitating mechanical activation of TRPV4. 
In this study fluid shear stress did not induce a TRPV4 current at room temperature. 
However, a robust TRPV4 current was evident when the temperature was increased to 37°C 
(Gao et al., 2003). This again highlights the important potentiator effect of temperature on 
TRPV4 gating.
Endogenous TRPV4 activation in response to mechanical stimulation such as uniaxial 
stretching, static stretch and shear stress, has been reported in a number of cell types
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including endothelium (Thodeti et al., 2009; Mendoza et al., 2009), urothelium (Mochizuki et 
al., 2009), keratinoeytes (Becker et al., 2009) and osteoblasts (Suzuki et al., 2013). Although 
the mechanism of activation has not been completely delineated, an interaction between 
TRPV4 and the actin cytoskeleton seems to be a common feature. Interestingly, in 
keratinoeytes TRPV4 co-localizes with F-aetin. When these cells are subjected to 
hypoosmotic stimulation they demonstrate a charaeteristie increases in cell volume and a 
concurrent increase in intracellular calcium (in a TRPV4-dependent manner). However, the 
calcium response is inhibited by latrunculin A (an agent that inhibits aetin polymerization) 
despite a pronounced cell swelling response (Becker et al., 2009). Thus, it appears two modes 
of TRPV4 activation in response to mechanical/osmotic stimuli may exist, the first requiring 
PLA2-metabolite formation, the other requiring restructuring of the actin cytoskeleton. 
Alternatively, these distinct pathways may reflect different stages of the same activation 
pathway.
1.9.3 TRPV4 ligands
TRPV4 activity is modulated by a number of structurally disparate ligands. These range from 
endogenous lipids, including anandamide and EETs, to fully synthetic agents such as 
GSK1016790A and GSK2193874, which activate and inhibit TRPV4, respectively. The 
poteneies of various TRPV4 ligands are displayed in Table 1.1 (agonists) and Table 1.2 
(antagonists).
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Table 1.1; Chemical structures and  potencies of TRPV4 agonists
Agonist Structure Sp ecies Potency (ECso fiM) Reference
4a-PDD
Human
M ouse
0.14-0.2
0.2-3.0
4.4
2.0
W ctan a b e  e t ci., 2002b
W atan a b e  e t a!., 2002b; Vriens e t  oL, 2007; 
Thorneloe e t a!..2008; Kiausen e t  ci., 2009
Vincent e t  al., 2009
Phan e t  al., 2009
M ouse 0.13 W atan a b e  e t a l ,  2003
A nandam ide M ouse 2.0 Nilius e t  al., 2004
Arachidonic a c id  / = \ y = = \ y \ J ^ ^ 2^ M ouse 2.0 W atan a b e  e t  a l ,  2003
BisandrographoSde 4^
HO^
Human 0.79-0.95 Smith e t a l ,  2006
O O l f Xy-NH0
GSK634775 O Human 0.025 Thorneloe e t  a l ,  2012
GSKI0i6790A do o
Human
M ouse
Rat
Bovine
Dog
0.003
0.003-0.018
OX)i
0.001
0.001
Willette e t  al., 2008
Thomeloe e t  al.,2008; Willette e t  a l ,  2008;
Jin e t  a l ,  2011
Willette e t  a l ,  2008
Willette e t  a l ,  2008
Willette e t  a l ,  2008
( y )  Human
tous
Rat
0.77 V incent e t  a l ,  2009
4.0 V incent e t  a l ,  2009
4.1 V incent e t  a l ,  2009
TRPV4 Agonists
1.9.3.1 Phorbol esters
The first specific small molecule activator of TRPV4 to be discovered was the lipophilic 
phorbol ester, 4a-phorbol 12, 13-didecanate, or 4a-PDD (Watanabe et al., 2002a). 4a-PDD 
is structurally similar to the classic protein kinase C (PKC) activator phorbol 12-myristate 13- 
acetate (PMA). Indeed, both compounds activate TRPV4 at physiological temperatures;
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however, 4a-PDD is ~50-times more potent than PMA (which only exhibits partial agonist 
activity, Emax = 65%), and its mode of activation is independent of PKC (Gao et al., 2003; 
Watanabe et al., 2002b). Whether PMA activates TRPV4 via a PKC-dependent mechanism is 
unclear. The effect of 4a-PDD is present in native and heterologous expression systems and 
activation is retained against TRPV4 orthologs from various species (see Table 1.1; Klausen 
et al., 2009; Thomeloe et al., 2008; Vriens et al., 2007; Watanabe et al., 2002b). 4a-PDD 
activity is absent in trpv4'^' mice and cellular derivatives thereof, suggesting that the molecule 
is a specific TRPV4 activator (Vriens et al., 2005; Zhang et al., 2009). However, a recent 
report has questioned this specificity after demonstrating channel activation in neurons 
derived from both wild-type and trpv4'^' mice (Alexander et al., 2013). Moreover, it was 
noted by Thorneloe and colleagues that 4a-PDD activated a small non-specific current in 
untransfected HEK293 cells, suggesting 4a-PDD may modulate other ion channels, in 
addition to TRPV4 (Thomeloe et a l, 2008).
Unlike osmotic-gating, 4a-PDD-mediated TRPV4 activation is direct and is independent of 
PLA2 or cytochrome P450 epoxygenase activation (Watanabe et al., 2003a; Watanabe et al., 
2002b). Moreover, the relative efficacies of these two stimuli reveal that 4a-PDD induces 9- 
times more current activation than hypotonic solutions in heterologous expression systems 
(Watanabe et al., 2002a). However, the kinetics of channel activation appear to be similar 
between methods, inasmuch as both induce a relatively slow activation current (Watanabe et 
al., 2002a). The latency of the 4a-PDD response, as well as its ability to activate current 
following cytoplasmic application (in inside-out patches) suggests an intracellular mode of 
activation (Watanabe et al., 2002b). Consistent with this, a number of intracellular residues 
distributed between the 3^^^ and 4^  ^ transmembrane segments (of TRPV4) appear critical for 
4a-PDD activity. Interestingly, these residues which include Tyr^^ ,^ Leu^ "^^  and Trp^^  ^ are
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also key regulators of thermal activation (Vriens et al., 2004; Vriens et al., 2007). The 
similarities between these activation modes has led to speculation that the elusive heat- 
evoked ligand may share structural similarity to phorbol-esters, or at least share an 
overlapping binding site between the 3^  ^ and 4^  ^ transmembrane domains (Vriens et al., 
2007). Related to this, Tyr^^  ^seems to play an important role in facilitating channel activation 
by interacting with the lipophilic side chains on the C-ring of 4a-PDD (and derivatives 
thereof) to enable correct orientation of the molecule into the aforementioned binding pocket 
(Klausen et al., 2009; Vriens et al., 2007). Lipophilic side chain length is also a critical 
determinant of ligand binding affinity and potency (Klausen et al., 2009; Vriens et al., 2007).
1.9.3.2 Endogenous lipid activators
The search for potential endogenous TRPV4 activators followed the discovery and 
characterization of 4a-PDD. The endogenous lipid anandamide (or N- 
arachidonoylethanolamine), an endocannabinoid with potent TRPVl activating properties, 
also activates TRPV4 (Smart et al., 2000; Watanabe et al., 2003). Moreover, its major 
metabolite -  following the action of fatty acid amidohydrolase -  is arachidonic acid, which 
activates TRPV4 indirectly, via the formation of EET species (Watanabe et al., 2003) by 
cytochrome P450 epoxygenase (Vriens et al., 2005).
1.9.3.3 Bisandrographolide
Plant-derived compounds activate a number of TRP channels. For example, TRPVl is 
activated by capsaicin from chili peppers (Caterina et al., 1997), TRPV3 is activated by 
eugenol in thyme (Xu et al., 2006) and TRPM8  is activated by eucalyptol from the eucalyptus 
tree (Behrendt et al., 2004). Similarly, TRPV4 is activated by an extract from the Chinese 
herbal plant Andrographis paniculata (Smith et al., 2006). The active component in
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Andrographis paniculata extract is bisandrographolide (BAA) which selectively activates 
TRPV4 in the high nanomolar (EC50 800-950 nM) range without influencing other group 1 
vanilloid members (TRPVl-V3) in either an agonistic or an antagonistic manner (Smith et 
al., 2006). BAA functions in cell-free (inside-out) patches indicating a membrane delimited 
action (Smith et al., 2006). Mutational analysis demonstrates a critical role for residues Leu^ "^^  
and Trp^^  ^(S4) in mediating BAA activity, analogous to heat and 4a-PDD gating. However, 
unlike thermo- and 4a-PDD-gating, Tyr^^  ^is dispensable for BAA-activity, thus highlighting 
a degree of separation between these mechanisms (Vriens et al., 2007).
L9.3.4 RN-1747
By evaluating the structure-activity relationship data from two GlaxoSmithKline (GSK) 
patent applications, Renovis, Inc. (a former subsidiary of Evotec) conducted a focused screen 
of ortho- and para-substituted aryl sulfonamides and identified a number of molecules with 
affinity for the TRPV4 channel (Vincent et al., 2009). One of the molecules identified, RN- 
1747, activated human, mouse and rat TRPV4 in the low-to sub-micromolar range (EC50 0.8- 
4.1pM). The efficacy and potency of this compound was comparable to 4a-PDD against 
human TRPV4 but was lower against mouse and rat TRPV4 (Vincent et al., 2009). 
Selectivity profiling against a limited set of TRP channels demonstrated RN-1747 to be 
selective for TRPV4 over TRPV3, but exhibited weak agonist activity at TRPVl (25% of 
capsaicin EmA) at high concentrations (lOOpM) and modest antagonist activity at TRPM8  
(IC50 4pM). The effect of this compound in vivo has not been evaluated.
L9.3.5 GSK1016790A
Pertinent to this thesis is the piperazine-linked TRPV4 agonist GSK1016790A. This 
compound was identified in a small molecule screen conducted by GSK, circa 2006. Based
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on observations that TRPV4 agonism reduced proteolytic enzyme release from chrondrocytes 
it was hypothesized that TRPV4 activation may have therapeutic utility in the treatment of 
inflammatory bone disorders. However, in vivo application of GSK1016790A resulted in the 
rapid death of animals administered this compound; this effect was later characterized by 
Willette and colleagues and is discussed further below (Willette et al., 2008).
GSK1016790A demonstrates single-digit nanomolar potency against human, canine and 
bovine TRPV4 (EC50 3-lOnM), whilst its potency is slightly reduced at rodent channels 
(Willette et al., 2008). Although initial reports indicated that GSK1016790A was a modestly 
potent TRPVl agonist (EC50 50nM; Thomeloe et al., 2008; Willette et al., 2008), further 
investigation revealed it to be devoid of TRPVl activity (Willette et al., 2011). HEK293 cells 
express endogenous TRPV4 (Mergler et al., 2011); GSK1016790A elicited similar increases 
in [Ca^^Ji levels in untransduced, null transduced and TRPVl transduced HEK293 cells, 
indicating that what was considered to be “TRPVl” activation, was in fact activation of 
endogenous TRPV4 channel in HEK293 cells (Willette et al., 2011). Furthermore, the 
specificity and selectivity of GSK1016790A has been verified in trpvE"'' mice (and cellular 
derivatives thereof) and against other TRP channels including TRPM8 and TRPAl 
(Alexander et al., 2013; Thorneloe et al., 2008; Willette et al., 2008).
TRPV4 activation with GSK1016790A is both rapid and robust and typically results in steep 
concentration-effect relationships (Jin et al., 2011; Thomeloe et al., 2008). Although 
speculative, the kinetics of channel activation may suggest an extemal binding location; 
however, further studies are required to determine the precise binding site for this agent. In 
comparison to 4a-PDD, GSK1016790A elicits twice the current activation (710 ± 144 pA.pF" 
 ^vs. 323 ± 88 pA.pF'^), highlighting that it is not only more potent but also more efficacious
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than 4a-PDD (Thomeloe et a l, 2008). In fact, functional studies demonstrate GSK1016790A 
is 300-1000 times more potent than 4a-PDD (Thomeloe et al., 2008; Willette et al., 2008). 
Finally, GSK634775, a structural analogue of GSK1016790A, was recently reported to be a 
novel and potent TRPV4 agonist (EC50 = 25nM; Thomeloe et al., 2012).
TRP V4 Antagonists 
1.9.3.6Ruthenium Red
Ruthenium Red, also known as ammoniated ruthenium oxychloride, was one of the first 
pharmacological agents discovered to inhibit TRPV4 activity (Watanabe et al., 2002b). This 
inorganic polycationic molecule antagonizes TRPV4 activity with micromolar potency in a 
voltage-dependent manner (Vincent & Duncton, 2011; Watanabe et al., 2002b). Inhibition is 
mediated by plugging the aqueous pore, thus preventing extracellular cation entry. An 
aspartate residue (Asp^^ )^ on the extracellular region of the pore appears critical for its 
activity (Voets et al., 2002). However, at concentrations required to inhibit TRPV4, 
ruthenium red also inhibits a large number of other targets including TRPVl, TRPV2, 
TRPV3, TRPV5, TRPV6, TRPM6, TRPM8, TRPAl, CatSperl (cation channel sperm- 
associated protein 1), TASK (TWlK-related acid-sensitive K(+) channel 1), ryanodine 
receptors (RyRl-3), Ca^^-ATPase, mitochondrial Ca^  ^uniporter, tubulin, myosin light-chain 
phosphatase and calmodulin, highlighting the lack of specificity of this molecule (Vincent & 
Duncton, 2011; Vriens et al., 2009 and references therein).
41
Table 1.2: Chemical structures and potencies of TRPV4 antagonists
Antagonist Structure Species Potency {iCjo pM) Reference
Copsdzeplne
HO. Human
Rat
18.6
13.9
Vincent e t ai., 2009
HC-067047
Human
Mouse
Rat
0.048
0.017
0.133
Everaerts e t a!., 2010
GSK205 Pig 0.6 Phan e t ai., 2009
GSK2193874
Human
Mouse
Rat
0.04-0.05
0.005
0.002 Thorneloe e t a l, 2012
Dog 0.1
GSK2263095 -00
Human
Mouse
Rot
0.003-O.CK5S
0.002
0.001 Thomeloe e t a!., 2012
cr.
Dog 0.016
RN-1734
Human
Mouse
Rat
2.3
5.9
3.2
Vincent e t al.. 2009
Human <0.12=
RN-9S93 Unknown Mouse <0.06= Vincent & Duncton, 2011
Rat <0.12=
Human 0.086-1.0 W atanabe e t ai., 2002b; Vincent e t a l,  2ÎXS9
Mouse 0.21-1.0 W atanabe e t a l, 2002b; Vincent e t a l, 2009Ruthenium Red {(NHaJjRuORutNHaJjORulNHaJijCij Rat 0.33 Vincent e t a l, 2009
Pig 0.005 Phan e t a!., 2009
%  value
1.9.3.7 HC-067047
HC-067047 was recently identified by Hydra Bioseienees in a high-throughput screen for 
small-moleeule antagonists of TRPV4 (Everaerts et al., 2010). This molecule rapidly and 
reversibly inhibited both recombinant and native TRPV4 channels across species with 
nanomolar potency (IC50 20-140nM). Moreover, inhibition was observed against a variety of 
TRPV4 activating stimuli including heat, hyposmotic solution, arachidonic acid, 4a-PDD and 
GSK1016790A. Selectivity profiling revealed HC-067047 to be inactive against the closely 
related group 1 vanilloid family members TRPVl-V3, in addition to a variety of other ion
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channel targets; however, it did display submieromolar inhibitory activity against TRPM8  
and hERG (IC50 = 780 ± 120 nM and 368 ± 32 nM, respectively). HC-067047 improved 
bladder function in two rodent models of cyelophosphamide-indueed cystitis, which 
mimicked observations in trpv4'^' mice, thus demonstrating it to be efficacious in vivo. 
Interestingly, HC-067047 did not affect core body temperature, thermal selection behavior, 
locomotor activity, heart rate or water intake in mice (Everaerts et al., 2010), which is 
somewhat unexpected given the phenotypic manifestations of trpv4'^' mice (Lee et al., 2005; 
Liedtke & Friedman, 2003; Suzuki et al., 2003).
L9.3.8 RN-1734
RN-1734 was identified in the same focused screen as the TRPV4 agonist RN-1747; 
however, RN-1734 inhibits human, mouse and rat TRPV4 with comparable single digit 
mieromolar potency (EC50 2.3-5.9pM; Vincent et al., 2009). Importantly, RN-1734 fully 
inhibited, with similar potency, the activation of TRPV4 by three different agonists 
(hypotonieity, 4a-PDD, RN-1747). Selectivity profiling against TRPVl, TRPV3 and TRPM8  
demonstrated RN-1734 to be selective for TRPV4 (Vincent et al., 2009). Interestingly, this 
same study also identified eapsazepine, a TRPV1 antagonist, to have weak antagonist activity 
at both human and rat TRPV4. Recently, the same group identified another TRPV4 
antagonist, RN-9893. This molecule exhibits submieromolar potency against human, mouse 
and rat TRPV4 and is selective over the same panel of TRP channels noted above. In 
addition, the molecule is orally bioavailable in the rat; however, the molecular structure has 
not been published (Vincent & Duncton, 2011).
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1.9.3.9 GSK antagonists
The most potent and selective TRPV4 antagonists described to date are the quinoline 
derivatives GSK2193874 and GSK2263095. Both molecules were discovered in a TRPV4 
antagonist screen following chemical optimization of SB390570, and inhibit TRPV4 with 
nanomolar potency across a number of species with a rank order of potency of: rat > mouse > 
human > dog (Thorneloe et al., 2012). Mechanistically, it is likely that TRPV4 inhibition 
with GSK2193874 is mediated by binding to an extracellular site, as GSK2193874 inhibits 
activation of TRPV4 currents when applied to the extracellular solution at concentrations as 
low as 3nM but is ineffective at concentrations up to lOpM when applied to the inside of the 
cell by inclusion in the intracellular pipette solution. Importantly, the potency of both agents 
is consistent in response to various TRPV4 activation modes (i.e. GSK634775, GSK1016790 
and hypotonieity). Both compounds are devoid of agonist activity and are inactive against 
other TRP channels (TRPVl, TRPAl, TRPM8, TRPC3 and TRPC6), although they display 
low inhibitory potency (mieromolar range) at hERG and Cavl.2. The selectivity of 
GSK2193874 has been demonstrated against an extensive list of targets (~ 200) including 
many receptors, ion channels and enzymes. Importantly, in the context of this thesis, 
GSK2193874 inhibits native endothelial TRPV4 channels in vitro and displays efficacy 
against its target in vivo, making it an excellent tool for exploring TRPV4 biology (Thomeloe 
et al., 2012).
In addition to the above, another TRPV4 antagonist, designated GSK205, has also been 
described. This aminothiazole derivative is chemically distinct from GSK2193874 and 
GSK2263095 and inhibits both recombinant and native TRPV4 in porcine chrondrocytes 
with modest potency (IC50 = 600 nM). GSK205-mediated TRPV4 inhibition is consistent 
against physical (hypotonieity) and ligand (4a-PDD)-indueed TRPV4 activation. However,
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despite being described as a selective TRPV4 antagonist, the selectivity profile for this agent 
has not been reported (Phan et al., 2009). More recently, a series of potent piperidine-linked 
benzimidazoles were identified in a chemical screen analogous to the one that identified 
GSK2193874 and GSK2263095. Many of these compounds demonstrate favorable 
pharmacokinetic profiles and exhibit in vivo efficacy against TRPV4, making them 
potentially useful tool compounds (Hilfiker et al., 2013).
1.10 Role of TRPV4 in the vasculature
1.10.1 Expression
The first cell type to demonstrate endogenous and functional TRPV4 channel expression was 
the endothelium (Watanabe et al., 2002a; Watanabe et al., 2002b). In the subsequent decade, 
TRPV4 expression has been demonstrated in several vascular beds, in vessels ranging in size 
from large, conduit arteries (aorta, pulmonary, carotid arteries) to small resistance arteries 
(arteria gracilis, bronchial, coronary, cerebral, eremaster and mesenteric arteries) (Alvarez et 
al., 2006; Bagher et al., 2012; Bubolz et al., 2012; Earley et al., 2009; Kohler et al., 2006; 
Loot et al., 2008; Marrelli et al., 2007; Thomeloe et al., 2012; Vriens et al., 2005; Willette et 
al., 2008; Zhang et al., 2009). The channel is also expressed in small vessels including dermal 
capillaries and mierovascular cells within the alveolar septal region of the lung (Adapala et 
al., 2011; Alvarez et al., 2006; Pla et al., 2012; Sullivan et al., 2012; Willette et al., 2008). 
TRPV4 is ubiquitously expressed in endothelial cells, while expression within smooth muscle 
cells has also been demonstrated in the aorta, cerebral, coronary, mesenteric and pulmonary 
arteries, in addition to extra-alveolar vessels in the lung (Marrelli et al., 2007; Alvarez et al., 
2006; Martin et al., 2012; Yang et al., 2012; Gao & Wang 2010b; Bubolz et al., 2012; Zhang 
et al., 2009). TRPV4 is however more abundantly expressed in endothelial cells versus
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smooth muscle cells in carotid, cerebral and coronary vessels (Zhang et al., 2009; Bubolz et 
al., 2012; Marrelli et al., 2007).
Given the potent pharmacodynamie effects of luminally delivered TRPV4 agonists and 
immunolabelling studies, it appears that TRPV4 resides on the luminal side of the endothelial 
layer (Bubolz et al., 2012; Hartmannsgruber et al., 2007; Kohler et al., 2006; Loot et al., 
2008; Marrelli et al., 2007). However, in certain vessels (cerebral and eremaster arteries, for 
example) TRPV4 is basolaterally polarized within myoendothelial junctions that lay in close 
apposition to intimai myocytes (Marrelli et al., 2007; Bagher et al., 2012). At the subeellular 
level, TRPV4 channels co-loealize with other molecular entities including connexins and 
eaveolin-1  in eaveolae, as well as ealeium-aetivated potassium channels of the small- (SKca, 
or Kca2.3) and intermediate- (IKca, or Kca3.1) conductance varieties (Saliez et al., 2008; Gao 
& Wang, 2010b; Bagher et al., 2012; Ma et al., 2013), the latter of these are critical players in 
certain vasodilatory functions (see below). Interestingly, in the absence of stimuli, TRPV4 
may predominantly reside eytoplasmieally in a quiescent state, only translocating to the 
plasma membrane following exposure to a gating stimulus (Loot et al., 2008; Sonkusare et 
al., 2012; Sullivan et al., 2012). Finally, TRPV4 expression can be upregulated by a variety 
of factors including the inflammatory cytokine IL-ip (Ma et al., 2008), a high salt diet (Gao 
et al., 2009) and following malignant transformation of cells (Pla et al., 2012).
1.10.2 Role in endothelial-mediated vasodilation
One of the critical functions of the endothelium is the regulation of vascular tone. This in turn 
regulates local and systemic blood pressure which is crucial for maintaining end organ 
perfusion. The endothelium achieves such regulation by releasing a range of vasoactive 
molecules that cause the relaxation (vasodilatation) and contraction (vasoconstriction) of the
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underlying smooth muscle. Three major vasodilatory pathways exist in vivo: 1) the 
endothelial-derived hyperpolarizing factor (EDHF) pathway; 2) the nitric oxide (NO) 
pathway; and 3) the prostacyclin (PGI2) pathway. Engagement of these pathways is broadly 
mediated by either neurohormonal mediators e.g. acetylcholine (ACh), bradykinin ( B K ) ,  etc, 
or by hemodynamic forces including shear stress or the circumferential effect of pulsatile 
blood flow through the vessel (Félétou et al., 2010). PGI2 and NO pathways are regulated by 
activation of the enzymes cyclooxygenase (COX) and nitric oxide synthase (NOS), 
respectively. Whereas, EDHF -  which accounts for the vasodilatation that occurs when the 
former two pathways are inhibited -  is characterized by hyperpolarization of the smooth 
muscle layer (Félétou & Vanhoutte, 2000). EDHF is mediated by at least two potential 
mechanisms. The first involves hyperpolarization of the endothelium following the opening 
of SKca, and IKca channels. This electrical signal is transmitted to the underlying smooth 
muscle either directly via myoendothelial gap junctions or by accumulation of ions in the 
intercellular space, which in turn activates myocyte Na^/K^-ATPase and/or inwardly 
rectifying K^-ehannels ( K i r ) ,  thus causing hyperpolarization (Garland et al., 2011). The 
second pathway involves release of a difhisible factor. Evidence suggests EETs are important 
mediators of the EDHF response, however, a number of other factors have also been 
identified. Mechanistically, EETs hyperpolarize the myocyte by activating the large 
conductance Kca channels ( B K c a )  (Félétou et al., 2 0 1 0 ). The common “denominator” linking 
all three endothelial-derived vasodilatory pathways is their strict dependence on an increase 
in [Ca^^ji (Nilius et al., 2003). As stated previously, rises in [Ca^^i can be mediated by 
release from endoplasmic stores and/or influx via membrane permeant channels. The 
molecular identity of these membrane permeant channels is still an area of intense research; 
however, TRP channels, and especially TRPV4, are believed to be major contributors.
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1.10.3 Shear induced dilatation
Shear stress arises due to the viseous drag of blood flowing over the endothelial surface. In 
many vascular beds changes in shear result in the release of vasodilatory factors (from the 
endothelium) and subsequent vasodilation; this phenomenon is termed ‘flow-induced 
dilation’ (Busse & Fleming, 2003). Vasodilatation is preceded by an increase in endothelial 
[Ca^’^ Ji. Accumulating evidence supports a critical role for meehanosensitive TRPV4 
channels in sensing and initiating the vasodilatory response to changes in flow by increasing 
Ca^  ^influx in cultured endothelial cells (Mendoza et al., 2009; Ma et al., 2010) and mediating 
dilatation in several isolated blood vessels (Kohler et al., 2006; Mendoza et al., 2009; Ma et 
al., 2010; Bagher et al., 2012; Bubolz et al., 2012; Hartmannsgruber et al., 2007). Of the three 
major vasodilatory mechanisms, EDHF and NO are the most important with regard to flow- 
induced dilation in response to TRPV4 activation, with a relatively small contribution -  if 
any -  provided by PGH in the vessels studied. Importantly, the relative contributions of 
EDHF and NO differ between species and vascular bed as discussed below.
In isolated rat carotid arteries, flow-mediated vasodilatation is attenuated by pharmacological 
inhibition of either TRPV4 or NO, suggesting that TRPV4-mediated NO release is critical to 
this process in this vessel (Kohler et al., 2006). Interestingly, in isolated mouse carotid 
arteries, flow-mediated dilatation appears to be mediated by both NO and EDHF pathways; 
however, the reported relative contributions range from approximately equal 
(Hartmannsgruber et al., 2007) to entirely EDHF-mediated (Loot et al., 2008). Moreover, the 
relative contribution of TRPV4 to flow-induced dilatation in the mouse carotid artery has 
been reported as partial in one study (Loot et al., 2008) but complete in another 
(Hartmannsgruber et al., 2007). The reasons for these discrepancies between studies remain 
to be determined; however, methodological differences with respect to the relative viscosity
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of the perfusate have been touted as a potential meehanism (Loot et ah, 2008). In all three 
studies, pharmacologieal inhibition of COX did not abrogate the vasodilatory response, 
strongly indicating that PGI2 is not required for flow-mediated dilatation in this conduit 
artery.
TRPV4 also mediates flow-induced dilation in resistance arteries. Kohler et al, demonstrated 
that in the arteria gracilis, shear stress induced a more pronounced vasodilatory response 
(73% of maximum vasodilation) than in carotid arteries (15% of maximum vasodilation). 
Similar to the carotid artery (also investigated in the study), the dilatory effect was NO- 
dependent (Kohler et al., 2006). In mouse mesenteric arteries, flow-induced dilation is 
mediated by both NO and EDHF pathways and activation of these pathways is significantly 
impaired in vessels obtained from trpv4-/~ mice (Mendoza et al., 2009). A graded 
vasodilatory response to increases in luminal pressure was also demonstrated in human 
carotid arteries. This response was attenuated by both pharmacological inhibition and gene 
knockdown of TRPV4. Interestingly, release of mitoehondrial-derived hydrogen peroxide, a 
putative EDHF, was highlighted as the meehanism responsible for this response (Bubolz et 
al., 2 0 1 2 ).
In a recent report, TRPV4 activation was demonstrated in response to low intravaseular 
pressure (~5 mmHg) in rat eremaster arterioles (Bagher et al., 2012). Here, decreased 
intraluminal pressure increased the number of Ca^^ sparklets (discrete Ca^^ influx events), in 
a TRPV4-dependent manner, which in turn activated adjacent IKca channels, causing smooth 
muscle hyperpolarization and subsequent vasodilatation. Although this finding is somewhat 
at odds with previous studies it suggests that TRPV4 is meehanosensitive to both high and 
low intraluminal pressures.
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Mechanistic analysis has revealed an important role for PLA2 and its downstream metabolites 
in TRPV4-mediated dilatation in response to shear stress. Pharmacologieal inhibition of 
PLA2 with arachidonyl trifluoromethyl ketone (AACOCF3) attenuated flow-induced 
dilatation in mouse and rat carotid arteries (Hartmannsgruber et al., 2007; Kohler et al., 
2006). Moreover, Loot et al., demonstrated that flow-induced EDHF-mediated dilatation in 
mouse carotid arteries was attenuated by the cytochrome P450 epoxygenase inhibitor N- 
(methylsulfonyl)-2-(2-propynyloxy)-benzenehexanamide (MS-PPOH). The inhibitory 
response to MS-PPOH was similar to pharmacological inhibition by ruthenium red and 
genetic deletion of TRPV4. Interestingly, eo-treatment with ruthenium red and MS-PPOH 
had no cumulative effect (Loot et al., 2008). These studies indicate that TRPV4 activation 
and EET generation are involved in flow-induced vasodilatation and are consistent with 
studies in isolated endothelial cells (Vriens et al., 2005). In contrast, PLA2 inhibition did not 
affect low-pressure induced Ca^ "^  sparklet generation in eremaster arterioles; however, PEC 
inhibition completely ablated this response (Bagher et al., 2012). This finding implies that 
low and high pressure (shear or flow) -induced TRPV4 activation may be mediated by 
distinct phospholipase isoforms and pathways.
Collectively these findings demonstrate that TRPV4 activation in mammals is a conserved 
mechanism responsible for transducing mechanical stimuli into endothelial calcium transients 
and subsequent vasodilatation. It should be noted that TRPV4 expressed on vascular smooth 
muscle cells is also functional and can mediate vasodilation of cerebral (Earley et al., 2005) 
and mesenteric arteries (Earley et al., 2009). Meehanistieally this response requires 
endothelial-derived EETs (specifically 11,12-EET) to activate myocyte TRPV4 which, via a 
series of subsequent events, hyperpolarizes the myocyte via activation of BKca channels, 
resulting in vasodilatation (Earley et a l, 2005).
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1.10.4 Agonist-induced dilatation
Pharmacological TRPV4 activation induces robust vasodilatory responses in mouse and rat 
aortae (Willette et al., 2008), mouse carotid arteries (Loot et al., 2008; Hartmannsgruber et 
al., 2007), rat carotid arteries (Kohler et al., 2006), human coronary arterioles (Bubolz et al., 
2012), mouse mesenteric arteries (Mendoza et al., 2009; Sonkusare et al., 2012) and rat 
gracilis muscle arterioles (Kohler et al., 2006). These responses are absent in trpv4-/~ arteries 
(Hartmannsgruber et al., 2007; Mendoza et al., 2009; Loot et al., 2008), following pre­
treatment with pharmacological inhibitors of TRPV4 (Sonkusare et al., 2012; Willette et al., 
2008; Kohler et al., 2006; Mendoza et al., 2009) or in endothelium denuded vessels (Willette 
et al., 2008; Mendoza et al., 2009; Bubolz et al., 2012), indicating that vasodilatation is 
contingent upon an increase in endothelial intracellular calcium via TRPV4 activation. 
Recent investigations have revealed that pharmacological activation of TRPV4 with 
GSK1016790A recruits previously quiescent TRPV4 channels into clusters within the 
endothelium, wherein activation of only 3-8 channels per cell is sufficient to evoke maximal 
agonist responses, while the remaining channels remain silent (Sonkusare et al., 2012; 
Sullivan et al., 2012). These studies highlight the fact that profound pharmacodynamic effects 
can be elicited following activation of incredibly small numbers of TRPV4 channels in the 
endothelium.
The vasodilatory pathways responsible for agonist-induced TRPV4 activation vary between 
vessels. As a general rule, the relative contributions of EDHF and NO appear to be inversely- 
and directly- proportional to vessel diameter, respectively (Hwa et al., 1994). 
GSK1016790A-mediated dilatation was completely attenuated by pharmacological inhibition 
of NOS with Nm-Nitro-L-arginine methyl ester (L-NAME) or genetic deletion of cNOS in rat 
and mouse aorta (Willette et al., 2008). In the carotid artery 4a-PDD-indueed dilatation
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varies from completely NO-dependent in the rat (Kohler et ah, 2006), to roughly 50% NO- 
and 50% EDHF-dependent in the mouse (Hartmannsgruber et ah, 2007). This difference is 
also apparent in the mesenteric artery where one study revealed that GSKl 016790A-indueed 
dilatation is mediated by a combination of NO (-60%) and EDHF (-40%) (Mendoza et ah, 
2009), whereas a second study showed it was completely EDEOF-dependent (Sonkusare et ah, 
2012). These eontradicatory findings might be explained by the fact that Sonkusare utilized 
smaller diameter (100pm) mesenteric artery branches than Mendoza (-200pm) to conduct 
studies. In contrast, 4a-PDD-evoked dilatations were completely EDHF-mediated in the 
arteria gracilis (Kohler et ah, 2006). Interestingly, in this same vessel TRPV4-mediated 
shear-induced vasodilatation was devoid of EDHF activation. This suggests that the mode of 
TRPV4 activation (i.e. mechanical vs. pharmacological) can influence the downsteam 
vasodilatory pathway engaged.
1.10.5 TRPV4 vascular responses in vivo
The studies mentioned hitherto have evaluated TRPV4 vascular responses in vitro, either 
using cultured cells or in isolated vessels profiled ex vivo. Collectively these studies have 
demonstrated an important role for the channel in modulating vascular reactivity by 
facilitating vasodilatation. Pharmacological activation of TRPV4 in vivo promotes a robust 
depressor response and marked hypotension (Gao et ah, 2009, 2010a, 2010b; Thomeloe et 
ah, 2012; Willette et ah, 2008; Zhang et ah, 2011), which is absent in trpv4-/~ mice (Willette 
et ah, 2008; Zhang et ah, 2011) and is attenuated by TRPV4 antagonists (Thorneloe et ah, 
2012; Gao et ah, 2009; Gao & Wang, 2010b). Mechanistically, Gao and colleagues 
demonstrated that the depressor response to 4a-PDD was largely (>50%) EDHF driven (Gao 
& Wang 2010a; 2010b); whether this applies to GSK 1016790A-induced hypotension is 
uncertain, although it is likely that the effect of GSK1016790A is predominately attributable
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to increased vascular permeability (Willette et al., 2008). Given the pronounced 
hemodynamic effects of TRPV4 activation it is curious that trpv4'^' mice are phenotypieally 
normotensive (Earley et al., 2009; Willette et al., 2008; Zhang et al., 2009); moreover, acute 
(1 hour infusion) and chronic (7 day) pharmacological inhibition of TRPV4 with 
GSK2193874 does not alter blood pressure (Thomeloe et al., 2012). Thus, under basal 
conditions TRPV4 may play a limited role in the regulation of blood pressure. Conversely, 
under pathological conditions, such as experimentally-induced hypertension, TRPV4 
activation appears to be a critical mechanism that eounter-regulates blood pressure elevation 
(Earley et al., 2009; Gao & Wang 2010b). It remains to be determined whether TRPV4 
expression and/or activity are similarly regulated in human hypertensive patients.
1.11 TRPV4 and endothelium permeability
In addition to regulating vascular tone, the endothelium is also critically involved in the 
regulation of vascular permeability. Under basal conditions vascular permeability is typically 
low, although. Starling forces (i.e. the balance of fluid flux across the capillary) do permit a 
net efflux of fluid into the interstitial space. This interstitial fluid forms an important matrix 
that nourishes cells whilst permitting the removal of cellular waste products. Under 
pathological conditions endothelial permeability can be increased, resulting in the formation 
of tissue edema. On a macroscopic level, enhanced vascular permeability depends on 
perturbations in endothelial adhesive forces, either disruption of eell-eell connections 
(resulting in gap formation) and/or disruption of the tethering forces between the endothelium 
and the underlying matrix (Mehta & Malik, 2006). A critical facilitator of these processes is 
increased endothelial intracellular calcium (reviewed by Tiruppathi, et al., 2002). In the 
pulmonary mierovasculature, accumulating evidence supports a vital role for TRPV4- 
mediated calcium influx in regulating endothelial permeability, specifically in the alveolar
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septum. Studies using isolated lung preparations as well as in vivo studies demonstrate that 
TRPV4 activation causes fluid passage fi'om the vascular compartment into the alveolar space 
in response to mechanical (increased pulmonary vascular pressure or increased pulmonary 
inflation pressure) and agonist gating (by 4a-PDD, GSK1016790, 5,6-EET, 14,15-EET ), in a 
ealeium-dependent manner (Alvarez et al., 2006; Hamanaka et al., 2007; Jian et al., 2008; 
Thomeloe et al., 2012; Willette et al., 2008; Wu et al., 2009; Yin et al., 2008). Importantly, 
TRPV4-mediated pulmonary edema formation is attenuated pharmacologically using 
ruthenium red (Alvarez et al., 2006; Hamanaka et al., 2007; Jian et al., 2008; Wu et al., 2009) 
and GSK2193874 (Thorneloe et al., 2012; Huh et al., 2012) and by genetic deletion of the 
channel (Alvarez et al., 2006; Hamanaka et al., 2007; Jian et al., 2008; Wu et al., 2009; Yin et 
al., 2008). Ultrastruetural analysis of the rat lung revealed that enhanced permeability results 
from disruption of eell-matrix tethering (Alvarez et al., 2006), an effect that is recapitulated 
in vitro using the TRPV4 agonist GSK1016790A (Willette et al., 2008; Thomeloe et al., 
2012). However, the cellular/molecular mechanisms regulating the endothelial detachment 
phenotype remain elusive.
1.12 Clinical relevance of systemic vasodilation and pulmonary edema
The hemodynamic and vascular permeability changes associated with pharmacological 
TRPV4 activation mimic, in many ways, the clinical condition, circulatory shock, or simply 
shock. Shock is a life-threatening condition where tissue perfusion is insuffleient to support 
cellular oxygenation in multiple organ systems, which ultimately results in circulatory failure 
and death, if unresolved (Vincent & De Backer, 2013). Shock can be subdivided into four 
classes based on distinct pathophysiological mechanisms, these include: 1) cardiogenic, 2 ) 
distributive, 3) hypovolemic and 4) obstructive (Vincent et al., 2012). Of these, cardiogenic 
(16%) and distributive shock -  which is generally attributed to sepsis (62% of all cases) -
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predominate (Vincent & De Backer, 2013). With respect to cardiogenic shock, the underlying 
cause is a dysfunction in the pumping capacity of the heart, most often the result of an acute 
myocardial infarction; although a variety of additional cardiac pathologies can also mediate 
the response, e.g. cardiomyopathy, mitral regurgitation, myocarditis, free-wall rupture (a 
more exhaustive list can be found in Patel & Hollenberg, 2011). This cardiac dysfunction 
results in a reduction in cardiac output, the clinical manifestation of which is a reduction in 
systemic blood pressure, or hypotension (Vincent & De Backer, 2013). Despite the decrease 
in systemic blood pressure, there is a concurrent increase in pulmonary venous pressure. This 
is attributable to a larger volume of blood being retained in the ventricle, due to the reduced 
stroke volume, that leads to an increase in end-diastolie pressure which is subsequently 
transduced, in a backwards manner, through the left atrium to the pulmonary vein. The 
increased hydrostatic pressure in the pulmonary vasculature favors the movement of vascular 
fluid into the interstitial and alveolar spaces of the lung, causing pulmonary edema (Clark & 
Cleland, 2013; Maelver et al., 2013). This sequence of events is also a characteristic feature 
of patients with congestive heart failure (Clark & Cleland, 2013). At a molecular level, 
TRPV4 is believed to be an important contributor to the enhanced vascular permeability 
response for two reasons; 1) it is meehanosensitive and gated in response to enhance vascular 
pressure; and 2 ) its activation, as noted previously, elicits morphological changes in the 
endothelium, leading to barrier disruption (Alvarez et al., 2006; Hamanaka et al., 2007; Jian 
et al., 2008; Thomeloe et al., 2012; Willette et al., 2008; Wu et al., 2009; Yin et al., 2008). 
The importance of TRPV4 in mediating the pathophysiological effects associated with 
cardiogenic shock was recently investigated by Thomeloe et al. (2012) using two pre-elinieal 
models, characterized by elevated left ventricular diastolic pressures and pulmonary edema. 
These included, transaortie banding in rats and myocardial infarction, due to permanent 
ligation of the left anterior ascending coronary artery, in mice. Pharmacological inhibition of
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TRPV4, with GSK2193874, significantly attenuated the formation of pulmonary edema, and 
moreover, promoted the resolution of pre-established edema (Thorneloe et al., 2012). These 
findings highlighted the potential therapeutic value of utilizing TRPV4 inhibitors in patients 
with pathological disorders where pulmonary edema is evident.
1.13 Aims of this study
This literature review highlights an accumulating body of evidence supporting an important 
role for TRPV4 channels, especially those present on endothelial cells, in regulating two 
critical components of vascular function, namely regulation of vascular tone and vascular 
permeability. TRPV4 has been demonstrated to modulate vascular tone by activating 
endothelial-dependent vasodilatory pathways mediated by NO and EDHF. Yet evidence 
linking TRPV4 to endothelial-derived vasoregulatory prostaglandins, such as prostacyclin 
(PGI2), is lacking, despite reports showing that TRPV4 can elicit prostaglandin release from 
non-vaseular cell types (including chondrocytes and urothelial cells; Phan et al., 2009; Xu et 
al., 2009, respectively). Furthermore, numerous reports highlight a clear coupling of TRPV4 
and PLA2 (an upstream regulator of prostaglandin production) in endothelial and non- 
endothelial cells, further supporting the possibility that TRPV4 is potentially involved in 
prostanoid signaling. Consequently, a major aim of this thesis was to establish whether 
TRPV4 is able to induce or modulate prostaglandin release from endothelial cells.
As noted above, TRPV4 activation enhances endothelial permeability. This response is 
particularly apparent in endothelia lining the alveolar region in the lung. The mechanisms 
responsible for this permeability response downstream of TRPV4-mediated calcium influx 
are not fully established, although endothelial detachment/disruption is considered an
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important cellular meehanism. As such, a second aim of this study was to identify the 
mechanism(s) governing TRPV4-mediated endothelial disruption.
An enhanced understanding of the role TRPV4 plays in the two processes, endothelium- 
dependent vasodilation and vascular permeability, may have implications for the treatment of 
vascular disorders such as hypertension and pulmonary edema associated with congestive 
heart failure.
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Chapter 2
TRPV4 activation induces prostaglandin release 
from endothelial cells in vitro and in vivo
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2.1 Introduction
2.1.1 General Introduction
The endothelium is an important endocrine organ that controls a number of critical 
homeostatic functions including regulation of vascular tone, permeability and platelet 
coagulation. Meehanistieally, the endothelium performs many of these functions via the 
release of vasoactive substances including, but not limited to EDHF, endothelin, NO and 
prostanoids (Félétou & Vanhoutte, 2009). The latter of these agents mediate many profound 
effects on vascular function and encompass a group of cyclic lipid molecules comprised of 
the prostaglandins (e.g. PGE2, PGI2, etc) and thromboxane (TXA2). All prostanoids are 
derived from the 2 0  earbon-eontaining precursor, arachidonic acid, which is liberated from 
membrane phospholipids via activation of the enzyme phospholipase A2 (PLA2) -  in response 
to agonist stimulation (reviewed by Narumiya et al., 1999). Prostanoids are subsequently 
generated in a multi-step process; the rate limiting step requiring the activation of the enzyme 
prostaglandin-endoperoxide synthase (more commonly known as cyclooxygenase or COX). 
COX, which exists as two isozymes (COX-1, the constitutive isoform and COX-2, the 
inducible isoform), has two distinct activities: firstly, a eycloxygenase activity which 
catalyses the formation of prostaglandin G2 (PGG2) from arachidonic acid, and secondly, a 
peroxidase activity which reduces the hydroperoxide group of PGG2 to form prostaglandin 
H2, (PGH2; Narumiya et al., 1999). PGH2 forms the substrate for a number of prostanoid 
synthases (Kim, 2011). In vivo, there are 5 principal bioaetive prostanoids: PGD2, PGE2, 
PGp2a, PGI2, and TXA2. Of these, PGI2 and PGE2 are the predominant endothelial derived 
species; PGD2, PGp2a and TXA2 are largely produced by leukocytes, uterine tissue, and 
platelets, respectively (Rieeiotti & FitzGerald, 2011). Following synthesis, PGI2 and PGE2 
are released from the endothelium and exert their actions on neighboring smooth muscle cells 
by activating specific seven-transmembrane domain spanning G protein-coupled receptors
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(reviewed by Breyer & Bagdassarian, 2001). In the vasculature, prostanoid receptors EP2, 
EP4 (for PGE2) and IP (for PGI2) are coupled to adenylate eyelase, via Gs, which increases 
intracellular cAMP resulting in vasodilation (Narumiya et al., 1999).
A key driver of prostanoid synthesis is a sustained increase in endothelial calcium, which 
facilitates PLA2 activation (White & Martin, 1989). The molecular identities of the 
endothelial plasma membrane calcium permeable channels that permit this calcium response 
remain unresolved; however, transient receptor potential channels are leading candidates. 
Amongst the multiple transient receptor potential channels expressed by the endothelium, 
TRPV4 has been shown to play an important functional role. Numerous studies have 
demonstrated that TRPV4 exerts endothelium-dependent actions in a number of vascular 
beds in several species (Bubolz et al., 2012; Kohler et al., 2006; Loot et al., 2008; Mendoza et 
al., 2010; Thomeloe et al., 2012; Willette et al., 2008), where it has been implicated in the 
regulation of vascular permeability (Miyahara et al., 2008; Thomeloe et a l, 2012), 
angiogenesis (Troidl et al, 2010; Troidl et a l, 2009) and vascular tone (reviewed by Zhang & 
Gutterman, 2011). The importance of TRPV4 is highlighted in murine gene deletion studies 
where impaired vasodilatory responses in vitro are observed in response to TRPV4 agonists 
and shear stress (Mendoza et a l, 2010; Zhang et a l, 2009). It is clear that TRPV4 activation 
elicits endothelium-dependent vasorelaxation mediated by NO (Kohler et a l, 2006; Willette 
et a l, 2008; Zhang et a l, 2009; Mendoza et al, 2010) and via EDHF pathways (Kohler et a l, 
2006; Earley et a l, 2009; Zhang et al, 2009; Mendoza et a l, 2010). However, no studies, to 
date, have identified a role for TRPV4 in modulating prostaglandin production or prostanoid- 
mediated vasodilatation (Kohler et al, 2006; Loot et a l, 2008; Zhang et a l, 2009; Mendoza 
et a l, 2 0 1 0 ).
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2.1.2 Hypothesis
TRPV4 activation in endothelial cells mediates a calcium-dependent prostaglandin release 
which can modulate blood pressure.
2.1.3 Aim
The present study was designed to evaluate whether TRPV4 activation is able to mediate 
prostaglandin production in the endothelium. Human umbilical vein endothelial cells 
(HUVECs) were used as a model system for studying the potential involvement of TRPV4 in 
prostaglandin production based on their reported expression of the key prostanoid generating 
machinery i.e. PLA2 (Murakami et al., 1993), COX-1 and COX-2 (Camacho et al., 1998; 
Rirai et al., 1997), PGR and PGE2 synthases (Camacho et al., 1998; Camacho & Vila, 2000; 
Uracz et al., 2002), as well as TRPV4 (Loot et al., 2008; Rath et al., 2012). In vivo studies 
were used to profile the effect of pharmacological TRPV4 activation on circulating 
prostaglandin levels. Moreover, these studies were designed to examined the role of 
prostaglandins in TRPV4-mediated cardiovascular and pulmonary processes, i.e. hypotension 
and pulmonary edema formation (Thorneloe et al., 2012; Willette et al., 2008)
2.1.4 Objectives
1. To validate HUVECs as a model cell line for exploration of TRPV4 endothelial biology 
by confirming channel expression at the mRNA and protein level (using 
immunofluorescent staining).
2. To evaluate prostanoid release from HUVECs using selective pharmacological TRPV4 
activators
3. Also, to examine the effect of non-pharmacological TRPV4 activating stimuli e.g. 
hypotonicity
61
4. Should TRPV4 mediate prostanoid release, characterize the mechanism using 
pharmacological modulators of intracellular signaling pathways.
5. To examine prostanoid release, following TRPV4 activation, in non-endothelial cell 
type’s e.g. peripheral blood mononuclear cells.
6 . To assess prostaglandin levels following systemic activation of TRPV4 in vivo with 
GSK1016790A.
7. Evaluate the potential role of prostanoids in TRPV4-mediated hypotension and 
pulmonary edema responses.
8 . To profile the potential involvement of TRPV4 in modulating prostaglandin levels in 
Spontaneously Hypertensive Rats (SHR) in vivo.
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2.2 Methods
2.2.1 Pharmacological agents
GSK1016790A, GSK634775, GSK2193874 and GF109203X were synthesized at 
GlaxoSmithKline Pharmaceuticals. 4a-PDD, ethylene glycol tetraacetic acid (EGTA), 
indomethacin, PD98059, 1 -(5-Iodonaphthalene-1 -sulfonyl)-1 H-hexahydro-1,4-diazepine
hydrochloride (ML-7), L-NAME, apamin and charybdotoxin were all obtained from Sigma- 
Aldrich (St Louis, MO, USA). A23187, thapsigargin and cyclopiazonic acid were obtained 
from EMD Chemicals (Gibbstown, NJ, USA), Life Technologies (Grand Island, NY, USA), 
and Enzo Life Sciences (Farmingdale, NY, USA), respectively. The CPLA2 inhibitor, N- 
{(2S,4R)-4-(Biphenyl-2-ylmethyl-isobutyl-amino)-l-[2-(2,4-difluorobenzoyl)-benzoyl]- 
pyrrolidin-2-ylmethyl}-3-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)-phenyl]acrylamide, HCl, 
(cPLA2i) was obtained from EMD Millipore (Billerica, MA, USA). CAVITRON® 
cyclodextrins were obtained from ISP Pharmaceuticals (Wayne, NJ, USA).
2.2.2 Drug formulation
For in vitro evaluation of prostaglandin release (see 2.2.14) all compounds were dissolved in 
100% dimethyl sulphoxide (DMSG) sufficient to give a stock concentration of lOmM. 
Compounds were diluted, or serially diluted for concentration response studies, in 100% 
DMSG before addition to cell culture medium or buffer. The final concentration of DMSG 
under in vitro experimental conditions did not exceed 0 .2 % to ensure optimal cell health and 
prostaglandin assay performance; the latter of which is sensitive to organic solvents. For in 
vivo evaluation, both GSK1016790A and GSK2193874 were first suspended in 100% 
DMSG. The volume of drug was adjusted -  according to the mass of compound utilized -  by 
adding 29% volume/volume CAVITRGN® with gentle vortexing. The final percentage of 
DMSG (in the dosing solution) was 1% volume/volume. For the bolus dose model (see
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section 2.2.16) GSK2193874 was administered at loading doses of 0.1 and 0.3 mg kg"\ 
Details of the dosing regimen for GSK1016790A are contained in section 2.2.16. For the 
steady state dosing model (see section 2.2.16) a total dose of 0.1 mg kg"^  GSK1016790A was 
administered via the i.v. cannula. See section 2.2.16 for further details pertaining to the 
dosing regimen for GSK2193874. Indomethacin was suspended in 100% DMSO, the volume 
of drug was adjusted using PEG-200 sufficient obtained a final DMSO percent 
volume/volume of 1% for loading doses of 0.3, 1.0 and 3.0 mg kg'*. Apamin and 
charybdotoxin were both dissolved in distilled H2O and L-NAME was dissolved in 0.9% 
pharmaceutical grade saline sufficient to provide loading doses of 1 0 0  pg kg'* (apamin and 
charybdotoxin) and 1 0  mg kg'*, respectively.
2.2.3 Endothelial cell studies
Pooled donor HUVECs were obtained from Lonza (Walkersville, MD, USA) and cultured in 
a humidified atmosphere (5% CO2, 95% O2, 37°C) using endothelial cell basal medium- 2  
(EBM-2) containing 2% fetal bovine serum (FBS); hydrocortisone; human fibroblast growth 
factor; vascular endothelial growth factor; insulin-like growth factor; ascorbic acid; human 
epidermal growth factor; GA-1000 and heparin (Lonza). Pooled donors HUVECs, as opposed 
to single donor HUVECs, were selected to limit any bias with respect to donor age, race or 
gender. When the cells reached 70-80% confluence, culture media was aspirated and 
discarded. Residual serum and growth factors, that can inhibit cellular dissociation, were 
removed by washing cells with phosphate buffered saline (PBS). HUVECs were then 
incubated for 5 minutes with trypsin-EDTA (0.05%) to detach and passage cells. HUVECs 
were utilized at passages 2-9, as this, in conjunction with the defined endothelial growth 
media described above, ensures the cells maintain their endothelial morphology, proliferative
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capacity and phenotype (Bala et al., 2011). Cells were seeded into 24-well plates at a density 
of 1.0 X 10^  cells per well and incubated overnight.
HUVECs were serum deprived for 90 minutes in 450pL EBM-2 media -  to limit basal 
prostaglandin release and resynchronize the cells -  prior to 30 minute treatment with 
GSK1016790A, GSK634775 or 4a-PDD (TRPV4 activators) at 37°C, or were pre-incubated 
for 15 minutes with selective inhibitors of: TRPV4 (GSK2193874); cytosolic phospholipase 
A] (cPLA2i); cycloxygenase (indomethacin); protein kinase C (GF109203X); mitogen- 
activated protein kinase kinase (MEK, PD98059) and myosin light chain kinase (MLCK, 
ML-7) prior to stimulation with GSK1016790A. For agonist studies, compounds were diluted 
in culture media sufficient to obtain a drug concentration 1 0 -times the desired final 
concentration. 50pL of this solution was added to the cells resulting in a 1:10 dilution into the 
well. For pre-incubation studies, 50pL of a lOX solution of inhibitor was added to the cells, 
prior to the addition of 55 pL of a lOX solution of agonist. To evaluate calcium dependence 
HUVECs were pre-incubated for 10 minutes with 1) calcium ATPase inhibitors (thapsigargin 
or cyclopiazonic acid) to deplete endoplasmic calcium stores or 2) medium containing 2mM 
EGTA to chelate extracellular calcium. To evaluate the effect of osmolality, HUVECs were 
treated with GSK1016790A or vehicle (as above) in EBM-2 media at 270 or 192 milli- 
osmolar (mOsm) (see 2.2.9 for osmolality determination). Following treatment, cellular 
supernatants were harvested, briefiy centrifuged (400 x g) to remove particulates and utilized 
for prostaglandin measurements (see 2.2.14).
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2.2.4 Culture of HEK293 cells and TRPV4-overexpressing HEK293 cells
All culture reagents, unless otherwise stated, were obtained from Life Technologies. Non­
transfected, wild-type HEK293 cells were obtained from the American Type Culture 
Collection (Manassas, VA, USA).
WT-HEK293 and TRPV4-HEK293 (see section 2.2.5 for details of cell line generation) cells 
were incubated at 37°C in a humidified atmosphere containing 5% CO2 9 5 % 0 2  in media 
containing 1:1 Dulbecco’s minimum essential media/F-12 (Ham’s) supplemented with 2mM 
L-glutamine, 10% FBS and 100 lU penicillin lOOmg.mf* streptomycin (WT-HEK293) or 
Eagle’s minimum essential medium supplemented with 10% FBS and 0.4 mg.ml * geneticin 
G418 (TRPV4-HEK293). Cells were passed, or used for assay when reaching 90% 
confluency.
2.2.5 Generation of TRPV4 stably overexpressing HEK293 cells.
It should be noted that HEK293 cells, stably overexpresssing TRPV4, were generated at GSK 
by the Enzymology and Mechanistic Pharmacology group, not by the author. In brief, full 
length human TRPV4 cDNA was inserted into a pcDNA3.1 expression vector containing a 
CMV promoter (to drive TRPV4 gene expression) and a G418 resistance gene, under the 
control of an SV40 promoter. The correct TRPV4 DNA insert sequence was confirmed using 
a combination of restriction enzyme digestion and full-length sequence analysis 
methodologies (not shown). Wild-type HEK293 cells were grown to 90% confluency in 6  cm 
Petri dishes in complete growth media: DMEM-F12 with 10% FBS. 1 hour prior to 
transfection, growth media was removed and replaced with 5 mis serum-free basal DMEM- 
FI2. TRPV4 plasmid DNA (8 pg) was added to 500pL Opti-MEM (Invitrogen). In a separate 
tube, 20pL of Lipofectamine™ 2000 (Invitrogen) was also added to 500pL Opti-MEM and
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allowed to incubate at room temperature for 5 minutes. Diluted DNA and Lipofectamine 
were combined and incubated for 20 minutes at room temperature. The DNAiLipofectamine 
complex (1:3 ratio) was carefully added to the cells in a drop-wise manner. Cells were then 
incubated for 18 hours at 37°C before transfection media was removed and replaced with 
complete media. 24 hours post transfection cells were passed into fresh Petri dishes, at a split 
ratio of 1:10, in complete media. 400pg/ml G418 (Invitrogen) was added to the media 24 
hours after seeding to initiate selection. Cells were expanded for a further 3 days before 
dissociation into fresh 6  cm Petri dishes. 50 single cells were subsequently isolated; each cell 
was expanded, initially in the well of a 96-well plate, then subsequently in larger volume 
plates.
Clones were triaged according to their response to the pharmacological TRPV4 agonists, 4a- 
PDD and GSK634775, in a calcium influx assay (see section 3.2.3 for assay details). The 
response of each clone was compared to: 1) wild-type HEK293 cells; and 2) HEK293 cells 
transiently overexpressing human TRPV4. Clone 27, hereafter referred to as TRPV4- 
HEK293, was selected based on its electrophyiological profile matching published reports 
and its expression of TRPV4 (Voets et al., 2002; Watanabe, Davis, et al., 2002). The latter 
being characterized by both western blotting and immunohistochemistry (data not shown).
2.2.6 Whole blood studies
Human peripheral blood was obtained via venopuncture from consenting healthy donors in 
accordance with GSK and Institutional Review Board guidelines (refer to the Appendix for 
GSK Blood Donor Informed Consent document) in 10 ml sodium heparin (150 units) lined 
vacutainers (BD Bioscience, Franklin Lakes, NJ USA). Donors were requested to abstain
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from ingestion of non-steroidal anti-inflammatory drugs 24 hours prior to the blood draw. 
Whole blood was either: 1) utilized for peripheral blood mononuclear cell (PBMC) isolation 
(see sections 2.2.7 and 2.2.8); or 2) treated with GSK1016790A or A23187. With respect to 
the later, 2.5 mis whole blood was added to a 15 ml conical tube. 2.5pL of a lOOOX solution 
of GSK1016790A or A23187 in DMSO was added to the blood and triturated with a p i000 
pipette. Samples were incubated with compounds for 30 or 120 minutes at 37°C in 5% CO2. 
Following treatment plasma was isolated by centrifugation (1500 x g, 10 minutes 4°C) and 
utilized for prostaglandin analysis.
2.2.7 Separation of PBMC from peripheral blood
PBMC were isolated from peripheral blood using a standard density gradient centrifugation 
procedure under sterile conditions. Briefly, peripheral blood was diluted in sterile PBS (1 part 
blood to 4 parts PBS without calcium or magnesium). 35 mis was carefully overlaid onto 15 
mis Ficoll-Paque PLUS (GE Healthcare) in a 50 ml conical tube. The blood/Ficoll-containing 
tube was centrifuged at 400 x g (no brake) for 40 minutes at 18-20°C. Following 
centrifiigation the upper layer, containing plasma, was aspirated then discarded, leaving the 
mononuclear cell layer (lymphocytes and monocytes). Mononuclear cells were carefully 
aspirated and dispensed into a fresh 50 ml conical tube; excess Ficoll-Paque PLUS was 
removed by centrifuging the cells in sterile PBS (400 x g for 10 minutes), the volume 
adjusted to 50 mis, for a total of two washes. Following the final wash step, the cell pellet, 
containing PBMCs was resuspended in RLT lysis buffer (Qiagen, Valencia, CA, USA). RNA 
was isolated as described below (see 2.2.9).
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2.2.8 PBMC characterization using flow cytometry
Flow cytometry was employed to characterize PBMC isolation using the Ficoll-Paque PLUS 
protocol. This method relies on the fact that different cellular fractions in peripheral blood 
exhibit differing cellular morphology characteristics that can be profiled using the forward 
(FSC) and side scatter (SSC) channels on a flow cytometer. Essentially, monocytic cells (i.e. 
PBMCs) are less granular than neutrophils (i.e. granulocytes) and demonstrate a lower side 
scatter profile; this characteristic is used to characterize the isolation procedure.
Firstly, a 200|LiL aliquot of peripheral blood was taken prior to PBS dilution and subsequent 
Ficoll-Paque centrifugation (see section 2.2.6). Erythrocytes, which can disrupt flow 
cytometric analysis, were removed using the BD Pharm Lyse^M (BD Bioscience) lysing 
solution. 2.0 ml of lysing solution, pre-warmed to room temperature, was added to the FACS 
tube containing whole blood and gently vortexed. The blood/lysis solution was incubated at 
room temperature, in the absence of light, for 15 minutes. Following lysis, the tube was 
centrifuged (200 x g, 5 minutes at 4®C) and the supernatant was carefully aspirated, not to 
disturb the pellet. Excess lysis buffer was removed by centrifugation (200 x g for 5 minutes at 
4°C) in 2 mis FACS buffer (PBS containing 2% fetal bovine serum and 2mM EGTA). The 
supernatant was again carefully aspirated and the pellet was resuspended in 0.5 ml of FACS 
buffer and stored on ice prior to flow cytometric analysis. In addition, a lOOpL aliquot of 
freshly isolated PBMCs was taken and washed, by centrifugation (200 x g for 5 minutes at 
4®C), in 2 mis FACS buffer and subsequently resuspended in 0.5 mis of fresh FACS buffer.
The FSC and SSC characteristics of the prepared cells (i.e. peripheral blood minus 
erythrocytes, and PBMCs) were profiled using the FACS Canto II flow cytometer (BD 
Bioscience). The analysis parameters were determined by investigating the optimal cytometer 
settings that would enable the ready detection of all peripheral blood cell populations (i.e.
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granulocytes and PBMCs) in the FSC vs. SSC gate. For the dataset indicated below (see 
Figure 2.1) the following parameters were employed: forward scatter threshold = 20,000 (to 
limit events attributable to cellular debris); FSC and SSC voltages were fixed at 140 and 400, 
respectively. The cytometer settings for analysis of peripheral blood and PBMCs, were the 
same except 10,000 events were obtained for whole blood, whereas, only 5000 events were 
collected for PBMCs due to the diminished cell numbers. Data analysis was carried out using 
FACSDiva software version 6.0 (BD BioScience).
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Figure 2.1: Light scatter profiles of human peripheral blood cells (i.e. whole blood, left panel) 
and PBMCs (right panel) isolated from the same donor using the Ficoll-Paque method. 
Unfractionated peripheral blood (i.e. whole blood) harbors both granulocytes and PBMCs 
(indicated), whereas the levels of the former are greatly diminished, or absent, following 
PBMC isolation with Ficoll-Paque. Each dot represents a single event. The profiles from a 
typical characterization experiment are shown.
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2.2.9 Osmolality determination.
Media osmolarity was determined with a freezing point osmometer (Multi-Osmette 2430; 
Precision Systems, Natick, MA, USA). The osmometer was calibrated within the 0 -  2000 
milli-osmolar (mOsm) range using a 6 -point standard curve. The standard curve, consisting 
of 100, 300, 500, 1000, 1500 & 2000 mOsm solutions, was prepared, in duplicate, using the 
manufacturers pre-made calibration standards, i.e. solutions with a verified solute 
concentration (see table 3 for calibration results). Once calibrated, the osmolality of the 
endothelial medium (EBM-2) was profiled by carefully adding 50p,l of prepared media to a 
fresh osmometer sample tube. The Multi-Osmette osmometer calculates the solution 
osmolarity directly, therefore negating the need to calculate the osmolality of the unknown 
solution from the calibration curve. Basal EBM-2 media osmolarity was found to be 270 
mOsm, which represents the iso-osmotic set-point. Hypo-osmotic medium was prepared by 
adding distilled water to iso-osmotic EBM-2 medium (ratio 70% EBM-2: 30% H2O). The 
osmolality of this solution was found to be 192 mOsm.
Table 3. Osmometer calibration results
standard # Expected Osmolality (mOsm) Determined Osmo1alit\' (mOsm) Average Determined Osmolality (mOsm)
1 100 100
2 100 100 100
3 300 300
4 300 301 300.5
5 500 500
6 500 499 499.5
7 1000 986
8 1000 997 991.5
9 1500 1500
10 1500 1509 1504.5
11 2000 2000
12 2000 2000 2000
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2.2.10 RNA isolation and cDNA synthesis
Total RNA was isolated from WT-HEK293 cells, TRPV4-HEK293 cells, HUVECs and 
PBMCs using the RNeasy Mini Kit spin technology procedure (Qiagen), according to the 
manufacturer’s instructions. All steps were carried out at room temperature. An aliquot (~1 x 
10^  cells) of each cell type was lysed, following cell pelleting by centrifugation (5 minutes, 
300 X g), in 350pL of guanidine isothiocyanate containing Buffer RLT (supplemented with 
1% v/v P-mercaptoethanol). An equal volume of 70% ethanol was added to the lysate to 
ensure optimal RNA binding to the silica-gel-containing RNeasy spin column membrane. A 
15 second centrifugation (8000 x g) step was employed to apply the sample to the RNeasy 
spin column membrane. Residual genomic DNA, which can interfere with downstream Real 
Time PCR analysis, was removed by performing a 15 minute on-column DNase digestion 
with DNase I (Qiagen). DNase and other non-RNA contaminants were removed by washing 
the membrane by centrifugation (15 seconds, 8000 x g) with 500pl of Buffer RPE. The 
washing procedure was performed in duplicate. Following washing, RNA was eluted by 
adding 30pl RNase-ffee water directly to the spin column membrane and centrifuging for 15 
seconds (8000 x g). The eluate was reapplied to the membrane and centrifuged, as before, to 
maximize RNA yield.
The NanoDrop 2000 spectrophotometer (NanoDrop, Wilmington, DE, USA) was used to 
quantify RNA yield. 0.5pg of total RNA was used to synthesize cDNA using the High 
Capacity cDNA reverse transcription kit (Applied Biosystems, Carlsbad, CA, USA) 
according to the manufacturer’s instructions. Briefly, a 2X reverse transcription master mix 
was prepared by combining: 2.0pl lOX RT Buffer; 0.8jul 25X dNTP Mix (100 mM); 2.0pl 
lOX RT Random Primers; l.Opl MultiScribe™ Reverse Transcriptase; l.Opl RNase Inhibitor; 
3.2pl Nuclease-free H2O per reaction. lOpL of the 2X reverse transcription master mix was
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added per well of a 96-well MicroAmp™ Optical reaction plate (Applied Biosystems). To 
this, lOpL of RNA sample was added and mixed by pipetting. The plate was sealed with 
MircoAmp™ Optical caps, to ensure no loss of sample, and loaded into a GeneAmp® PCR 
system 9700 (Perkin Elmer, Waltham, MA) thermal cycler. The reaction conditions were: 10 
minutes at 25°C, 2 hours at 37°C for a reaction volume of 20pL. 2.5pL of cDNA was used 
for real-time PCR quantification.
2.2.11 Real time PCR analysis
Gene expression levels were quantified using the ABI Prism 7900 Sequence detection system 
(Applied Biosystems). A lOpL reaction containing 5pL of 2X Universal PCR Master Mix, 
2.5pL cDNA and 2.5pL of 4X Taqman® Asssay-on-Demand™ primer/probe sets (Applied 
Biosystems) was conducted in 384-well MicroAmp™ Optical reaction plates (Applied 
Biosystems). TRPV4 expression was evaluated using the exon spanning assay 
Hs01099348_ml (amplicon length = 65 base pairs. Ref Seq: NM 021625.4). To confirm 
equal loading of cDNA into reverse transcription reactions, GAPDH mRNA was amplified 
(Hs99999905_ml, amplicon length = 122 base pairs. Ref Seq: NM 002046.4). The specific 
primer/probe oligonucleotide sequence for both TRPV4 and GAPDH are proprietary; 
however, the amplicon location for both assays is available on the manufacturers’ website 
fhttps://bioinfo.appliedbiosvstems.com/genome-database/gene-expression.htmB. TRPV4 is 
reported to span the 3*^  ^and 4^  ^exon boundaries and GAPDH the 2"  ^and 3"^  ^exon boundaries. 
Polymerase chain reaction conditions were 50 °C for 2 minutes, 95 °C for 10 minutes, 
followed by 40 cycles of 95 °C for 15 seconds and 60 °C for 1 minute. All data extracted was 
in the exponential phase of the reaction, as amplification is 1 0 0 % efficient in this phase, i.e. 
there is a doubling of product (amplicon) with each reaction cycle. Data was analyzed using 
SDS 2.2.3 software (Applied Biosystems). The delta delta Comparative Threshold (CT)
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method (2 ^ ^ )  was used to quantify the fold change between the samples (see formula 
below). Expression was normalized to GAPDH, and levels of gene expression were made 
relative to PBMC gene expression levels.
Formula
A ACT = (CT(target,untreated) -  CT(ref untreated)) -  (CT (target,treated) -  CT(ref,treated)) 
where
CT(target,untreated) = Mean CT value for TRPV4 in PBMCs*
CT(ref,untreated) = Mean CT value for GAPDH in PBMCs
CT(target,treated) = CT value of TRPV4 in each cell type (i.e. HUVEC, HEK-293, TRPV4- 
HEK-293 and individual PBMC samples).
CT(ref,treated) = CT value of GAPDH in each cell type (as above)
The ratio of TRPV4 in PBMCs to other cell types was calculated by taking 2^^^^.
*PBMCs acted as the reference cell type to which all other cell types were compared. In 
essence, they acted as the “untreated” control; however, it is important to note that none of 
the cells were actually treated. All CT values reflect basal expression.
2.2.12 Immunofluorescent staining
WT-HEK293, TRPV4-HEK293, and HUVECs were seeded onto BD BioCoat™ poly-D- 
lysine coated 96-well plates (BD Biosciences) at a density of 3x10^ cells per well in 200pL 
media and allowed to adhere overnight at 37°C (5% CO2, 95% O2). The adhesivity of 
HEK293 cells to plastic, i.e. non-coated wells, is very weak; therefore substrate (poly-D-
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lysine is most optimal) is required to ensure sufficient numbers of cells remain attached 
following the procedure described hereafter. Following seeding, cells were washed with 
200pL PBS then fixed in lOOpL of 4% paraformaldehyde (Electron Microscopy Science, 
Hatfield, PA, USA) for 15 minutes at room temperature. Fixed cells were washed twice in 
PBS then permeabilised with lOOpL 0.1% Triton-X 100 in blocking buffer (70% SuperBlock 
(Thermo Scientific), 30% PBS, 0.05% Tween20) for 1 hour at room temperature then 
incubated overnight, at 4°C, with lOOpL primary antibodies in blocking buffer (see Table 3). 
After washing (wash buffer: 70% PBS, 30% Superblock) cells were incubated with Alexa- 
Fluor 488 conjugated secondary antibody (Life Technologies, 1:250 dilution) for one hour at 
room temperature. Nuclei were counterstained with Hoechst 33342 (1:5000). For all 
experiments isotype controls (rabbit IgG or mouse IgG2b) were used to confirm specificity. It 
should be noted that four distinct anti-TRPV4 antibodies were profiled (see Table 4). The 
staining profile of three of these antibodies is discussed in section 2.3.1 (also refer to Figure 
2.3). The C-terminal antibody from Alomone demonstrated an intense nuclear staining 
pattern, which contrasted to the other antibodies profiled (data not shown).
Table 4. Antibody Characteristics
Antibody (clone) Host Isotype Terminus (amino acids) Source Dilution
Human TRPV4(N42) Rabbit IgG N (1-16) GSK^ 1:100
Human TRPV4(11F5.2) Mouse Ig02b C (656-672) GSK^ 1:1000
Human TRPV4 (H-79) Rabbit IgG N (62-134) Santa Cruz 1250
Human TRPV4 Rabbit IgG C (853-871) Alomone^ 1250
Human VE-Cadherin Rabbit IgG C (Proprietry) Cell Signaling 1:100
Mouse isotype Mouse IgG2b Abeam 1:1000
Rabbit isotype Rabbit IgG Invitrogen 1:100 or 1:250
*GSK, Harlow, UK. ^GSK, King O f Prussia, USA. ^datanot shown
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2.2.13 Immunofluorescence Imaging
Cells were imaged using the automated InCell Analyser 1000 cellular imaging system (GE 
Healthcare, Piscataway, USA) in 200jul PBS. This system was selected as it allows fast, 
automated multiwavelength imaging with high resolution in fixed cells. An imaging protocol 
was first developed to specifically recognize the dimensions of the BD BioCoat™ poly-D- 
lysine coated 96-well plates utilized for cell culture and immunofluorescent staining (see 
section 2.2.12), in addition to the fluorophore combinations used. For each well, 2 random 
field images were captured using a 20X objective with a 505 light pass dichroic, 480/535 nm 
filter set, 500 ms exposure (Alexa-Fluor 488, for TRPV4 and VE-Cadherin) and 360/460 nm 
filter set, 300 ms exposure (Hoechst, nuclear stain). The exposure times for TRPV4 and VE- 
cadherin were determined by profiling the signal in the cells with the highest expression of 
the respective markers, i.e. in TRPV4-HEK293 and HUVECs, respectively. A similar 
approach was adopted for nuclear imaging with Hoechst.
Phase contrast images were photographed with the Olympus ix71 inverted fluorescent 
microscope using the DP71 digital camera. DP controller software was used to analyze 
images.
2.2.14 Prostaglandin measurements
All prostaglandin measurements were analyzed by enzyme immunoassay according to the 
manufacturer’s instructions (Cayman Chemicals, Ann Arbor, MI, USA). In vitro PGE2 was 
assayed directly from the cellular supernatant, whereas, for in vivo studies using plasma the 
stable PGE2 metabolite -  a derivative of 13,14-dihydro-15 -keto PGE2, referred to as PGEM 
hereafter -  was evaluated. Since PGI2 has a very short half-life under physiological 
conditions, the stable breakdown product, 6-keto prostaglandin Fia (6-keto PGFia) was
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evaluated. For each analyte (i.e. PGE2, PGEM or 6-keto PGFia), 50pl of cellular supernatant 
or plasma was added to a 96-well assay plate containing SOpl of specific PG antiserum 
(PGE2, -PGEM or -6-keto PGFia) in the presence of a fixed concentration of 
acetylcholinesterase-conjugated tracer (50p,L volume). The antiserum complex (either free 
PG-analyte or tracer) was immobilized using an anti-IgG antibody that was pre-coated onto 
the well. For analyte quantification, an 8-point calibration curve was prepared and added to 
the same assay plate by serially diluting a high concentration stock solution of PGE2, PGEM 
and 6-keto PGFia into 8 fresh microfuge tubes containing assay buffer. The dilution sequence 
varied for each analyte as did the dynamic range of the assay. Because the relationship 
between response and concentration can change from one assay run to another, calibration 
curves were included in each assay run. For examples of calibration curves from a typical 
experiment see Figure 2.2. The assay plates were incubated overnight at either 4°C (6-keto 
PGFia, PGE2) or room temperature (PGEM). Following washing, 200pl of a solution 
containing acetylthiocholine and 2-nitrobenzoic acid was added to the well. The colorimetric 
signal was allowed to develop by incubating the assay plate for either 60 minutes (for PGE2, 
PGEM) or 120 minutes (for 6-keto PGFia) at room temperature, in the absence of light. The 
colorimetric signal was then quantified spectrophotometerically by reading the absorbance at 
412nm using the SpectraMax Plus384 absorbance microplate reader (Molecular Devises, 
Sunnyvale, CA, USA). Cell culture supernatants were assayed directly, whereas plasma 
prostanoids were diluted in assay buffer (1:10, i.e. lOuL plasma, 90uL assay buffer) prior to 
analysis. Prostanoid quantification was determined using the manufacturer’s analysis 
templates (www.cayanchem.com/analysis/eia).
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Figure 2.2: Examples of calibration curves from a typical 6-kcto PGFia (top) and PGE2
(bottom) enzyme immunoassay. An 8-point calibration curve was used for each analyte. The
y-axis shows the natural logarithm (Eogit) of the ratio of B/Bo (i.e. standard bound (B) to the
maximum bound (Bo)). The x-axis shows the concentration of analyte evaluated. The output
of a linear regression analysis is indicated within each graph.
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2.2.15 Animal husbandry
All experimental protocols adhered to the current laws governing animal experimentation in 
the USA and were approved by the Institutional Animal Care and Use Committee of 
GlaxoSmithKline, and followed the NIH guidelines for the care and use of laboratory 
animals. Male Sprague Dawley (SD) rats (300-350 grams) and male spontaneously 
hypertensive rats (360-390 grams) were purchased from Charles River Laboratories 
(Horsham, PA, USA). Sprague Dawley rats contained jugular vein and carotid artery 
catheters where catheter tips were secured at the nape of the neck with surgical staples. All 
rats were individually housed under controlled conditions with a constant temperature (23 ± 
3°C), a 12-h light/dark cycle and ad libitum access to water and standard powdered rodent 
chow.
2.2.16 In vivo studies with Sprague Dawley rats
Sprague Dawley rats used in in vivo studies were initially anesthetized using isoflurane 
(Abbott Laboratories, Illinois, USA). First, the animal was carefully placed in an induction 
chamber (Harvard Apparatus, Holliston, MA, USA) attached to an isoflurane vaporizer 
(Viking Medical, Minneapolis, MN, USA). The oxygen flow rate was set to 500 ml min"\ 
with 4% isoflurane. The oxygen/isoflurane gas mixture was allowed to flow into the chamber 
until the animal became unresponsive to stimuli (i.e. no response to rocking of the induction 
chamber). The animal was then transferred from the induction chamber to a nose cone 
(Viking Medical) to maintain anesthesia; the oxygen flow rate was reduced to 200 ml min'* 
and the isoflurane level to 2%. Here, surgical staples were removed to gain access to the 
jugular and carotid catheters. This was followed by a switch to urethane anesthesia, 
performed by slowly dosing 1.2 g kg'^ i.v. urethane (0.5g ml"^  stock in saline, obtained from 
Sigma Aldrich) in the absence of isoflurane. The level of anesthesia was monitored every 10
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minutes using the pedal reflex throughout the study. Following the completion of the study 
all rats were killed humanely, while still under urethane anesthesia, by thoracotomy followed 
by excision of the lungs and heart. Urethane anaesthetized rats were placed on a heating pad 
(Viking Medical) to maintain body temperature (37°C). The carotid catheter was connected 
via a 3-way connector (Fisher Scientific, Pittsburgh, PA, USA) to a Harvard PHD 200 
infusion pump (Harvard Apparatus) and a P23XL pressure transducer (Harvard Apparatus). 
Saline, containing 30 Units ml"^  heparin (APP Pharmaceuticals, Schaumburg, IL, USA), was 
infused throughout the study at a rate of 10 pi min'^ to keep the arterial line patent. Blood 
pressure was monitored throughout the study using the Powerlab data acquisition system 
(ADInstruments Ltd, Chalgrove, Oxfordshire, UK). Two distinct dosing paradigms were 
utilized: i) administration of bolus doses of the test agents followed by TRPV4 agonist bolus 
treatment (bolus dose model) or ii) a continuous infusion of TRPV4 agonist and/or antagonist 
(steady state infusion model).
In the bolus dose model GSK2193874, L-NAML, indomethacin, apamin & charybdotoxin 
were given via the i.v. cannula 15 minutes prior to the first dose of GSK1016790A. 
GSK1016790A was administered via the i.v. cannula in a cumulative fashion at 0.0003, 
0.001, 0.003, 0.01, 0.03, 0.1 and 0.2 mg kg‘^  using a Hamilton syringe (Hamilton Company, 
Reno, NV, USA). Lach dose of GSK1016790A was separated by a 5 minute interval. At the 
end of study peripheral blood was collected into 1.5 ml lithium heparin tubes (BD 
Bioscience) and used to analyze 6-keto PGFia and PGLM levels in rats treated with 
indomethacin. Both lungs were harvested, weighed and a lung weight:body weight ratio was 
calculated. The lung wet weight to body weight ratio is the preferred gravimetric edema 
assessment method in acute lung injury models, as little-to-no remodeling occurs that would 
result in a change in lung dry weight (Parker & Townsley, 2004).
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In the steady state infusion model a bolus loading dose of GSK2193874 (71 pg.kg'^ in lOOpl) 
was administered via the i.v. cannula to satisfy the previously determined GSK2193874 
volume of distribution in the rat (Thorneloe et al., 2012). This was immediately followed by a 
60 minute continuous infusion of GSK2193874 (73 ng.kg.min'^) at a rate of 10 pl.min'^ in 
order to counteract the metabolic rate of clearance of GSK2193874 and therefore provide a 
steady state plasma level (Thorneloe et al., 2012). A 10 minute infusion of GSK1016790A at 
a rate of 10 pg.min.kg'^ with the continued simultaneous infusion of GSK2193874 or vehicle 
followed. At the end of the study, blood was collected via the arterial line into lithium heparin 
tubes for analysis of 6 -keto PGFi« levels.
2.2.17 In vivo studies with Spontaneously Hypertensive Rats
Spontaneously Hypertensive (SH) rats were dosed for 7 days with vehicle (6 % Cavitron, 5% 
DMSO, 10 mL.kg.d'^) or GSK2193874 (10 mg.kg.d'^ UID) via oral gavage, as outlined in 
Thorneloe et al. (2012). 24 hours after the final dose, a terminal blood sample was collected 
from the abdominal aorta of isoflurane (2-3%) anesthetized rats into lithium-heparin treated 
tubes (BD Bioscience) for 6 -keto PGFia evaluation.
2.2.18 Statistical analysis
Data are presented as mean ± s.e.m for n observations, where n represents the number of 
separate experiments or the number of individual animals. EC50 values were calculated using 
Graph Pad Prism 5.01 (GraphPad Software Inc., CA, USA). Statistical analysis was 
conducted using one-way ANOVA with a Dunnett post hoc test when comparison was made 
with GSK1016790A or a one-way ANOVA with Bonferroni post hoc test when all treatment 
groups were compared to each other. A two-way ANOVA followed by Bonferroni post hoc
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test was employed when evaluating the effect of two independent parameters. For all 
analyses, a value of p<0.05 was considered statistically significant.
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2.3 Results
2.3.1 TRPV4 expression in cultured HUVECs
To validate HUVECs as a model for investigating endothelial TRPV4 biology, TRPV4 
expression was profiled in this cell line at the mRNA and protein level. Although TRPV4 
protein expression in HUVECs has been reported previously (Loot et al., 2008; Rath et a l, 
2012), TRPV4 gene expression has not been characterized in this cell type, whereas its 
expression in wild-type HLK293 (WT-HLK293) and PBMCs has been demonstrated 
(Mergler et a l, 2011 and Spinsanti et a l, 2008, respectively). Accordingly, TRPV4 mRNA 
expression was evaluated by quantitative RT-PCR analysis in HUVECs and compared to 
PBMCs, WT-HLK293 as well as HLK293 cells over-expressing TRPV4 (TRPV4-HLK). 
TRPV4 mRNA was found to be expressed in HUVECs; the level of expression was higher 
than in PBMCs and WT-HEK293 (not significant), but drastically lower than TRPV4-HEK 
cells (p<0.001; Figure 2.3A). Next, TRPV4 protein levels and loealization were explored 
using immunofluorescent staining. Three distinct TRPV4 antibodies were used for this 
purpose. The N-terminal recognition antibodies, N42 and H-79, have been characterized 
previously (Facer et a l, 2007; Lee et a l, 2012, respectively). The C-terminal recognition 
antibody, 11F5.2, which has hitherto not been characterized, demonstrated low intensity 
staining in WT-HEK293; however, staining intensity was dramatically increased in TRPV4- 
HEK (Figure 2.3C). The specificity of 11F5.2 being due to the primary antibody itself was 
further confirmed by the absence of immunofluorescent signal in cells incubated with isotype 
control antibodies. In HUVECs, a consistent immunofluorescent staining pattern was 
observed with all three TRPV4 antibodies, namely a punctate and perinuclear localization of 
the TRPV4 channel (Figure 2.3D, top panels). This finding is consistent with previous 
immunolabelling studies in HUVECs (Loot et al, 2008; Rath et a l, 2012) as well as other 
human endothelial cell types including: brain capillary (Hatano et a l, 2013); breast tumor
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(Pla et al., 2012); and microvascular cells (Sullivan et al., 2012). Cellular morphology and 
vascular endothelium (VE)-cadherin immunofluorescent staining was used to confirm the 
endothelial phenotype of HUVECs (De)ana et al., 1999). HUVECs displayed a characteristic 
cobblestone morphology (Figure 2.3B) and VE-cadherin immunoreactivity that was 
predominately membranous and localized to regions of cell-cell contact (Figure 2.3D, bottom 
right), consistent with its role as a cell-cell adhesion molecule (Dejana & Giampietro, 2012).
In aggregate, TRPV4 expression was confirmed in HUVECs at both the mRNA and protein 
level. The levels of TRPV4 gene expression in HUVECs as well as HEK293 (both WT and 
TRPV4 expressing) were consistent with the observed relative immunofluorescent staining 
intensities.
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Figure 2.3: TRPV4 mRNA and immunofluorescent staining in HUVECs. (A) TRPV4 mRNA 
expression in human PBMCs, wild-type HEK293 cells (WT-HBK293), stably transfected TRPV4 
overexpressing HEK293 cells (TRPV4-HEK293) and HUVECs. Relative expression versus PBMCs 
is shown based on Taqman® qRT-PCR analysis. TRPV4 mRNA expression was normalized to 
GAPDH mRNA. Values above bars represent fold-change versus PBMCs. Values in parentheses 
represent the number of individual samples or donors (for PBMCs) used in each group. Data were 
analysed using one-way ANOVA with Bonferroni post hoc. ***p<0.001 vs. PBMC. (B) Phase 
contrast image showing HUVEC morphology. Scale bar = 20pM. (C) Characterization o f the anti- 
TRPV4 monoclonal antibody 11F5.2 in WT-HEK293 and TRPV4-HEK293. Cells were incubated 
with 11F5.2 (top panels) or isotype control antibody (bottom panels) before addition of Alexa-Fluor 
488 (green) conjugated secondary antibody. TRPV4 immunostaining was enhanced in TRPV4 
overexpressing HEK293 versus WT-HEK293 cells. (D) TRPV4 immunofluorescent staining in 
HUVEC was evaluated using three distinct anti-TRPV4 antibodies: H-79 (top, left); 11F5.2 (top, 
middle); and N42 (top, right). VE-cadherin immunofluorescent staining (bottom, right) confirmed the 
endothelial phenotype of HUVECs. Anti-rabbit IgG (compare H-79, N42 and VE-cadherin) and anti­
mouse Ig02a (compare 11F5.2) were used as isotype controls to confirm specificity. (C) and (D) are 
representative images from at least 3 independent experiments. Nuclei in (C) and (D) were 
counterstained with Hoechst (blue). Original magnification x 20 (C) and (D).
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2.3.2 TRPV4 activation induces prostaglandin release in HUVECs
Evidence supporting the ability of TRPV4 to regulate vascular prostaglandin production is 
lacking in the literature, therefore the role of TRPV4 activation in modulating prostanoid 
release from isolated endothelial cells was investigated. GSK1016790A was selected as a 
pharmacological tool to explore the potential role of TRPV4 in endothelial prostanoid release 
on account of its demonstrated efficacy in HUVECs to activate TRPV4 currents and evoke 
morphological changes (Thomeloe et al., 2012; Willette et al., 2008). HUVECs exposed to 
GSK1016790A (lOnM) demonstrated a time-dependent release of both 6-keto-PGFiaD (a 
surrogate for PGU production) and PGE2. Detection of both prostanoids was clearly evident 
after 15 minutes, with the response peaking at 30-60 minutes (Figure 2.4A and B). Next, the 
concentration-effect relationship of GSK1016790A-mediated prostanoid release was 
investigated. For this purpose, the 30 minute time point was selected on account of the 
maximal prostanoid induction observed with this treatment duration. GSK1016790A elicited 
a concentration-dependent release of both 6-keto-PGFia and PGE2. The half maximal 
effective concentrations, as log(EC5o), for 6-keto-PGFia and PGE2 release were -9.1 ±0.1 
(0.87nM) and -8.8 ± 0 . 1  (1.7nM), respectively (Figure 2.4C and D). The potency of 
GSK1016790A demonstrated here in HUVECs is consistent with the reported EC50 for this 
molecule in calcium assays using recombinant human TRPV4 expressed in HEK293 cells 
(2.1nM and 3.0nM, reported by Thomeloe et al. (2008) and Willette et al. (2008), 
respectively).
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Figure 2.4: TRPV4 activation induces robust prostanoid release from HUVECs in a time and 
concentration-dependent manner. Timeeourse of GSK1016790A (‘790, 1 GnM)-induced 6- 
keto PGFia (A) and PGE2 (B) release. Data were analyzed using two-way ANOVA followed 
by Bonferroni post hoc, *p<0.05, ***p<0.001 vs. vehicle. Concentration-dependent increase 
in 6-keto PGFia (C) and PGE2 (D) release following 30 minute incubation with ‘790. Results 
shown are the mean ± s.e.m of n=3 independent experiments.
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To confirm TRPV4-mediated prostanoid release in endothelial cells, two additional TRPV4 
activators, GSK634775 and 4a-PDD, were also profiled. The poteney of GSK634775 and 
4a-PDD in calcium influx studies versus reeombinant human TRPV4 expressed in HEK293 
cells was reported previously (EC50 of 25nM and IpM, respectively; Thomeloe et ah, 2012), 
thus indicating that the order of potency of these TRPV4 activators is GSK1016790 > 
GSK634775 > 4aPDD. All three pharmaeological activators were profiled at concentrations 
at-or-around their respeetive EC50 values. A concentration-dependent release of 6-keto- 
PGFiawas observed with all 3 agents, with significant induction observed at concentrations 
above the EC50 (Figure 2.5). Interestingly, the maximal magnitude of 6-keto-PGFia release 
differed with each agonist. Consistent with their respeetive potencies, the rank order of 
intrinsie activity at TRPV4 was -  GSK1016790A > GSK634775 > 4aPDD.
In a separate set of experiments a potent and selective TRPV4 blocker, GSK2193874 (IC50 = 
40nM versus hTRPV4; Thomeloe et ah, 2012 at lOOnM) completely inhibited 
GSK1016790A-mediated 6-keto-PGFia release (Figure 2.6) confirming the TRPV4 
selectivity of the response.
These data demonstrate that TRPV4 activation induces a robust and reprodueible release of 
prostanoids fi"om cultured endothelial eells. The degree of TRPV4-mediated 6-keto-PGFiaD 
release (i.e. maximal response) appeared to be greater than that observed with PGE2. 
Consequently, 6-keto-PGFi« in conjunetion with GSK1016790A -  the most efficacious 
agonist -  was selected for subsequent mechanistic studies
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Figure 2.5: Three structurally distinct pharmacological activators of TRPV4 induce 6-kcto 
PGFia release from HUVECs. 6-keto PGFia was evaluated following treatment with the 
TRPV4 activators: GSK1016790A (’790), GSK634775 (‘775) and 4a-PDD, or vehicle for 
30 minutes. Results shown are the mean ± s.e.m of 4 independent experiments. Data were 
analysed using one-way ANOVA with Dunnett’s post hoc. *p<0.05 & ***p<0.001 vs. 
vehicle.
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Figure 2.6: TRPV4-mediated 6-keto PGFia release from HUVECs is attenuated by the 
selective TRPV4 blocker, GSK2193874. HUVECs were pre-treated with GSK2193874 (‘874, 
lOOnM) prior to treatment with GSK1016790A (‘790, lOnM) for 30 minutes. Cellular 
supernatants were harvested for 6-keto PGFia evaluation. Results shown are the mean ± s.e.m 
of n=6 independent experiments. Data were analysed using one-way ANOVA with 
Bonferroni post hoc. # p<0.001 vs. vehicle, ***p<0.001 vs. ‘790 alone.
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2.3.3 The role of calcium in TRPV4-mediated 6-keto-PGFia release
Intracellular calcium concentration is elevated by release from endoplasmic stores or influx 
across the plasma membrane. To determine which mechanism was responsible for mediating 
GSK1016790A-induced 6-keto-PGFia release from HUVEC, intracellular calcium stores 
were first depleted with thapsigargin or cyclopiazonic acid, or external calcium was chelated 
with EGTA, prior to challenge with GSK1016790A. Calcium store depletion had no effect on 
6-keto-PGFia release, but chelation of extracellular calcium significantly attenuated the 
response (Figure 2.7A). Consistent with these findings, the calcium ionophore, A23187, 
induced a concentration-dependent release of 6-keto-PGFia that was abated by EGTA (Figure 
2.7B). The magnitude of the A23187 response was approximately 8-fold less than that 
observed with GSK1016790A. These data demonstrate that TRPV4-induced 6-keto-PGFia 
□release is dependent on extracellular calcium influx and are accordant with TRPV4 acting as 
a calcium channel in the endothelial plasma membrane.
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Figure 2.7: TRPV4-mediated 6-keto PGFia release from HUVEC is dependent on 
extracellular Ca^ .^ (A) HUVEC were pre-treated for 10 minutes with thapsigargin (TG), 
cyclopiazonic acid (CPA) or EGTA before challenge with vehicle or GSK1016790A (‘790, 
lOnM). Results shown are the mean ± s.e.m of n=4 independent experiments. Data were 
analyzed using two-way ANOVA followed by Bonferroni post hoc. **p<0.01 vs. Control + 
‘790, NS = not significant. (B) HUVECs were treated with the calcium ionophore A23187 for 
30 minutes in the presence (no EGTA) or absence (2mM EGTA) of extracellular Ca^ "^ . Data 
(mean ± s.e.m) were analyzed using one-way ANOVA followed by Dunnett’s post hoc. 
*p<0.05 and **p<0.01 vs. Vehicle, n= 3 independent experiments.
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2.3.4 Effect of signaling pathway inhibitors on TRPV4-mediated 6-keto-PGFia release
To determine the mechanism responsible for TRPV4-mediated 6-keto-PGFia release from 
HUVEC, the effect of inhibiting intracellular signaling pathways previously associated with 
prostaglandin production was profiled (Alberghina, 2010). All inhibitors were evaluated at 
concentrations sufficient to completely abate the activation of their respective target based on 
IC50 values reported for cell based assays (cPLA] inhibitor, Seno et al., 2000; indomethacin, 
Meade et al., 1993; PD98059, Alessi et al., 1995; GF109203X, Toullec et al., 1991; ML-7, 
Krarup et al., 1998). Two enzymes critical to prostaglandin production are cPLA: and COX. 
Inhibition of COX with indomethacin (IpM) and cPLA] with cPLA] inhibitor (IpM) reduced 
6-keto-PGFia release by 98% and 83%, respectively (Figure 2.8). Inhibition of PKC with 
GF109203X (lOpM) and MEK (a kinase upstream of ERK) with PD98059 (2)uM) resulted in 
95% and 93% reductions in 6-keto-PGFia release, respectively. Myosin light chain kinase 
(MLCK) has not been implicated in prostanoid synthesis, and was used as a negative control. 
MLCK inhibition by ML-7 (3pM) had no effect on GSK1016790A-mediated 6-keto-PGFia 
release. These data demonstrate that cPLA], cycloxygenase, PKC and MEK, but not MLCK, 
are required for TRPV4-mediated 6-keto-PGFia release from HUVECs.
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Figure 2.8: TRPV4-mediated 6-keto PGFia release from FlUVEC requires cPLA], 
cycloxygenase, MEK and PKC activation. HUVEC were pre-treated with selective inhibitors 
of: cPLA] (PLA2i, IpM); cycloxygenase, (indomethacin, IpM); PKC, (GF109203X, lOpM); 
MEK, (PD98059, 2pM); & MLCK, (ML-7, 3pM) for 15 minutes prior to treatment with 
GSK1016790A (lOnM). Results shown are the mean ± s.e.m of >3 independent experiments. 
Data were analysed using one-way ANOVA with Dunnett’s post hoc. ***p<0.001 vs. ‘790 
(lOnM).
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2.3.5 Effect of hypotonieity on TRPV4-mediated 6-keto-PGFia release
As outlined above (see section 1.9.2), hypotonieity is a well characterized mechanism for 
activating the TRPV4 channel (Liedtke et al., 2000; Strotmann et al., 2000; Vriens et al., 
2004). Previous studies in isolated endothelial cells have demonstrated that hypotonic 
challenge mediates TRPV4-dependent increases in intracellular calcium (Mergler et al., 2011; 
Vriens et al., 2005). To determine if hypotonic challenge also induced or modulated TRPV4- 
mediated 6-keto-PGFia release, HUVECs were treated with vehicle or GSK1016790A in 
either isotonic medium (270mOsm) or hypotonic medium (192mOsm; 30% reduction in 
osmolality) using the same protocol as outlined above (see section 2.3.2). The addition of 
hypotonic medium resulted in a readily observable increase in cell size (swelling), whereas 
cell size remained unchanged in isotonic medium (data not shown). Hypotonic challenge by 
itself did not induce 6-keto-PGFia release from HUVECs (Figure 2.9; vehicle). However, 
hypotonieity elicited a significant augmentation in GSK1016790A-mediated 6-keto-PGFia 
release (p<0.05, 270mOsm ‘790 vs. 192mOsm ‘790; Figure 2.9).
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Figure 2.9: TRPV4-mediated 6-keto PGFia release is augmented by hypotonieity in 
HUVECs. HUVECs were incubated with media at different osmolalities (270 mOsm and 192 
mOsm) in the presence or absence of GSK1016790A (‘790, lOnM) for 30 minutes. Results 
shown are the mean ± s.e.m of n=3 independent experiments. Data were analysed using one­
way ANOVA with Bonferroni post hoc *p<0.05, **p<0.01, ***p<0.001.
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2.3.6 TRPV4-mediated release of prostacyclin in vivo
Having demonstrated an ability of TRPV4 to release prostanoids from endothelial cells in 
vitro, the existence of this mechanism was profiled in vivo. In rats i.v. administration of 
GSK1016790A induced a dose-dependent increase in the plasma levels of 6-keto-PGFia 
(Figure 2.10A). GSK10I6790A-induced 6-keto-PGFia release was completely inhibited by a 
pre-treatment infusion with a potent and selective TRPV4 blocker, GSK2193874, at a steady- 
state plasma concentration of 140nM (Figure 2.10B). The GSK2193874 plasma concentration 
was selected based on prior understanding of the pharmacokinetic properties of the molecule 
and its potency at TRPV4 in calcium influx assays (Thomeloe et al., 2012). TRPV4 
activation with GSK1016790A also induced a dose dependent drop in mean arterial blood 
pressure (MAP) and a concurrent increase in lung wet weight, as reported previously 
(Thomeloe et al., 2012; Willette et al., 2008). These effects were completely inhibited by 
GSK2193874 (Figures 2.10C & 2.I0D).
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Figure 2.10: Systemic activation of TRPV4 with GSK1016790A (‘790) causes a robust 6-keto PGFia 
release, hypotension and pulmonary edema, which are all attenuated with the selective TRPV4 
blocker, GSK2193874 (‘874). (A) Plasma 6-keto PGFia levels were evaluated in SD rats following 
cumulative i.v. bolus dose administration of ‘790 (filled squares) or vehicle control (open squares). 
Data analyzed using a two-way ANOVA with repeated measures followed by a Bonferroni post hoc. 
*** p<0.001 vs. vehicle (n=4 per group). (B) Separate rats received a 1 hour i.v. infusion o f the 
TRPV4 blocker ‘874 (final plasma concentration 140nM) prior to a 10 minute i.v. challenge with ‘790 
at an infusion rate of 10 pg.min.kg'^ (total dose 0.1 mg kg'^). Data were analyzed using a one-way 
ANOVA with Bonferroni post hoc, *p<0.05 & **p<0.01. (C) In a further group o f rats ‘790-mediated 
decrease in mean arterial blood pressure (MAP) was significantly attenuated by inhibition of TRPV4. 
Rats were pre-treated with ‘874 (0.1 & 0.3 mg kg'*) 10 minutes prior to the addition o f cumulative i.v. 
bolus doses or ‘790. Data analyzed using a two-way ANOVA with repeated measures followed by a 
Bonferroni post hoc. *p<0.05 & ***p<0.001 vs. ‘790. (D) ‘790-induced lung weight increase is 
attenuated by ‘874. Rats were treated as outlined in (C). 5 minutes after the final dose o f ‘790 (0.2 mg 
kg-1) both lungs were harvested and a lung weight to body weight ratio was calculated. Data were 
analyzed using a one-way ANOVA with Dunnetf s post hoc. # p<0.01 vs. control. ** p<0.01 vs. 
‘790. Data is expressed as mean ± s.e.m. Values in parentheses represent the number of rats used in 
each group.
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2.3.7 The effects of NO, EDHF and cyclooxygenase inhibition on GSK1016790A- 
induced TRPV4 activation in vivo
Given the robust 6-keto-PGFia release in response to GSK1016790A administration in vivo 
(Figure 2.10A) the potential eontribution of prostaglandins to TRPV4-mediated MAP 
reduetion and inereases in lung weight were probed using indomethaein. GSK1016790A 
indueed a significant increase in the plasma levels of both 6-keto-PGFiaand PGEM. 
Importantly, indomethacin significantly reduced the plasma levels of both prostanoids 
(Figure 2.11B & 2.11C). Indomethacin (0.3, 1.0 and 3.0 mg kg'^) had no effect on MAP 
during the pretreatment, but dose-dependently blunted the GSK1016790A-mediated decrease 
in MAP at the two highest doses of GSK10I6790A tested (Figure 2.11 A). Indomethacin 
pretreatment did not significantly affect lung wet weight; rather there was a trend to further 
increase the GSK1016790A-mediated lung weight response (Figure 2.1 ID). Importantly, 
indomethacin administration alone had no discernible effect on lung wet weight, MAP or 
baseline prostaglandin levels. These results suggest that prostanoids contribute to the 
decrease in MAP but not to the increased lung wet weight as a result of TRPV4 activation 
with GSKI0I6790A.
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Figure 2.11: The role of prostanoids in TRPV4-mediated hypotension and pulmonary edema. Rats 
were pre-treated with the indicated doses of indomethacin (Indo) 20 minutes prior to the addition of 
cumulative i.v. bolus doses of GSK1016790A (‘790). (A) TRPV4-mediated decrease in MAP is 
inhibited by indomethacin. Data analyzed using a two-way ANOVA with repeated measures followed 
by a Bonferroni post hoc. **p<0.01 & ***p<0.001 vs. ‘790 alone. Indomethacin dose-dependently 
inhibited TRPV4-mediated plasma increases in 6-keto PGFia (B) and PGEM (C). Controls represent 
plasma prostanoid levels prior to dosing of indomethacin or ‘790. Data were analyzed using a one­
way ANOVA with Bonferroni post hoc. *p<0.05 vs. ‘790, ***p<0.001 vs. ‘790. (D) TRPV4- 
mediated lung wet weight increase in the presence or absence of indomethacin. Data is expressed as 
mean ± s.e.m. Values in parentheses represent the number of rats used in each group. Indo alone 
represents 3 mg kg'^ indomethacin administration without ‘790. MAP, mean arterial blood pressure.
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NO and EDHF constitute two major endothelial-dependent vasodilatory pathways in vivo. In 
order to determine the contribution of these vasodilators to the effects of GSKI016790A in 
vivo pharmacological inhibitors were used: L-NAME (10 mg kg'^) to inhibit nitric oxide 
synthase, and apamin combined with charybdotoxin (both 100 pg kg’ )^ to inhibit 
hyperpolarization associated with EDHF. Consistent with previous reports, both L-NAME 
and apamin + charybdotoxin independently increased MAP during the pretreatment period 
(Figure 2.12A; Gao & Wang, 2010a; Rees et al., 1990). However, upon challenge with 
GSK1016790A, neither of these agents attenuated the decrease in MAP (Figure 2.12B), and 
additionally did not affect the lung weight increase. These data suggest that the TRPV4- 
mediated decrease in MAP and induction of pulmonary edema are independent of NO and 
EDHF.
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Figure 2.12: Evaluation of the roles of nitric oxide and EDHF in TRPV4-mediated 
hypotension. Rats were pre-treated with L-NAME (lOmg kg’ )^ or apamin & charybdotoxin 
(both 100 fig kg'^) 15 minutes prior to administration of GSK1016790A (‘790). (A) Pressor 
responses of indicated agents, prior to treatment with ‘790. Data analyzed using a one-way 
ANOVA with Dunnett’s post hoc test. ***p<0.001 vs. vehicle. (B) Change in MAP in 
response to ‘790 (0.2 mg kg'^). Data is expressed as mean ± s.e.m. Values in parentheses 
represent the number of rats used in each group. Apa, Apamin; CTX, charybdotoxin; MAP, 
mean arterial blood pressure.
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2.3.8 Evaluation of TRPV4-mediated PG I2 release in hypertensive rats
The results described hitherto demonstrate that pharmacological TRPV4 activation mediates 
a robust prostanoid release in vivo. Previous reports have demonstrated TRPV4-mediated 
vasodilatory pathway activation is augmented in hypertension (Earley et ah, 2009; Gao & 
Wang, 2010b), therefore, a study to examine whether 6-keto PGFia levels were regulated in 
hypertensive rats in a TRPV4-dependent manner was performed. Following 7 day treatment 
with the TRPV4 blocker, GSK219874, plasma 6-keto PGFia was reduced by 27% in SHR 
rats (290.8 ± 30.8 and 213.1 ± 29.5 pg mf* control vs. ‘874, respectively; Figure 2.13). 
Although this decrease was not statistically significant (p=0.098) there was a trend toward an 
overall reduction in 6-keto PGFia levels following chronic TRPV4 inhibition. It is 
noteworthy that chronic TRPV4 inhibition did not affect MAP in either hypertensive (SHR) 
or normotensive (SD) rats during the entire study period (Thomeloe et ah, 2012). Thus, these 
finding suggests that even if the TRPV4-mediated prostanoid pathway activation is engaged 
under hypertensive conditions, it is not sufficient to modulate blood pressure.
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Figure 2.13: Effect of chronic TRPV4 inhibition on plasma 6-keto PGFia levels in 
spontaneously hypertensive rats. Rats were treated with GSK2193874 (‘874, 10 mg.kg.d'^ 
UID) or vehicle (control) for 7 days. Plasma 6-keto PGFia levels were evaluated 24 hours 
post final dose. Results are expressed as mean ± s.e.m, n = 6 rats per group. Data analyzed 
using an unpaired Student’s /-test.
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2.3.9 Effect of TRPV4 activation on prostaglandin release from peripheral blood cells
In order to examine other potential endothelium-independent sources contributing to 
prostanoid release in vivo, circulating leukocytes -  which are capable of releasing prostanoids 
(Sudlow et al., 1996) -  were profiled. Treatment of whole blood with GSK1016790A 
(lOOnM) did not induce release of PGE2 or 6-keto PGFia even after prolonged incubation 
periods (up to 2 hours). However, A23187 elicited the release of both prostaglandins (Figure 
2.14). These studies suggest that circulating leukocytes do not contribute to TRPV4-mediated 
prostaglandin release in vivo.
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Figure 2.14: TRPV4 activation does not induce prostanoid release from human peripheral 
blood cells. Whole blood was treated with GSK1016790A (‘790, lOOnM) or the calcium 
ionophore, A23187 (lOpM) for the indicated time points. Plasma was analysed for 6 -keto 
PGFiot (A) or PGE2 (B) levels. Results shown are the mean ± s.e.m of n=3-4 independent 
studies with different donors. Data were analysed using one-way ANOVA with Bonferroni 
post hoc. *p<0.05 and ***p<0.001 vs. vehicle (Veh) or ‘790. **p<0.01.
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2.4 Discussion
The results described herein demonstrate that TRPV4 activation can mediate the release of 
prostaglandins in vitro from cultured endothelial cells as well as in vivo in rats. Evidenee also 
supports a potential role of prostaglandins in modulating the blood pressure responses elicited 
by pharmaeological TRPV4 activation in vivo.
2.4.1 General Discussion
These data provide the first demonstration that TRPV4 activation mediates the release of 
prostaglandins from endothelial cells. Although, two prior studies in chondrocytes (Phan et 
al., 2009) and urothelial cells (Xu et al., 2009) have linked TRPV4 to prostaglandin release. 
TRPV4-mediated endothelial PGI2 release is dependent on extraeellular calcium influx and 
independent of endoplasmic calcium stores, which is consistent with the findings of Adapala 
et al. (2011) who showed that TRPV4 activation leads to endothelial calcium elevation via 
the same mechanism. Furthermore, thrombin- and shear stress-indueed PGI2 release has been 
demonstrated to occur via external calcium entry into endothelial cells (Macarthur et al., 
1993; Sato et al., 1999). The ealcium dependence of TRPV4-mediated PGI2 release is 
eonsistent with observations made here using selective pathway inhibitors, in that PGI2 
release requires the independent aetivation of cycloxygenase, MEK, PKC and CPLA2, of 
which PKC and CPLA2 are calcium-dependent enzymes (Gliki et al., 2001; Hirabayashi, 
1999). The mechanism proposed from the results outlined above is as follows: TRPV4 
aetivation permits external calcium entry in cells whieh activates PKC which in turn activates 
MEK (Gliki et al., 2001). MEK then activates extraeellular regulated kinase (ERK) which 
phosphorylates CPEA2. ERK phosphorylation of CPLA2 in conjunction with calcium binding 
results in its full activation of CPLA2 (Lin et al., 1993; Schalkwijk et al., 1996), thus enabling 
liberation of arachidonic acid, which forms the substrate for prostanoid synthesis.
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The results from the in vitro studies described above were corroborated by in vivo 
investigations. Systemic activation of TRPV4 in vivo with GSK1016790A induced a striking 
prostaglandin release and drop in MAP. Indomethacin eliminated the prostaglandin 
production and significantly blunted the MAP decrease at GSK1016790A doses in whieh the 
induction of 6-keto-PGFia was apparent (compare Figure 2.10A and Figure 2.11 A). Studies 
conducted with pharmaeologieal inhibitors suggest a role for prostaglandin but not NO and 
EDHF pathways in the GSKl 016790A-mediated decrease in MAP. The lack of involvement 
of NO is eonsistent with previous findings in which the GSK1016790A depressor response 
was unaffected by eNOS knoekout (Willette et a l, 2008). However, these findings contrast 
with those of Gao & Wang (2010a), who demonstrated that TRPV4 aetivation with 4a-PDD 
reduced MAP via an EDHF-(not cyclooxygenase) dependent mechanism. The reasons for 
this diserepancy are not clear. Different TRPV4 activators were utilized in these two studies, 
however an “off-target” effect of either TRPV4 activator is unlikely as the depressor effects 
of both agents are absent in TRPV4 knockout mice (Willette et a l, 2008; Zhang et a l, 2009). 
An intriguing possibility is that 4a-PDD and GSK1016790A may exhibit different 
pharmacological properties at the reeently described TRPV4-TRPC1 heterotetrameric 
channel, whieh is funetionally expressed in native endothelial cells (Ma et a l, 2010a,b; 
2011). However, the pharmacological properties and the physiologieal role of this complex in 
vivo still remain to be established. Alternatively, it is conceivable that TRPV4-mediated 
prostanoid release requires a high level of TRPV4 activation. In support of this, prostaglandin 
release (in this study) was evident when the MAP reduction was >50 mmHg (Figure 2.11). In 
studies utilizing 4a-PDD, the maximum MAP depression following administration of a high 
dose (5 mg kg‘ )^ of this agent was -50 mmHg (Gao et a l, 2009; Gao & Wang, 2010a). 
Consequently, failure to detect TRPV4-induced prostaglandin release in prior studies maybe
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attributable to the inferior efficacy of 4a-PDD compared to GSK1016790A with respect to 
blood pressure reduction.
The demonstrated correlation between enhanced systemic prostaglandin production and a 
decrease in MAP following TRPV4 activation are consistent with reports of both PGI2 and 
PGE2 infusion evoking blood pressure reductions in rodents (Audoly et al., 1999; Kennedy et 
al., 1999; Pace-Asciak et al., 1978; Weeks & Compton, 1979). Of these two prostanoids, 
PGI2 is considered the more potent hypotensive agent (Pace-Asciak et al., 1978). Based on 
the plasma concentrations of PGE2 and PGI2 detected in this study and the depressor dose 
response curves observed following direct infusion of these prostanoids in vivo (Pace-Asciak 
et al., 1978), it is likely that PGI2 is the main contributor to TRPV4-mediated hypotension, 
although, further investigation is required to substantiate these claims. In humans, the 
importance of prostanoids in modulating blood pressure was highlighted in a meta-analysis of 
non-steroidal anti-inflammatory agents, in which indomethacin and piroxicam increased 
blood pressure in hypertensive patients (Johnson, et al., 1994). Interestingly, in this study, 
chronic (7 day) TRPV4 inhibition with GSK2193874 demonstrated a trend towards a 
reduction in plasma PGI2 levels in SHRs -  suggesting that the TRPV4-mediated 
prostaglandin release mechanism may be engaged in this pathological model -  however, no 
change in blood pressure was observed (Thomeloe et al., 2012). The lack of blood pressure 
alteration, despite a reduction in PGI2 levels, is unsurprising given that high concentrations of 
PGI2 ( - 1 2 0  ng ml"\ Figure 2 .1 1 ) are required to elicit depressor responses (following 
GSK1016790A administration) yet plasma PGI2 levels in SHRs are nearly 400-fold lower 
(0.21-0.29 ng m f \  Figure 2.13). PGI2 also serves an important anti-thrombotic function in 
vivo via its physiological antagonism of platelet-derived TXA2 (Martmez-Gonzalez &
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Badimon, 2007); therefore TRPV4 regulation of PGI2 could potentially influence platelet 
aggregation.
Previous reports demonstrated that GSK1016790A-mediated decrease in MAP was driven by 
endothelial-barrier disruption and the resultant increased vascular permeability (Thomeloe et 
al., 2012; Willette et al., 2008). This proposed mechanism is supported by numerous in vitro 
studies (Alvarez et al., 2006; Hamanaka et al., 2007, 2010; Jian et al., 2008; Wu et al., 2009). 
Here it is shown that GSK1016790A-mediated lung permeability, as assessed by lung weight, 
is inhibited by TRPV4 blockade, but unaffected by inhibition of NO or EDHF pathways. 
Although the MAP decrease was inhibited by indomethacin, there was no inhibitory effect on 
lung weight. In fact the inhibition of cycloxygenase by indomethacin in the presence of 
TRPV4 activation demonstrated a trend towards an increased lung weight. This is consistent 
with reports in which prostaglandins have afforded protection against enhanced lung 
permeability (Birukova et al., 2007; Birukova et al., 2010; Victorino et al., 2004), and 
suggests that in the absence of cycloxygenase inhibition TRPV4 activation may normally 
release prostanoids that limits the TRPV4-evoked permeability increase in the lung. 
Altematively, the increased lung weight with indomethacin may simply reflect the blunted 
depressor effect of GSK1016790A, thereby facilitating a heightened MAP, driving the 
passage of more fluid into the lungs.
Although the in vitro studies described here are consistent with the vascular endothelium 
being the source of prostaglandins following TRPV4 activation in vivo, the exact cell type(s) 
responsible for prostaglandin production requires further delineation. TRPV4 and PGE 
synthase are both expressed in the kidney collecting tubule (Gao et al., 2009; Govindarajan et 
al., 1987; Schlondorff, 1986; Tian et al., 2004; Vitzthum et al., 2002; Willette et al., 2008).
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Consistent with this, functional observations in pilot studies demonstrated PGE2 production 
from isolated kidney collecting tubules following TRPV4 activation with both 4a-PDD and 
GSK1016790A (data not shown). Interestingly, PGI synthase expression is absent from all 
nephron segments examined in male Sprague-Dawley rats, (Vitzthum et a l, 2002), 
suggesting that the kidney is unlikely to be the source of PGI2 in vivo, although it may 
contribute to PGE2 production. Furthermore, circulating immune cells are unlikely to be the 
source of prostaglandins given the negative findings with GSK1016790A in whole blood. 
Although TRPV4 has demonstrated a clear role in mediating vasodilation in studies of 
isolated vessels, none of these reports have provided evidence of PGI2 playing a significant 
role in vasodilatory mechanisms in either small or large vessels (Kohler et a l, 2006; Loot et 
a l, 2008; Zhang et a l, 2009; Mendoza et a l, 2010). It is plausible that these previous reports 
have failed to implicate TRPV4 in PGI2 production and a role in vasodilation as the vessels 
selected, which include the carotid (Kohler et al, 2006; Loot et a l, 2008), mesenteric (Zhang 
et al, 2009; Mendoza et al, 2010) and arteria gracilis (Kohler et a l, 2006) arteries are not the 
source of TRPV4-mediated prostaglandin release in vivo. Thus, the vessels responsible for 
TRPV4-mediated prostanoid release may reside in different anatomical locations. 
Alternatively, the PGI2 production observed here in vivo may not reflect release from the 
vasculature.
Despite clearly demonstrating that TRPV4 activation induces prostaglandin release these 
findings have certain limitations. First, the magnitude of PGI2 release in response to TRPV4 
activation with GSK1016790A in vivo appears to be quite high and conceivably may not be 
attained under conditions of non-pharmaeological TRPV4 activation. Supporting this, PGI2 
release in vivo was only observed at the highest doses of GSK1016790A, suggesting that a 
high level of TRPV4 activation is required to enable this mechanism. Moreover, a non-
i l l
pharmacological mode of TRPV4 activation (i.e. hypotonicity) applied to HUVECs alone 
failed to induce prostanoid production in vitro (Figure 2.9). Secondly, as mentioned above, 
the exact cellular source of prostanoids in vivo is incompletely defined. Finally, only PGI2 
and PGE2 were measured in these studies; other eieosanoids may also be released with 
pharmacological TRPV4 activation, therefore further evaluation of additional arachidonie 
acid pathway products may be of relevance.
In summary, these data show for the first time that activation of TRPV4 elicits the robust 
release of prostaglandins in vivo and also from isolated endothelial cells in vitro. The release 
of prostaglandins in vivo contributes to the hypotensive effects observed following 
pharmacological TRPV4 activation, and moreover, may also modulate the magnitude of the 
TRPV4-mediated lung permeability response.
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Chapter 3
Evaluation of the mechanism of TRPV4-mediated 
endothelial detachment in vitro
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3.1 Introduction
3.1.1 General Introduction
The eireulatory system in vertebrates is responsible for the transport of materials such as 
oxygen, nutrients, water and hormones to tissues and removal of unwanted waste products 
from tissues. The exchange of these materials is actively regulated by the vascular 
endothelium, which acts as a semipermeable barrier between the blood and the underlying 
tissue. Under physiological conditions, the permeability of the endothelial layer is tightly 
regulated, thereby maintaining circulatory homeostasis and organ perfusion. However, under 
pathological conditions the integrity of the endothelial barrier can be perturbed, causing the 
extravasation of blood components which result in tissue edema and dysfunction. In fact, 
increased endothelial permeability is the hallmark of a number of pathological conditions 
including acute lung injury, heart failure and diabetic retinopathy (Antonetti et al., 2009; 
Gheorghiade et al., 2006; Lucas et al., 2009). Moreover, increased vascular permeability is 
postulated to be responsible for the circulatory collapse observed in sepsis (Hinshaw, 1996). 
Despite the pathophysiological importance of enhanced vascular permeability, the precise 
mechanisms mediating endothelial disruption are not completely understood. However, an 
increase in the level of intracellular calcium appears to be crucial for the initiation of 
endothelial barrier disruption (Kumar et a l, 2009).
The data presented in chapter 2, in conjunction with a number of published reports, 
demonstrate that TRPV4 activation elicits an increase in vascular permeability, particularly in 
the lung (Alvarez et al., 2006; Hamanaka et al., 2007; Jian et al., 2008; Thomeloe et al., 
2012; Willette et al., 2008; Wu et al., 2009). The permeability response has been related 
primarily to endothelial disruption/detachment, which facilities the passage of vascular fluid 
into the extravascular space (Alvarez et al., 2006; Willette et al., 2008), although the alveolar
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epithelium (Huh et al., 2012) and alveolar macrophages (Hamanaka et ah, 2010) have also 
been implicated in this response. To date, the intracellular signaling pathways downstream of 
TRPV4 activation that mediate endothelial detachment have not been interrogated.
3.1.2 Hypothesis
TRPV4-mediated endothelial detachment is dependent upon an increase in intracellular 
calcium and subsequent cytoskeletal reorganization.
3.1.3 Aim
The present study was designed to investigate the intracellular signaling pathways 
responsible for mediating endothelial detachment following TRPV4 activation (a mechanism 
contributing to enhanced lung permeability), using a combination of 1) intracellular calcium 
monitoring and 2 ) pharmacological inhibitors of intracellular signaling pathways associated 
with endothelial permeability. Moreover, the effects of different pharmacological TRPV4 
activators were examined. HUVECs were selected as a model endothelial cell line based on 
previous reports demonstrating the existence of a TRPV4-mediated detachment phenotype in 
these cells (Willette et al., 2008; Thomeloe et al., 2012).
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3.2 Methods
3.2.1 Pharmacological agents
GSK2412532A and SB239063 were synthesized at GlaxoSmithKline Pharmaceuticals. 
Atorvastatin, genistein, herbimycin A, rolipram, Triton X-100 and (i^)-(+)-fra«5 -4 -(l- 
aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide (Y27632) were all obtained from Sigma- 
Aldrich. Forskolin, nocodozole and paclitaxel were all obtained from Tocris (Bristol, UK). 
Blebbistatin and cytochalasin D were obtained from Enzo Life Sciences (Farmingdale, NY, 
USA). Cytochalasin B and the FLIPR® calcium kit were obtained from MP Biomedicals 
(Solon, OH, USA), and Molecular Devices (Sunnyvale, CA, USA), respectively. For all in 
vitro studies compounds were dissolved in 100% DMSG at a stock concentration of lOmM, 
then diluted in either cell culture medium or Hanks balanced salt solution. The final 
concentration of DMSG under experimental conditions was 0.1-0.2%.
3.2.2. HUVEC detachment
HUVECs were seeded into 96-well plates (Fisher Scientific) at a density of 2.0 x 10"^  cells per 
well in 200pL of endothelial growth media (see section 2.2.3 for details) and incubated 
overnight at 37°C. HUVEC growth medium was removed and replaced with 50pL EBM-2 
medium containing 2% FBS. To investigate the response of HUVECs to TRPV4 agonist 
stimulation, cells were treated with GSK1016790A and GSK634775 at various 
concentrations for 3 hours at 37°C in 5% CG2. To evaluate detachment kinetics HUVECs 
were treated with GSK1016790A (lOnM) or vehicle for 30 minutes, 1 hour or 3 hours. For 
calcium dependence studies, HUVECs were pre-ineubated for 10 minutes with calcium 
ATPase inhibitors (thapsigargin or cyclopiazonie acid) or with medium containing various 
concentrations of EGTA (ImM, 2mM or 5mM) then treated with GSK1016790A. For
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investigation of the mechanism of detachment, HUVECs were pre-ineubated for 1 hour with 
pharmacological inhibitors (listed in Table 4) then stimulated with GSK1016790A or A23187 
for 3 hours. For agonist only studies (i.e. no inhibitors), compounds were diluted in culture 
media sufficient to obtain a drug concentration 2-times the desired final concentration. 5 0 jliL  
of this solution was added to the cells resulting in a 1:2 dilution into the well. A similar 
approach was adopted for pre-ineubation studies using inhibitors, except 50pL of a 3X 
solution of GSK1016790A (lOnM final concentration) was added following incubation with 
inhibitors -  the final well volume was 150pL. Following treatment with GSK1016790A, 
GSK634775 or A23187, cells were gently washed with PBS, then fixed with 50pL 4% 
paraformaldehyde (Electron Microscopy Science) and stained with lOOpL Diff-Quik cell 
identification solution (Fisher Scientific). To quantify the number of attached cells, each well 
was imaged with a high-resolution monochrome CCD camera coupled to a Sorcerer cell 
counting system (Optomax, NH, USA). HUVECs were photographed with the Olympus 1x71 
inverted fluorescent microscope using the DP71 digital camera. DP controller software was 
used to analyze images.
3.2.3 Intracellular calcium influx
HUVECs were seeded into 384-well poly-D-lysine coated, black, clear bottom plates 
(Greiner Bio-One, Monroe, NC, USA) at a density of 1.5 X 10"^  cells per well in 50pL of 
endothelial growth media for 24 hours in a humidified atmosphere containing 5% CO2 and 
95% O2. Following incubation EGM-2 medium was replaced with 20pL assay buffer 
containing the intracellular calcium indictor Fluo-4 (2pM) in addition to 500pM brilliant 
black (both Molecular Devises) and 2.5pM probenecid in Hank’s balanced salt solution (both 
Life Technologies) at room temperature for 1 hour in the absence of light.
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Agonist concentration response curves were prepared separately by diluting compounds in 
384-well polypropylene V-botton plates (Greiner Bio-One). Briefly, GSK1016790A and 
GSK634775 stock solutions (lOmM, see section 3.2.1) were diluted to 3mM (3.3pL 
compound added to 6.7jLiL DMSO). This 3mM stock was serially diluted, at a ratio of 1:3 
( 3 jliL  compound into 6\xL DMSO), a further 10 times. The diluted compounds were added to 
HBSS (IpL compound into 332.3p,L HBSS, i.e. 1:333.3 dilution) to prepare the assay-ready 
compound plate.
Subsequently, the plates were inserted into a fluorometric-imaging plate reader (FLIPR®, 
Molecular Devices) and the fluorescence from intracellular calcium (A-ex= 488 nm, lem=510- 
570 nm) was evaluated over a 3 minute period which included a 10 second read to determine 
baseline fluorescence levels before the application of lOpL of TRPV4 channel activators 
GSK1016790A and GSK634775, from the compound plate. After compounds were applied, 
the plates were read for an additional 2 minutes and 50 seconds. Calcium responses were 
measured as peak fluorescence intensity minus basal fluorescence intensity. EC50 values were 
calculated from eoneentration-response curves using Graph Pad Prism 5.01.
3.2.4 HUVEC viability measurement
HUVEC viability was measured using the Toxilight™ cytotoxicity assay kit (Lonza, 
Walkersville, MD, USA) according to the manufacturer’s instructions. The ToxiLight™ 
assay measures the release of adenylate kinase (AK), a cytoplasmic enzyme present in all 
eukaryotic cells, from damaged cells. The enzyme actively phosphorylates ADP (the 
substrate in the assay) to form ATP. The ATP generated from the conversion of ADP to ATP, 
by AK, is able to in turn catalyze a second reaction -  the formation of light (the output of the 
assay) from the reaction between ATP and luciferin in the presence of luciferase. As the level
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of cytolysis increases, the amount of AK in the supernatant also increases, which results in 
emission of higher light intensity by the ToxiLight™ reagent.
HUVECs were seeded into 96-well plates (Fisher Scientific) at a density of 2.0 x 10"^  cells per 
well in 200pL of endothelial growth media and incubated overnight at 37°C. Following 
incubation, cells were washed in 200pL EBM-2 media, before addition of 50pL of fresh 
EBM-2 media containing 2% FBS (Life Technologies). Cells were treated by adding 50pL of 
a 2X stock (1:2 dilution into plate) of GSK1016790A (at various concentrations), 
GSK634775 (300nM final), Triton X-100 (2% v/v in EBM-2 + 2% FCS) or vehicle for 3 
hours at 37°C. Following treatment, cellular supernatants were retrieved and centrifuged (300 
X g, 5 minutes) to remove particulates. 20pL of particulate-free supernatant was removed and 
transferred into a opaque white 96-well plate (Greiner Bio-One) where lOOpL of the 
Toxilight™ reagent was added per well. The plate was then equilibrated at room temperature 
for 5 minutes, and lumineseenee was detected using the EnVision® 2103 Multi-label reader 
from Perkin Elmer (Waltham, MA, USA).
3.2.5 Statistical analysis
Data are presented as mean ± s.e.m for n observations, where n represents the number of 
separate experiments. Statistical analysis was conducted using one-way ANOVA with a 
Dunnett post hoc test when comparison was made with vehicle, or a one-way ANOVA with a 
Tukey post hoc test when all groups were compared to each other. A two-way ANOVA 
followed by Bonferroni post hoc test was employed when evaluating the effect of two 
independent parameters. For all analyses a value of p<0.05 was considered statistically 
significant.
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3.3 Results
3.3.1 Comparison of the effects of two TRPV4 activators on HUVEC detachment
TRPV4 activation in vivo mediates a prominent endothelial disruption (Alvarez et ah, 2006; 
Willette et al., 2008; Wu et al., 2009). In vitro, TRPV4 activation with GSK1016790A 
manifests itself as an overt detachment of human vascular endothelial cells (HUVECs) from 
the tissue culture surface (Thorneloe et al., 2012; Willette et al., 2008). The cellular 
mechanisms responsible for the detachment response are undetermined. Moreover, the effects 
of alternative pharmacological TRPV4 activators to GSK1016790A on endothelial 
detachment have not been profiled. Here, two chemically distinct TRPV4 activators, 
GSK1016790A and GSK634775, were compared to determine whether the detachment 
phenotype was reproducible amongst TRPV4 agonists, as observed with prostacyclin release 
(Figure 2.5).
Consistent with previous studies, GSK1016790A induced HUVEC detachment (Figure 3.1 A, 
middle panel) in a concentration- (Figure 3.IB) and time-dependent manner (Figure 3.1C) 
(Thorneloe et al., 2012; Willette et al., 2008). The detachment response was characterized by 
an initial contraction and rounding of the cell (<15 minutes, data not shown) followed by a 
complete detachment with prolonged exposure (> 30 minutes) to GSK1016790A (Figure
3.1 A, middle panel). The concentration-effect relationship for GSK1016790A revealed a 
narrow window between the no effect concentration (< InM) and the maximal effect 
concentration (>10nM), EC50 of 2.4nM (Figure 3.IB). Surprisingly, GSK634775 did not 
induce any appreciable change in HUVEC morphology (Figure 3.1 A, right panel), nor did it 
elicit a cellular detachment response at concentrations up to IpM (Figure 3.IB). These data 
clearly demonstrate that pharmacological activation of TRPV4 with distinct ligands mediates 
differential effects on endothelial integrity.
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Figure 3.1: TRPV4 activation with GSK1016790A, but not GSK634775, induces HUVEC 
detachment. A) Representative images of HUVECs treated with vehicle (left), 
GSK1016790A (lOnM, middle) and GSK634775 (IpM, right) for 3 hours. Images are 
representative of a typical experiment. Scale bars, 20pm. (B) Effeets of the seleetive TRPV4 
activators GSK1016790A and GSK634775 on HUVEC detachment. Data are represented as 
the percentage of cells attached relative to vehicle. ***p<0.001 vs. corresponding 
eoncentration of GSK634775 (two-way ANOVA, Bonferroni post hoc test). (C) Time-course 
of GSK1016790A-mediated detachment (lOnM, blaek bars). ***p<0.001 vs. Control, (one­
way ANOVA, Dunnett’s post hoc test). All data are means ± s.e.m, n=4 independent 
experiments.
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3.3.2 The effect of TRPV4 activators on calcium influx in HUVECs
GSK1016790A and GSK634775 both increase intracellular calcium levels in HEK293 cells 
overexpressing the human TRPV4 channel (EC50 values of 3nM and 25nM, respectively; 
Thomeloe et ah, 2012; Willette et ah, 2008). Given the differential detachment responses 
elicited by GSK1016790A and GSK634775 in HUVECs (Figure 3.1) it was hypothesized 
that perhaps GSK634775 was ineffective at activating the endogenous TRPV4 channels 
present in HUVECs. Therefore, the activity of both molecules was evaluated in this cell type 
by measuring changes in intracellular calcium concentration following treatment. Both 
GSK1016790A and GSK634775 increased intracellular calcium in a concentration-dependent 
manner (EC50 values of 8.7nM and 343nM, respectively; Figure 3.2). The magnitude of the 
calcium response differed between agents, with GSK1016790A inducing a greater increase in 
calcium levels; although, a true comparison of the intrinsie activities of both agents cannot be 
made as the maximum response for GSK634775 eould not be determined in this study due to 
limited compound solubility above 30pM. Despite this, these results clearly demonstrate that 
both GSK1016790A and GSK634775 activate TRPV4 channels in HUVECs albeit with some 
differences in potency compared to heterologous systems (i.e. HEK293 cells expressing 
reeombinant TRPV4). Since only GSK1016790A induced endothelial detachment, all 
subsequent studies examining the detachment mechanism employed GSK1016790A only.
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Figure 3.2: GSK1016790A and GSK634775 induce a concentration-dependent increase in 
intracellular ealeium in HUVECs. HUVECs were loaded with Fluo-4 AM prior to stimulation 
with the TRPV4 activators GSK1016790A and GSK634775. Data is expressed as relative 
fluorescence units (RFU) and is presented as mean ± s.e.m. of quadruplicate determinations 
from > 8 independent experiments. The calculated ECsoS for GSK1016790A and GSK634775 
were 8.7nM and 343nM, respectively.
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3.3.3 The role of calcium in the GSK1016790-mediated HUVEC detachment response
Given that both GSK1016790A and GSK634775 caused a robust increase in intracellular 
calcium (Figure 3.2), but only GSK1016790A induced HUVEC detachment (Figure 3.1), the 
role of calcium in GSK1016790A-mediated detachment was examined. For this purpose, a 
strategy similar to that used to explore the role of ealeium in GSKl016790A-mediated PGU 
release (Figure 2.7) was utilized, i.e. looking at the impact of extracellular calcium influx and 
calcium release from endoplasmic stores. To examine the role of calcium influx, extracellular 
ealeium levels were depleted by adding 1, 2, and 5mM of the calcium chelator EGTA to the 
assay media. HUVECs were subsequently treated with GSK1016790A and eellular 
detachment was evaluated. Previously, 2mM EGTA significantly inhibited GSK1016790A- 
mediated PGU release; however, in the current experiments the detachment response to 
GSK1016790A in the presence of ImM and 2mM EGTA was no different to the response 
observed in the absence of EGTA. GSK1016790A induced a eoncentration-dependent 
detaehment in all 3 conditions; although a statistically significant attenuation of detaehment 
was observed at the 3nM GSK1016790A concentration (p<0.01 and p<0.001 at ImM and 
2mM EGTA vs. no EGTA, respectively). The highest concentration of EGTA (5mM) elieited 
a eonspieuous alteration in HUVEC morphology (in the absence of GSK1016790A), 
charaeterized by cell shrinkage and the appearanee of spindle-like projections from the cell 
body in addition to a 20% detaehment response (data not shown). This finding is unsurprising 
given the importance of calcium in maintaining cell-cell and eell-matrix interactions, coupled 
with the fact that calcium chelators are typically included in eellular dissociation solutions 
containing trypsin (Kawasaki et al., 2004; Tiruppathi et al., 2002). This effect made it 
impossible to evaluate the response to GSK1016790A under the 5mM EGTA conditions. The 
overall effect of EGTA on GSKl016790A-mediated HUVEC detachment -  when all
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concentrations of both GSK1016790A and EGTA were compared -  was not statistically 
significant (p=0.24, two-way ANOVA with Bonferroni host hoc).
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Figure 3.3: GSK1016790A-mediated HUVEC detachment is not extracellular calcium- 
dependent. (A) Effect of increasing concentrations of the ealeium chelator EGTA on 
GSK1016790A-mediated detachment. Data is presented as the percentage of cells attached 
relative to vehicle (No EGTA). Data were analyzed by two-way ANOVA with Bonferroni 
post hoc test, **p<0.01, ***p<0.001 vs. corresponding GSK1016790A concentration in No 
EGTA group. (B) GSK1016790A-mediated detaehment potency at indicated EGTA 
concentrations. E C 5 0  values are derived from data presented in (A) with associated 95% 
confidence intervals. (C) Effect of EGTA on free calcium concentrations in assay medium 
used in (A). Values obtained using the maxehelator algorithm, 
http://maxehelator.stanford.edu/. Data is presented as mean ± s.e.m, n=3 independent 
experiments.
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To evaluate the role of intracellular calcium on endothelial cell detachment, endoplasmic 
calcium stores were depleted with thapsigargin and cyclopiazonie acid prior to challenge with 
GSK1016790A. Calcium store depletion alone did not elicit detachment (data not shown). 
Moreover, calcium store depletion had no effect on GSK1016790A-mediated detaehment 
(Figure 3.4). This finding is analogous to the lack of involvement of endoplasmic calcium in 
TRPV4-mediated prostacyclin release (Figure 2.7A).
Finally, the calcium ionophore A23187, which increases intracellular calcium via a non- 
TRPV4 pathway, did not induce HUVEC detachment (Figures 3.5A, and E). This further 
supports the notion that GSK1016790A-mediated detaehment is not calcium-dependent per
se.
Overall, these data indicate that both extracellular and endoplasmic calcium are not involved 
in GSK1016790A-mediated detachment.
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Figure 3.4: GSK1016790A-mediated detachment is not regulated by endoplasmic calcium 
release. HUVECs were pre-treated with IpM thapsigargin (TG), IfiM cyclopiazonie acid 
(CPA) or vehicle for 10 minutes to deplete intracellular calcium stores prior to challenge with 
the TRPV4 activator GSK1016790A (‘790, lOnM). Data is presented as the percentage of 
cells attached relative to vehicle control (white bar). *p<0.05 vs. Control (one-way ANOVA, 
Tukey multiple comparison post hoc test). Data are means ± s.e.m, n=3 independent 
experiments. NS, not significant.
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3.3.4 Evaluation of the TRPV4-dependence of GSK1016790A-mediated detachment
To confirm GSKl016790A-mediated detachment was TRPV4 dependent, GSK2193874, the 
selective TRPV4 blocker, was employed. Consistent with a TRPV4-dependent mechanism, 
pre-treatment with GSK2193874 completely inhibited GSKl016790A-mediated detaehment 
in a concentration-dependent manner (Figures 3.5A, C, and D, Table 4).
3.3.5 Evaluation of the mechanism of GSK1016790A-mediated HUVEC detachment
As TRPV4-mediated detaehment to GSK1016790A was found to be calcium-independent, 
the mechanism(s) responsible for this phenotype was probed further using pharmacological 
agents that modulate signalling pathways involved in cell motility, adhesion and vascular 
permeability. Actomyosin engagement has been demonstrated to induce endothelial 
contraction (Schnittler et ah, 1990; Shen, Wu, & Yuan, 2009), a prerequisite to cell 
detachment. Accordingly, the effect of selective inhibitors of the actomyosin pathway, 
including blebbistatin (myosin II ATPase), ML-7 (MLCK), and Y27632 (Rho-associated, 
coiled-coil containing protein kinase, ROCK) were profiled. Each agent was evaluated at a 
concentration sufficient to achieve full inhibition of its respective target (blebbistatin. Straight 
et al., 2003; ML-7, Krarup et al., 1998; Y27632, Davies, et al., 2000). Surprisingly, none of 
the actomyosin modulators inhibited GSKl016790A-induced detachment (Figure 3.5B, Table 
4). Consequently, a larger panel of pharmacological agents, covering a broader range of 
targets and pathways was evaluated (Table 4). These agents included cytoskeletal 
modulators, kinase inhibitors, cyclic AMP modulators and atorvastatin -  all of which have 
been demonstrated to modulate endothelial permeability, although the permeability 
modulating mechanism of atorvastatin is not fully understood (reviewed in van Hinsbergh & 
van Nieuw Amerongen, 2002; van Nieuw Amerongen & van Hinsbergh, 2002). Finally, 
inhibitors of TRPV4-mediated prostacyclin release (Figure 2.8) were also included to
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ascertain whether any overlap in the detachment and prostanoid release mechanisms existed. 
Of the sixteen additional agents profiled, only GF1019203X (a PKC inhibitor) significantly 
inhibited GSK1016790A-mediated detachment, and only paclitaxel (a microtubule stabilizer) 
significantly augmented GSK1016790A-induced detachment (Table 4). However, it is 
important to note that paclitaxel induced HUVEC detaehment in the absence of 
GSK1016790A challenge (data not shown). As such the augmented detachment response, in 
cells treated with both paclitaxel and GSK1016790A, likely reflects an accumulation of the 
effect of the two molecules individually, as opposed to a bona fide augmentation of the 
GSK1016790A-mediated detachment effect. In summary, these data demonstrate that 
GSKl016790A-mediated detachment is TRPV4-dependent and is partially mediated by PKC 
activation.
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Figure 3.5: Evaluation of the mechanism of GSK1016790A-mediated HUVEC detachment. 
(A) GSK1016790A-mediated detachment is inhibited by a 1 hour pre-treatment with the 
selective TRPV4 blocker GSK2193874. *p<0.05, #p<0.001 vs. vehicle, ***p<0.001 vs. 
GSK1016790A (‘790), one-way ANOVA with Tukey multiple comparison post hoc test. (B) 
Pre-treatment with the cytoskeletal modulators blebbistatin (Bleb, lOpM), Y27632 (lOpM) 
and ME-7 (lOpM) does not inhibit GSK1016790A-mediated detachment. ***p<0.001 vs. 
vehicle, one-way ANOVA, Tukey multiple comparison post hoc test. Data in (A) and (B) are 
presented as the percentage of cells attached (mean ± s.e.m,) relative to control. n=4 
independent experiments. HUVEC morphology following treatment with GSK1016790A in 
the absence (C) or presence (D) of GSK2193874 or following incubation with the calcium 
ionophore, A23187 alone (E). Images are representative of a typical experiment. Seale bar, 
20pm. NS, non-signifieant.
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Table 4. Effect of signaling pathway modulators on GSK1016790A-mediated detachment
Compound Target Target Class M echanism o f action Concentration % inhibition o f detachm ent
GSK1016790A TRPV4 Ion Channel Activator lOnM 0.0 ±3.7
GSK2193874 TRPV4 Ion Channel Blocker 300nM 105.7 ±4.3***
GSK2193874 TRPV4 Ion Channel Blocker lOOnM 84.1 ±2.2***
GF1019203X PKC Kinase Inhibitor lOpM 38.0 ±0.8***
Cytochalasin D Actin Cytoskeletal Actin polyimerization inhibitor Ipg/m l 13.5 ±2.6
Cytochalasin B Actin Cytoskeletal Actin polyimerization Inhibitor lOpM 11.7 ±2.2
Latrunculin Actin Cytoskeletal Actin polyimerization inhibitor IfiM 6.9 ±1.7
Indomethacin COX Enzyme Inhibitor lOpM 6.3 ±2.2
Genistein Tyrosine kinase Kinase Inhibitor lOpM 6.2 ±2.1
ML-7 MLCK Kinase Inhibitor lOpM 5.4 ±1.4
Blebbistatin Myosin II ATPase Enzyme Inhibitor lOpM 3.3 ±2.1
Rolipram PDE-IV Enzyme Inhibitor lOpM 2.5 ±1.9
PD98059 MEKl Kinase Inhibitor lOpM 2.4 ±1.4
cPLAj inhibitor CPLA2 Enzyme Inhibitor lOpM 2.2 ±0.9
V27632 ROCK Kinase Inhibitor lOpM 1.5 ±1.3
Herbimycin A Tyrosine kinase Kinase Inhibitor lOpM 1.2 ±2.1
Atorvastatin HMG-CoA reductase Enzyme inhibitor lOpM 0.1 ±1.5
Forskolin AdenyiyI cyclase Enzyme Activator lOpM -2.7 ±0.8
Nocodozole Cytoskeletal Microtubule inhibitor lOpM -10.0 ±0.7
SB239063 p38 Kinase Inhibitor lOpM -10.9 ±0.5
GSX2412532A FAK Kinase Inhibitor lOpM -11.6 ±1.1
Paclitaxel Cytoskeletal Microtubule stabilizer lOpM -16.2 ±0.4**
**p<0.01, ***p<0.001 vs. GSK101S790A. One way ANOVA with Bonferroni multiple comparison post hoe test
3.3.6 GSK1016790A-mediated detachment cannot be reversed by pharmacological 
TRPV4 inhibition
To ascertain whether the detachment phenotype is reversible, HUVECs were treated with 
lOnM GSK1016790A (for 3 hours to promote detachment) then subsequently treated with the 
pharmacological TRPV4 blockers GSK2193874 (10, 30, 100 nM) or ruthenium red (0.1, 1, 
10 pM), for up to 24 hours, in the continued presence of GSK1016790A. As expected, 
GSK1016790A induced a significant detachment response. The addition of GSK2193874 or 
ruthenium red, post-detaehment, did not alter the number of attached cells (Figure 3.6). A 
slight increase in the number of attached cells was observed in vehicle treated HUVECs. This 
likely reflects cellular proliferation during the time-course of the experiment. These results 
clearly demonstrate that GSK1016790A-mediated detachment cannot be reversed by 
pharmacological TRPV4 inhibitors once established. However, as noted previously, pre­
treatment with a GSK2193874 -  at the same concentrations used here -  was able to prevent 
GSK1016790A-mediated detachment (Figure 3.5).
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Figure 3.6: GSK1016790A-mediated HUVEC detachment cannot be reversed with a TRPV4 
blocker after detachment has occurred. HUVECs were treated with GSKl016790A (‘790, 
lOnM), or vehicle, for 3 hours to promote detachment. Subsequently, the TRPV4 blockers 
GSK2193874 (‘874, A) or ruthenium red (RuRed, B) were added to the cells and incubated 
for an additional 3 or 24 hours, in the continued presence of GSK1016790A. Data is 
presented as the percentage of cells attached (mean ± s.e.m.) relative to control (vehicle, 0 
hours). ***p<0.001 vs. vehicle for all inhibitor concentrations (two-way ANOVA with 
Bonferroni post hoc test). n=4 independent experiments.
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3.3.7 GSK1016790A-induced detachment is a result of cell death
Cell detachment can be indicative of a loss of cellular viability. Consequently, the potential 
cytotoxic effect of GSK1016790A was investigated. Adenylate kinase (AK) is a cytoplasmic 
enzyme. Its presence in the cultured medium indicates the integrity of the plasma membrane 
has been compromised; therefore, AK release was used as a surrogate for cell death. 
GSK1016790A induced a concentration-dependent AK release (Figure 3.7B). In contrast, a 
high concentration of GSK634775 (300nM) did not cause any discernible difference in AK 
release relative to vehicle (Figure 3.1 A). Importantly, the eoneentration-response of 
GSKl016790A-mediated AK release correlates with that observed for both the detachment 
(Figure 3.IB) and the calcium responses (Figure 3.2), inasmuch as little or no effect was 
observed at concentrations < InM, but maximal responses were observed at concentrations 
>10nM. Consistent with this, the calculated EC50 for GSKl016790A-mediated AK release 
(5nM) was similar to that obtained for detachment (2.4nM) and calcium influx (8.7nM) 
measurements. Triton X-100, a non-ionic detergent which permeabilizes cell membranes, 
also induced a statistically significant AK release (Figure 3.7A). These results demonstrate 
that GSKl 016790A-induced detachment is likely mediated via a unique cytotoxic effect of 
this molecule that is absent with another TRPV4 activator, GSK634775.
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Figure 3.7: GSK1016790A induces cell death in HUVECs. AK release was used as a 
surrogate for cell death. AK activity in the cellular supernatant was quantified using a 
luminescent assay, where AK release is directly proportional to luminescence intensity 
(RLU). (A) HUVECs were treated with vehicle, GSK634775 (SOOnM), and Triton X-100 
(2% v/v) in addition to the indicated concentrations of GSK1016790A (B) for 3 hours. Triton 
X-100 was used as a positive control. The calculated EC50 for GSK1016790A was 5nM. 
***p<0.001 vs. Vehicle (one-way ANOVA, Dunnett’s post hoc test). All data are means ± 
s.e.m, n=4 independent experiments.
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3.4 Discussion
The results described herein demonstrate that pharmacological TRPV4 activation with 
GSK1016790A, but not GSK634775, induces detachment of isolated endothelial cells. The 
role of TRPV4 was substantiated by inhibition of the detachment response by the selective 
TRPV4 blocker, GSK2193874. GSKl016790A-mediated detachment was not attributable to 
activation of the actomyosin contractile machinery or to changes in the level of intracellular 
calcium, but appeared partly dependent upon activation of PKC. Once established, 
GSK1016790A-induced detachment could not be reversed. Consistent with this, 
GSK1016790A induced HUVEC toxicity, as assessed by cytoplasmic enzyme release.
These results clearly demonstrate that structurally distinct TRPV4 activators (see Table 1) 
differentially regulate HUVEC detachment. GSK1016790A induced a significant detachment 
response, in agreement with previous findings (Willette et al., 2008; Thomeloe et al., 2012), 
whereas GSK634775 did not promote endothelial detachment. The reason for this 
discrepancy is uncertain. Although both molecules exhibit different potencies at TRPV4, it is 
unlikely that this accounts for the differential detachment response given the broad 
concentration range profiled for both molecules in this study. Similarly, a lack of activity in 
HUYECs can also be discounted given that both agents mediated a concentration-dependent 
calcium influx in these cells. The divergent detachment responses elicited by GSK1016790A 
and GSK634775 are redolent of “biased agonism”, where two agonists of the same receptor 
induce different functional responses (DeWire et al., 2007). This is a well established 
phenomenon for seven transmembrane receptors and recent evidence suggests that this 
response also occurs with ion channels (Lefkowitz et al., 2006; Shenoy & Lefkowitz, 2011). 
A key facilitator of biased agonism is the recruitment of beta-arrestin. It was recently 
reported that TRPV4 associates with beta-arrestin, which facilitates channel internalization
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and degradation (Shukla et al., 2010). If beta-arrestin is involved in the differential effects of 
these two molecules one may conceive of two potential scenarios: 1) GSK634775 recruits 
beta-arrestin, which causes channel internalization and subsequent degradation. This would 
limit TRPV4 activity and potential downstream pathway activation. Moreover, this might 
explain the smaller calcium influx and PGI2 release elicited by this agent; or 2) 
GSK1016790A recruits beta-arrestin; however, instead of degrading the channel it could 
perform its other documented function, that being a signaling scaffold (reviewed by DeWire 
et al., 2007), and thus initiate the activation of some, yet to be determined, signaling pathway 
that mediates cellular detachment. Alternatively, GSK1016790A and GSK634775 may 
exhibit differing selectivity’s towards different TRPV4 homo/heterotetrametic channel 
compositions that may exist in HUVECs. One of these channel compositions may mediate 
the activation of the detachment mechanism. Further investigation is required to substantiate 
any of these explanations.
Increasing intracellular calcium via (1) endoplasmic calcium store release, (2) extracellular 
calcium influx, or (3) a combination of both is a critical event mediating morphological 
changes in endothelial cells which results in enhanced vascular permeability to physiological 
agonists such as thrombin and histamine (Dudek & Garcia, 2001; Langeler et al., 1989; Lum 
et al., 1992; Lum et al., 1989; Nguyen et al., 1997; Schnittler et al., 1990; Shasby et al., 1997; 
van Nieuw Amerongen et al., 1998). Consistent with this, TRPV4-mediated endothelial 
disruption in isolated lung preparations is similarly dependent on an increase in intracellular 
calcium (Alvarez et al., 2006; Hamanaka et al., 2007; Jian et al., 2008; Wu et al., 2009). 
Curiously, in this study GSK1016790A elicited a robust increase in intracellular calcium 
levels in HUVECs; however, the ensuing detachment response was independent of either 
intracellular or extracellular calcium mobilization pathways. It is noteworthy that 2mM
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EGTA caused near-complete inhibition of TRPV4-mediated PGI2 (Figure 2.7), yet the same 
concentration of EGTA did not affect detachment. Further support for the calcium 
independent nature of the detachment phenotype was provided by (1) the lack of detachment 
response with the calcium ionophore, A23187 and (2) a similar magnitude of calcium 
induction with both GSK1016790A and GSK634775 at 3nM and 300nM, respectively, while 
detachment was only elicited by GSK1016790A at these concentrations. The differential 
effects of calcium with respect to the responses observed with GSK1016790A and the 
physiological agonists thrombin and histamine may relate to subtle differences in the 
endothelial phenotypes observed; neither thrombin nor histamine induce overt cellular 
detachment but merely alter cell shape whilst increasing intracellular calcium (Dudek & 
Garcia, 2001; Langeler et al., 1989; Nguyen et al., 1997; Schnittler et al., 1990; van Nieuw 
Amerongen et al., 1998). As such, detachment and permeability may not necessarily be 
synonymous. Nevertheless, these data demonstrate that GSK1016790A-mediated detachment 
is highly unlikely to be dependent on changes in intracellular calcium levels.
The actin and myosin cytoskeleton is a key regulator of cellular shape, motility, contraction 
and in the case of the endothelium, permeability (Prasain & Stevens, 2009; Schnittler et al., 
1990). In endothelial cells, actomyosin interaction is regulated by phosphorylation of the 
regulatory light chain of myosin II (aka myosin light chain, MLC) by MLCK (Goeckeler & 
Wysolmerski, 1995). This phosphorylation event facilitates the movement of myosin over 
actin which generates the force necessary to influence cellular morphology. MLC- 
phosphatase dephosphorylates MLC, thus inhibiting contraction (Verin et al., 1995). ROCK 
inhibits MLC-phosphatase activity, thus promoting MLC phosphorylation and inducing 
actomyosin contraction (Kimura et al., 1996; Essler, 1998). Accumulating evidence supports 
an intimate association between TRPV4 and the actin cytoskeleton (Becker et al., 2009;
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Goswami et al., 2010; Matthews et al., 2010; Ramadass et al., 2007; Shin et al., 2012). For 
instance, in cultured neuronal cells TRPV4 activation with 4a-PDD elicits morphological 
disruption, characterized by retraction of growth cones and neurite branches (Goswami et al., 
2010). In this study, pharmacological inhibition of three of the critical components of the 
actomyosin machinery, namely MLCK (by ML-7), ROCK (by Y27632) and myosin II 
ATPase (by blebbistatin) did not attenuate GSK1016790A-mediated detachment. Moreover, 
inhibition of actin polymerization with cytochalasin B, cytochalasin D and latrunculin did not 
inhibit the detachment phenotype, although, a slight, but non-significant reversal of 
detachment was observed with cytochalasin B and D (Table 4). These latter findings contrast 
with reports demonstrating a robust inhibition of hypotonicity-induced TRPV4 currents in 
CHO cells treated with cytochalasin B and latrunculin (Becker et al., 2009; Suzuki, Hirao, & 
Mizuno, 2003). However, different modes of TRPV4 activation were employed between 
studies i.e. pharmacological versus mechanical. Despite these differences, the data 
demonstrate that GSK1016790A-mediated detachment is not regulated by the actomyosin 
cytoskeleton.
Another critical component of the cytoskeleton is the microtubules, which consist of 
heterodimeric assemblies of a- and P-tubulin (Schwartz, 2009). TRPV4, like its homologue 
TRPVl, interacts with the microtubule cytoskeleton directly via its C-terminus (Goswami et 
al., 2006; Goswami & Hucho, 2008; Goswami et al., 2010) and indirectly via microtubule- 
associated protein 7 (Suzuki et al., 2003). This interaction imparts an important regulatory 
function on TRPV4 (Goswami et al., 2010; Suzuki et al., 2003). In cultured neurons, 
microtubule stabilization with paclitaxel inhibits 4a-PDD-induced calcium currents 
(Goswami et al., 2010). In contrast, in this study, paclitaxel significantly increased the 
detachment response to GSK1016790A. However, as noted, paclitaxel induced detachment in
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the absence of GSK1016790A. Thus, the detachment observed here likely reflects the 
cytotoxic effect of this agent in endothelial cells and not an augmentation of the 
GSK1016790A response (Grant et al., 2003; Schwartz, 2009). Indeed, this characteristic is 
one of the reasons paclitaxel, as well as other taxane family members, are being profiled 
clinically as cancer chemotherapeutics on account of their prominent vascular-disrupting 
effects (Jordan & Wilson, 2004; Schwartz, 2009). Similarly, the microtubule inhibitor, 
nocodazole, also mediated a subtle increase in GSK1016790A-mediated HUVEC 
detachment. This finding is consistent with previous reports that have also demonstrated 
morphological changes in endothelial cells following nocodazole treatment (Birukova et al., 
2004; Catravas et al., 2010). Although counterintuitive, microtubule stabilization (by 
paclitaxel) and destabilization (by nocodazole) in this study had the same net effect: 
increased detachment. In fibroblasts, similar properties, with respect to cellular morphology 
modulation, were also noted with these two agents (Mikhailov & Gundersen, 1998). As such, 
the data in this study is consistent with that of Mikhailov & Gundersen (1998). However, like 
the actomyosin cytoskeleton, the microtubule cytoskeleton is not responsible for 
GSKl 016790A-mediated detachment response. Therefore, GSKl 016790A-mediated 
morphological disruption is most likely independent of cytoskeletal modulation.
Of the various cell signaling and pathway modulators profiled in this study, inhibition of 
PKC partially attenuated GSK1016790A-mediated detachment. Extensive literature evidence 
exists supporting the involvement of PKC in mediating endothelial hyperpermeability 
responses to agents including thrombin, histamine, bradykinin, platelet-activating factor, 
hydrogen peroxide and VEGF (Huang & Yuan, 1997; Johnson et al., 1990; Johnson et al., 
1989; Murray et al., 1991; Ramirez et al., 1996; Wu et al., 1999). Importantly, inhibition of 
PKC attenuates the increased transendothelial permeability response to these agonists. PKC
140
constitutes a family of serine/threonine kinases that can be divided into three subgroups 
according to their modes of activation: conventional, novel and atypical. Conventional PKC 
isoforms (PKC-a, -pi, -P2, and -y) are activated by phosphatidylserine, calcium, and 
diacylglycerol (DAG); novel PKCs (PKC-ô, -s, -0 and -q) are activated by
phosphatidylserine, DAG, but not by calcium; and atypical PKCs (PKC-^, - i  and -1 ) are not 
activated by calcium or DAG (Geraldes & King, 2010). In the endothelium, the most 
abundant PKC isoforms are a  and p (Bussolino et al., 1994), although, PKC-ô, -s, -y  and - 
are also present (Geraldes & King, 2010). With respect to endothelial permeability the PKC 
-a and -p isoforms are considered the main perpetrators of this response (Yuan, 2002). 
Mechanistically, PKC activation increases endothelial permeability in two ways: I) by 
increasing actomyosin engagement via ROCK-mediated MLC phosphorylation (Garcia et al., 
1995; Mehta et al., 2001; Stasek et al., 1992); and 2) by disrupting cell-cell adhesion through 
disassembly of YE-cadherin junctions (Alexander et al., 1998; Sandoval et al., 2001). In both 
instances PKC activation is contingent upon an increase in intracellular calcium. Given that 
GSKl 016790A-mediated detachment is independent of calcium and actomyosin engagement 
it would seem unlikely that this PKC-pathway is responsible for the detachment response. It 
is noteworthy that the pharmacological PKC inhibitor selected for these studies, GF109203X, 
inhibits a broad spectrum of PKCs isoforms including PKC-a, -pi, -p2, -y, -5, and -s 
(Martiny-Baron et al., 1993; Sakai et al., 2009; Toullec et al., 1991). At the concentration 
utilized in these studies (i.e. lOpM) GF109203X should fully inhibit all the aforementioned 
PKC isozymes. As, novel PKCs (-5, and -s) do not require calcium for activation it is 
conceivable that these may be the isoforms facilitating GSK1016790A-mediated detachment. 
Indeed, recent evidence supports an association between TRPV4 and PKCs in signaling 
complexes that regulate neuronal hyperalgesic responses (Alessandri-Haber et al., 2006;
Goswami et al., 2010). Further investigation is required to determine whether PKCs is
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responsible for mediating GSK1016790A-mediated detachment, and moreover, the 
mechanism that activates this PKC isoform. Alternatively, TRPV4 channel activation is 
known to be enhanced by PKC phosphorylation (Fan et al., 2009). It is possible that PKC 
inhibition (with GF109203X) attenuates this phosphorylation event, thus limiting the positive 
feedback loop that results in full activation of TRPV4 by GSK1016790A. In this scenario, 
PKC inhibition would be expected to simply reduce channel activation as opposed to 
completely blocking activity. This explanation may be more in line with the partial 
attenuation of detachment observed with PKC inhibition. As such, PKC may facilitate 
GSKl016790A-mediated endothelial detachment by enhancing channel activity beyond a 
certain threshold and/or via a mechanism involving PKCs activation.
A paucity of literature reports exist demonstrating endothelial detachment in vitro, although 
homocysteine and snake venom metalloproteinases have been shown to induce this 
phenotype (Dudman et al., 1991; Gutierrez et al., 2005). However, the physiological 
relevance of the in vitro detachment response, in both reports, was questioned due to 
discrepancies between the in vitro findings and the effects of these agents following in vivo 
administration. Indeed, the circulatory collapse following GSK1016790A administration in 
vivo is rapid (seconds-to-minutes) in comparison to the protracted (minutes-to-hours) 
endothelial detachment response observed with this agent in vitro (Willette et a l, 2008; 
Thomeloe et a l, 2012). Whether endothelial desquamation occurs following GSK1016790A 
administration in vivo remains to be determined. However, a relatively minor aberration in 
endothelial barrier integrity in vivo -  through subtle morphological changes -  would be 
expected to have potentially profound effects on fluid extravasation in the absence of overt 
endothelial detachment.
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The data in this study clearly demonstrate that GSK1016790A-induced detachment is non- 
reversible and is likely mediated by a cytotoxic effect of this molecule, characterized by 
cytoplasmic AK release via disruption of the plasma membrane. Recent reports have 
demonstrated that TRPV4 can facilitate the passage of small intracellular molecules (<0.5 
kDa) through membrane hemichannels (Shahidullah et al., 2012; Ueda et al., 2011). It is 
however unlikely that these structures, consisting of connexins and pannexins, would permit 
the passage of large cytoplasmic enzymes like AK, which is ~22kDa (Scemes et al., 2009). 
Whether GSK1016790A is able to disrupt the plasma membrane directly remains to be 
determined. Calcium overload is a well established mediator leading to necrotic cell death 
(Vanlangenakker et al., 2008), yet the data from the study do not support this as the likely 
mechanism. Additionally, anoikis -  cell death mediated by inappropriate cell-matrix 
interaction -  can also be discounted as this response is mediated by apoptotic pathways which 
maintain the integrity of the plasma membrane (Frisch & Screaton, 2001). Moreover, anoikis- 
mediated cell death in HUVECs takes many hours (12 hours, -25% apoptosis) to manifest 
(Aoudjit & Yuori, 2001), in contrast to the acute necrotic effect of GSK10I6790A (< 3 
hours). As such, further investigation is required to tease out the mechanism of 
GSKl016790A-mediated membrane disruption, and in turn cellular necrosis, in HUYECs.
Although the results presented here clearly demonstrate that GSKI016790A is able to induce 
HUYEC detachment in vitro, the findings have certain limitations. First, TRPY4 activation 
with GSK1016790A and GSK634775 induces divergent detachment responses. The 
differential effects of these molecules could not be explained by calcium influx alone, 
therefore further investigation is required to determine the reasons for this discrepancy. 
Secondly, the physiological relevance of the detachment phenotype is uncertain. Whether 
endothelial detachment occurs following GSK1016790A administration in vivo remains to be
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determined. Thirdly, the detachment studies were performed in the absence of extracellular 
matrix i.e. on plastic tissue culture plates. Dudman et al. (1991) noted a significant reduction 
in homocysteine-induced detachment in the presence of fibronectin, compared to plastic 
alone. Therefore, investigation of the detachment response in the presence of extracellular 
matrix may be warranted.
In summary, these results demonstrate that two selective, structurally distinct TRPV4 
activators, GSK1016790A and GSK634775, elicit divergent endothelial detachment 
responses in vitro. This raises the possibility that the TRPV4 channel may couple to a variety 
of downstream signaling pathways which can be modulated by different ligands. In addition, 
the mechanism of GSK1016790A-mediated detachment was further elaborated and found to 
be independent of intracellular calcium or cytoskeletal modulation, but mediated in-part by 
activation of PKC and disruption of the plasma membrane.
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Chapter 4
General Discussion
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4.1. Role of TRPV4 in prostanoid release
This thesis provides clear evidence that activation of TRPV4 can mediate a robust release of 
vasoactive prostanoids PGI2 and PGE2, from endothelial cells -  a link that hitherto has not be 
described. This response was evident in vitro in cultured endothelial cells, and subsequently 
was found to translate in vivo in rats. Systemic activation of TRPV4 in vivo with 
GSK1016790A mediated a striking prostaglandin release, a marked drop in blood pressure 
and a concomitant increase in lung permeability. Inhibition of prostaglandin formation with 
indomethacin significantly blunted the TRPV4-mediated blood pressure drop whilst 
demonstrating a trend towards an increase in lung permeability (over TRPV4 activation 
alone). These findings suggest that TRPV4-induced prostaglandin release may: 1) mediate, 
in-part, the depressor response, and/or 2) may counteract the TRPV4-mediated lung 
permeability effect. These results parallel those found following intravenous infusion of 
thrombin in vivo, inasmuch as indomethacin pre-treatment partially attenuated thrombin- 
mediated MAP reduction but significantly augmented the thrombin-mediated lung 
permeability response (Ahn et al., 1995). Whether thrombin -  via activation of its cognate 
receptors (protease-activated receptors (PAR)-1, -3 or -4) -  is able to elicit TRPV4 activation 
is unknown; however, accumulating evidence suggests TRPV4 is a downstream effector of 
PAR-2 signaling in neurons (Grant et al., 2007; Sipe et al., 2008; Poole et al., 2013). In 
addition to thrombin, endotoxin administration also elicits pronounced PGI2 release in vivo 
with an associated reduction in MAP and concomitant increase in lung permeability (Chang 
et al., 1989; Dubniks & Grande, 2008; Hales et al., 1981; Ikeda et al., 1983). Consistent with 
the thrombin findings, attenuation of PGI2 synthesis with indomethacin augments the 
pulmonary permeability response to endotoxin whereas infusion of exogenous PGI2 
counteracts the response (Dubniks & Grande, 2008; Ikeda et al., 1983; Smith et al., 1982), 
therefore suggesting a protective effect of PGI2 against enhanced lung permeability. The
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importance of prostaglandins in affording protection against enhanced lung permeability has 
also been demonstrated in mechanical (high ventilator pressures, ischemia reperfusion) lung 
injury models (Birukova et al., 2007; Birukova et al., 2010; Schutte et al., 2001). In 
aggregate, the findings in this thesis are consistent with a number of prior reports that have 
demonstrated PGI2 release following lung injury in response to disparate insults. Whether 
PGI2 release is a general marker of lung injury is unknown, although evidence suggests PGI2 
may offer vascular protective effects (Birukova et al., 2007; Birukova et al., 2010; Schutte et 
al., 2001). It is tempting to speculate that TRPV4 activation is the putative mechanism 
underlying the increased PGI2 synthesis observed following administration of thrombin and 
endotoxin in vivo (as well as GSK1016790A), although a role for other TRP channels, 
including TRPC4, cannot be discounted (Tiruppathi et al., 2002).
An alternative explanation for the enhanced lung permeability response to endotoxin, 
thrombin and GSK1016790A following prostaglandin synthesis inhibition is that 
indomethacin may shunt arachidonic acid metabolism from the cycloxygenase pathway into 
the lipoxygenase pathway resulting in the generation of leukotrienes (Docherty & Wilson, 
1987). Leukotrienes are known to mediate enhanced lung permeability (Martin et al., 1989; 
Sprague et al., 1989). The source of leukotrienes is generally considered to be cells of 
hematopoietic origin (Leff, 2001), although endothelial cells are capable of leukotriene 
synthesis (Rybina et al., 1997). Consistent with this, preliminary investigations revealed 
significant leukotriene B4 release from human and murine bronchoalveolar lavage-derived 
macrophages following GSK1016790A treatment in vitro (data not shown). Further 
investigation is however required to explore any potential role for alternative eicosanoid 
species e.g. leukotrienes in the pulmonary edema response observed in the model used in this 
study.
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Although a complete appraisal of all the potential cellular sources of prostaglandins was not 
feasible, the findings herein strongly suggest the vascular endothelium is likely a major 
source of TRPV4-mediated prostanoids. A number of studies have indicated that the lung is a 
major producer of PGI2 in vivo (Gryglewski, Korbut, & Ocetkiewicz, 1978; Gryglewski et al., 
1978; Korbut et al., 1981) -  PGI2 is the most abundant (Figure 2.11) and potent hypotensive 
prostanoid in vivo (Pace-Asciak et al., 1978) -  therefore, it is tempting to hypothesize that 
TRPV4-mediated PGI2 release is the result of activation of this channel in the pulmonary 
vasculature. Indeed, this would be consistent with the lack of prostanoid involvement in 
TRPV4-mediated vasodilation in isolated vessels from non-pulmonary vascular beds e.g. 
carotid artery, mesenteric artery, etc (Kohler et al., 2006; Loot et al., 2008; Zhang et al., 
2009; Mendoza et al., 2010). Furthermore, prostanoid release fî*om the pulmonary vasculature 
may add credence to the notion that TRPV4-mediated prostaglandin release is a mechanism 
that counteracts the lung permeability effect, also elicited by TRPV4-activation. It is 
noteworthy that in a murine model of ventilator-induced lung injury, produced by high peak 
inflation pressures, the downstream activation of all three major PLA2 effectors i.e. COX (for 
prostanoids), 5-lipoxygenase (for leukotrienes) and cytochrome P-450 epoxygenase (for 
EETs) was required for enhanced permeability (Miyahara et al., 2008). Permeability 
increases were not significantly affected by inhibition of one or two of the PLA2 downstream 
effectors (Miyahara et al., 2008), but were completely abated by TRPV4 inhibition in the 
same model (Hamanaka et al., 2007). These findings therefore highlight the importance of 
PLA2 pathways in mediating permeability responses in lung injury models and moreover the 
potential for arachidonic acid metabolites (e.g. prostanoids, EETs, leukotrienes) to have 
mutually potentiating effects. Whether multiple or single (e.g. COX) PLA2 downstream 
pathways are engaged following TRPV4 activation from the vascular side (i.e. following i.v. 
administration of GSK1016790A, or high pulmonary vascular pressure) compared to the
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airway side (ventilator injury) is undetermined. A potential method to explore such 
hypotheses would be via the use of an isolated lung preparation, as described by Korbut et al. 
(1981). Using this preparation the effect of pharmacological TRPV4 activation can be 
explored without the potential confounding effects of other non-pulmonary vascular 
segments. Prostaglandin release could be assayed from the lung effluent collected via the 
pulmonary vein. In addition, alternative TRPV4 activating stimuli, e.g. increased pulmonary 
vascular pressure could also be examined.
In addition to the cellular source of prostaglandins following TRPV4 activation, other 
important questions requiring further investigation are: 1) does the prostaglandin release 
mechanism exist when non-pharmacological modes of TRPV4 activation are employed? And 
2) what is the physiological or pathophysiological relevance of the mechanism? With respect 
to the former, the ex-vivo isolated lung preparation, described above, could be used. 
Alternatively, isolated endothelial cells could be treated with physiologically relevant stimuli 
including shear stress and/or mechanical stretch and prostaglandin release evaluated. With 
respect to the latter question, PGU levels have been shown to increase in various 
experimental models of hypertension including SHR, deoxycorticosterone acetate-salt 
(DOCA-salt) and renovascular (2-kidney, 1-clip (2K1C) and 1-kidney, I-clip(lKlC)) 
hypertension (Botha et al., 1979; Ishimitsu et al., 1991; Pace-Asciak et al., 1978; Uehara et 
al., 1988). The enhanced PGU production in these models has been suggested to be an 
adaptive response that counteracts the blood pressure elevation and limits baro-mediated 
vascular damage (Ishimitsu et al., 1991; Pace-Asciak et al., 1978a; Pace-Asciak & Carrara, 
1978b). However, the mechanism responsible for the augmented PGU release is not fully 
understood. Botha reported that enhanced PGU production (in the hypertensive state) is a 
mechanical phenomenon most likely mediated by enhanced wall stress and/or shear stress in
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hypertensive blood vessels (Botha & Leary, 1981). Given that mechanical stimulation is an 
established mode for vascular TRPV4 channel activation (Kohler et al., 2006; Mendoza et al., 
2009; Ma et al., 2010; Bagher et al., 2012; Bubolz et al., 2012; Hartmannsgruber et al., 2007), 
coupled with the trend towards a reduction in circulating PGL levels following chronic 
TRPV4 inhibition in SHR rats in this study, it is possible that TRPV4 activation contributes 
to the elevated PGL pool observed in experimental hypertension models. It is noteworthy that 
TRPV4 expression and function is impaired in Dahl salt-sensitive rats -  a genetic model of 
hypertension -  fed a high-salt diet (4% Na"^  by weight; Gao & Wang, 2010). Interestingly, 
PGI2 production in this model is unchanged (relative to control Dahl salt-resistant rats fed a 
high salt diet) following the establishment of overt hypertension (Ishimitsu et al., 1991; 
Uehara et al., 1987), which begs the question: is TRPV4 dysfunction in the Dahl salt- 
sensitive rat the reason why PGI2 levels are not elevated, in contrast to other experimental 
models of hypertension? TRPV4 expression and function in other (i.e. non Dahl salt- 
sensitive) experimental models of hypertension has not been investigated.
The relevance of TRPV4-mediated prostanoid release under physiological conditions is even 
less clear. Hypotonic stimulation of isolated endothelial cells did not elicit PGI2 release 
(Figure 2.9); although it did significantly augment the effect of GSK1016790A. A similar 
finding was described in kératinocytes where hypotonicity also failed to elicit TRPV4 
activation yet enhanced temperature-induced TRPV4 currents (Chung et al., 2004). Although 
TRPV4 acts as a sensor of both osmolality and flow (shear stress) in HEK293 cells and M-1 
renal collecting duct cells (Wu et al., 2007), the physiological relevance of hypotonicity with 
respect to the endothelium could be considered questionable. As such, shear stress or 
mechanical stretch may be more relevant endothelial stimuli, which may couple to the 
prostanoid generation pathway in a TRPV4-dependent manner? It is also noteworthy that
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infusion (for 1 hour) of a pharmacological TRPV4 blocker in normotensive SD rats (prior to 
challenge with GSK1016790A) did not alter PGI2 levels (data not shown), suggesting that 
under basal conditions TRPV4-mediated prostaglandin release is not engaged. A number of 
reports have demonstrated increased PGI2 synthesis and release following moderate to 
strenuous exercise in both humans (Mehta et al., 1983; Nadler & Yamamoto, 1986; Ritter et 
al., 1983; Wennmalm & Fitzgerald, 1988; Yajima et al., 1985) and rats (Chen et al., 1993). 
Mechanistically it is believed that hyperaemia is responsible for the augmented PGI2 releases 
evoked by exercise (Ritter et al., 1983; Wennmalm & Fitzgerald, 1988). This potential 
mechanical-based explanation again hints at the possible involvement of TRPV4 in the 
phenomenon, although further investigation will be required to evaluate this hypothesis.
4.2. The role of TRPV4 in endothelial disruption
The second part of this thesis explores the mechanism of TRPV4-mediated endothelial 
disruption in isolated endothelial cells in an effort to explain the lung permeability response 
described above. The results demonstrate a clear divergence in the endothelial detachment 
response with distinct pharmacological TRPV4 activators -  i.e. GSK1016790A and 
GSK634775 -  that could not be delineated based on ligand potency or calcium influx. 
GSKl 016790A-mediated detachment was independent of changes in the level of intracellular 
calcium and modulation of the cytoskeleton, but was in part dependent upon activation of 
PKC and disruption of the plasma membrane, suggesting a cytotoxic effect of the molecule. 
The lack of calcium involvement in HUVEC detachment in vitro is at odds with a number of 
reports, using isolated lung preparations, that have clearly demonstrated that calcium entry 
into endothelial cells is required for TRPV4-mediated lung permeability responses (Alvarez 
et al., 2006; Hamanaka et al., 2007; Jian et al., 2008; Wu et al., 2009). Moreover, the lack of 
involvement of the actomyosin cytoskeleton contrasts with the findings of Yin et al. (2008),
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who demonstrated that hydrostatic stress mediates TRPV4-dependent lung permeability 
increases via a mechanism requiring activation of MLCK. The reasons for the differences in 
outcomes between the studies outlined here and previous studies are curious; however, some 
potential reasons may include: 1) differences between isolated endothelial cells (used here) 
and endothelial cells from in an intact vascular system (in isolated lung preparations); 2) the 
use of a macrovascular endothelial cell (i.e. HUVECs) as opposed to a pulmonary 
microvascular endothelial cell; and 3) the potential importance of conducting studies in the 
presence of extracellular matrix e.g. fibronectin -  although these wouldn’t necessarily explain 
the divergent responses to the TRPV4 activators.
The contrasting endothelial detachment profiles of the two TRPV4 ligands examined in vitro 
is intriguing and will require further investigation to unravel. Potential differences between 
the TRPV4 ligands profiled here that might account for the contrary detachment responses, 
and could form the basis of future investigations, may involve biased agonism through p- 
arrestin recruitment (Shukla et al., 2010) and/or different intrinsic activities at TRPV4 
homotetramers vs. heterotetramers e.g. TRPV4-TRPC1 (Ma et al., 2010; Ma et al., 2011) as 
described previously (see section 3.4). Alternatively, the different chemical structures of the 
two ligands may account for the different endothelial detachment responses. The key 
structural difference between the two molecules is the inclusion of a piperazine ring in 
GSK1016790A, which is absent in GSK634775 (Table 1.1). Indeed, piperazine containing 
compounds have been shown to elicit cell death in a number of cancer cell lines (Liu et al., 
2012; Sampson et al., 2011; Zeng et al., 2009), although the mode of cell death is via 
apoptotic means, as opposed to the likely necrotic mechanism demonstrated here (Figure 
3.7). Evidence for the effect of piperazine containing compounds on endothelial viability is 
however lacking. It is noteworthy that RN-1747 (an alternative TRPV4 agonist, see Table
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1.1) also contains a piperazine moiety; as such, it would be interesting to see if this agent also 
elicits endothelial detachment.
Despite the differential effects of pharmacological TRPV4 activators on endothelial 
detachment in vitro the association between TRPV4 and endothelial permeability, 
particularly in the lung, is indisputable (Alvarez et al., 2006; Hamanaka et al., 2007; Jian et 
al., 2008; Thomeloe et al., 2012; Willette et al., 2008; Wu et al., 2009; Yin et al., 2008). As 
such, it might be necessary to validate the in vitro detachment bioassay by examining 
endothelial detachment in vivo. One method to examine this phenomenon would be to 
enumerate the number of circulating endothelial cells in peripheral blood, by flow cytometry, 
following GSK1016790A administration. An increase in the number of circulating 
endothelial cells would indicate that endothelial desquamation (indicative of detachment) 
occurs in vivo following TRPV4 activation, therefore confirming the validity of the in vitro 
assay. Moreover, such analysis could also be used to explore the hypothesis that TRPV4- 
mediated prostanoid release is vasculoprotective by examining circulating endothelial cell 
number in the presence or absence of prostaglandin synthesis inhibition. Alternatively, these 
studies could indicate that the detachment phenotype is an interesting cell culture anomaly 
which lacks relevance to the in vivo scenario. It is noteworthy that Alvarez et al. (2006) 
demonstrated that TRPV4 activation in the isolated lung preparation -  with 4a-PDD and 
14,15-EET -  resulted in blebbing and breaks in the alveolar endothelium, however, it was the 
type I alveolar epithelial cells that appeared to ‘peel o ff from the basal lamina. Although this 
finding ostensibly suggests that TRPV4 activation in isolated lung does not mediate 
endothelial detachment it may actually support the findings in this thesis inasmuch as the 
endothelial breaks -  described by Alvarez -  may be comparable to the membrane disruption
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(as measured by AK release) observed in this study following GSK1016790A administration 
in vitro.
4.3. Final conclusions
In conclusion, the studies described in this thesis demonstrate that pharmacological TRPV4 
activation elicits prostaglandin release from endothelial cells. The release of these vasoactive 
autacoids may serve a role in modulating blood pressure and endothelial permeability, which 
may be of relevance in hypertensive states. In addition, these studies also bring to light an 
intriguing differential coupling of the TRPV4 channel in isolated endothelial cells in response 
to structurally distinct activating ligands.
4.4. Study limitations
This results described in this thesis are not without limitations. Here, the three study 
limitations, considered most important, will be discussed in more detail, these include: 1) the 
choice of an endothelial detachment assay as a model of vascular integrity; 2) the selection of 
a macrovascular endothelial line i.e. HUVECs to model microvascular behavior; and 3) the 
design of the chronic TRPV4 inhibitor study (with GSK2193874) in the SH rat.
The primary limitation of this thesis was the selection of the HUVEC detachment assay as a 
measure of endothelial integrity, and a surrogate for TRPV4-mediated vascular disruption in 
vivo, in the lung. The findings herein highlight divergent detachment responses with 
structurally distinct TRPV4 ligands, GSK634775 and GSK1016790A. Where the detachment 
response induced by GSK1016790A is independent of changes in intracellular calcium levels 
and actomyosin reorganization, but is mediated, in-part, by membrane disruption. The latter
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finding strongly suggests that GSK1016790A is cytotoxic. As such, the contrary detachment 
responses may be attributed to this cytotoxic effect. Supporting this, changes in vascular 
permeability following TRPV4 activation with GSK1016790A in vivo occur rapidly, whereas 
the detachment response in vitro requires prolonged exposure (>1 hour) to GSK1016790A. 
Consequently, it might be reasonable to speculate that the detachment response is attributable 
to an extended incubation period with a highly efficacious agonist (i.e. GSK1016790A), 
which causes endothelial cell death. Arguably, a better method to explore TRPV4-mediated 
endothelial disruption in vitro would be to study changes in cellular monolayer impedance -  a 
method frequently cited in the endothelial permeability literature (Birukova et al., 2007; 
Garcia et al., 1995; Kawkitinarong et al., 2004; Schaphorst et al., 1997). This technique 
allows real-time assessment of endothelial morphology in live cells and was recently utilized 
by Thomeloe et al. (2012) who demonstrated a rapid reduction in cellular impedance (>75% 
within 20 minutes) in HUVECs, following GSK1016790A exposure, in a time-fi*ame more 
consistent with the permeability response observed in vivo in response to the same ligand -  
GSK634775 was not profiled in the same study. As noted previously, one might expect subtle 
changes in endothelial morphology to be able to elicit striking increases in vascular 
permeability in the absence of overt endothelial detachment. An impendence assay, therefore, 
maybe a more sensitive and pathophysiologically aligned method to assess the effect of 
TRPV4 ligands on endothelial integrity -  it remains possible that GSK634775 could elicit 
subtle changes in endothelial morphology without mediating detachment. It should be noted 
that a macromolecular permeability assay -  which measures the movement of fluorescently 
labeled albumin through a HUVEC monolayer -  was explored as an alternative to the 
detachment assay; however, a reliable signal could not be obtained in response to 
GSK1016790A, and other known vascular disrupters (e.g. cytochalasin D, latrunculin, Triton
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X-100 and camptothecin) despite clear morphological changes being observed by light 
microscopy (data not shown).
A second limitation of this thesis was the choice of HUVECs, a macrovascular endothelial 
cell line, as an all-encompassing model for endothelial behavior. Of particular importance is 
the use of HUVECs to model, in vitro, the endothelial disruption observed in the lung 
alveolus following TRPV4 activation in vivo, when alveolar endothelial cells and HUVECs 
are microvascular and macrovascular in origin, respectively. Endothelial heterogeneity, at a 
phenotypic and functional level, is well documented in vessels from anatomically distinct 
locations (for reviews see Aird, 2007a, 2007b). Yet, macrovascular (HUVECs) and 
microvascular (placental endothelial cells) endothelial cells derived from the same organ (i.e. 
the placenta) also exhibit phenotypic and physiological heterogeneity (Lang et al., 2003). 
From a permeability perspective, pulmonary-derived microvascular and macrovascular 
endothelial cells exhibit clear differences in their response to agents that increase vascular 
permeability, inasmuch as microvascular cells are more resistant to the effects of these agents 
(Kelly et al., 1998; Ofori-Acquah et al., 2008). Consequently, it might be more 
physiologically relevant to utilize microvascular endothelial cells of pulmonary origin to 
interrogate the role of TRPV4 in vascular permeability responses in the lung alveolus. 
Despite these shortcoming, HUVECs are been used routinely to explore the endothelial 
biology of TRPV4 (Loot et al., 2008; Willette et al., 2008; Rath et al., 2012; Thorneloe et al., 
2012); one of the major reasons for their use in this thesis.
Finally, the study to profile the effect of chronic TRPV4 inhibition (with GSK2193874) on 
plasma 6-keto FGFia levels, with hindsight might have been non-optimal. The conclusion
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from this study was there was a trend towards a reduction in plasma 6-keto PGFia levels 
following chronic TRPV4 inhibition, however, the effect was not statistically significant 
(p=0.098). As such, the null hypothesis stating “chronic TRPV4 inhibition has no effect on 
plasma 6-keto PGFia levels” was accepted. It is noteworthy that the actual primary aim of 
this study was to examine whether pharmacological TRPV4 inhibition could increase blood 
pressure in hypertensive rats (see Thomeloe et al., 2012), as noted by others (Gao et al., 
2009; Gao & Wang, 2010). As such, a prospective statistical power analysis to determine 
whether the sample size employed (n=6 per group) was sufficient to identify a difference 
between vehicle and GSK2193874 treated animals in light of the potential variability of the 
measurement, and the expected magnitude of drug effect, was not performed. Consequently, 
it is conceivably that the study was underpowered, and the null hypothesis was incorrectly 
accepted. In other words, a type II error has occurred. Although retrospectively assessment of 
study power is feasible, it is strongly discouraged, as power analysis is considered a uniquely 
prospective concept (Christley, 2010; Trout et al., 2007). As such, the importance of the 27% 
reduction in plasma 6-keto PGFia levels, following GSK2193874 treatment, may have been 
missed. A potential fix would be to increase the number of study animals, as larger studies 
are inherently more powerful (Trout et a l, 2007).
4.5. Future Work
This thesis has identified some novel features of TRPV4 biology; however, a number of 
questions remain unresolved and would benefit from additional investigation. Some of these 
questions, and avenues to explore them, have been touched upon in preceding sections. Here 
they will be outlined in more detail.
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1. The hypothesis that the lung vasculature is the source of prostanoids generated in 
response to pharmacological TRPV4 activation with GSK1016790A in vivo needs to be 
tested. An isolated rat lung preparation could be used for this purpose. The effluent 
generated from perfusing the isolated lung with GSK1016790A could be collected (from 
the pulmonary vein) and assayed for prostaglandins. In addition, an isolated lung model 
could also be used to explore two other intriguing questions, these include: a) establishing 
whether COX inhibition (with indomethacin) augments GSK1016790A-mediated 
permeability increases in the isolated lung, as the in vivo results described herein suggest; 
and 2) establishing whether a physiological/pathophysiological relevant stimulus, such as 
high vascular pressure (i.e. increased perfusion pressure), can engage the PGI2 release 
mechanism in a TRPV4-dependent manner.
2. TRPV4 channel blockers are being considered for therapeutic application in patients with 
congestive heart failure (Thomeloe et al., 2012). Given that chronic TRPV4 inhibition, in 
this study, resulted in a trend towards a reduction in circulating PGI2 levels, it might be 
important to determine whether this translates to an increased thrombogenic risk. A 
method to explore this experimentally would be to use the thrombosis assay developed by 
Ryszard Gryglewski (Gryglewski, Chlopicki, & Swies, 2005; Gryglewski et al., 1978; 
Gryglewski, 2005). In this assay, blood from the carotid artery of an anaesthetized animal 
is superfused, extracorporeally, over a thrombogenic surface (a strip of collagen) and 
retumed to the venous circulation via the jugular vein. A thrombus, with a defined mass 
(-100 mg), develops within 30 minutes and remains stable for up to 4 hours. 
Thrombolytic or thrombogenic responses can be elicited by i.v. administration of 
vasoactive agents e.g. bradykinin. Thrombolytic activity directly correlates with PGI2 
levels. As such, the thrombogenic potential of chronic TRPV4 inhibition, with
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GSK2193874, could be assessed and compared to vehicle treated animals. Any changes 
could be correlated with plasma 6-keto-PGFia levels.
3. The hypothesis that TRPV4 channels may couple to a variety of downstream signaling 
pathways in endothelial cells, which can be manipulated by different ligands (i.e. 
GSK634775 and GSK1016790A), should also be addressed. This would include profiling 
the ability of these ligands (as well as other TRPV4 agonists) to recruit p-arrestin, in 
addition to probing their activity at TRPV4 homo and heterotetramers e.g. TRPV4- 
TRPCl using patch clamping techniques. Recombinant expression systems would be a 
better starting point before endogenous expression systems are attempted.
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GSK blood donor informed consent form
INFORMATION AND CONSENT FORM
Protocol Title: Healthy volunteer blood donation for in vitro experimentation
Protocol #: 
Sponsor: 
Study Doctor:
Telephone Number: 
After Office Hours:
24109QMR
GlaxoSmithKline
GlaxoSmithKline 
1250 S. Collegeville Road 
Collegeville, PA 19426
You are being asked if you want to take part in a research study. Before you decide it is important 
for you to read the information in this form about why the  research is being done and what it will 
involve. Please take time to  read the following information carefully and discuss it with friends, 
relatives, your personal physician, or anyone you choose if you wish. Ask the  study doctor or study 
staff if there  is anything that is not clear or if you would like more information. Do not sign this form 
unless the study doctor or study staff has answered your questions and you decide th a t  you want to 
be part of this study. Take time to  decide w hether or not you wish to take part.
What is the purpose of the study?
Fresh human blood is required by groups within GSK Research & Development. These groups use 
the  blood to  help with research into a variety of diseases.
Researchers use a variety of in vitro (laboratory research) methods necessary for advancing GSK 
research activities in the identification, evaluation, and validation of targets, biomarkers, techniques, 
and drug candidates to  provide evidence tha t  new medicines may be effective in treating disease. 
Ask the  study doctor or study staff to  explain how the  identification, evaluation, and validation of 
targets, biomarkers, techniques, and drug candidates can help researchers test new medicines.
Information from your blood sample(s) may help scientists do this research now and in the future.
Research with your sample(s) could include the discovery, testing, or production of medicines and 
methods for the  diagnosis of a variety of diseases. This research is investigative and exploratory. 
Since no diagnostic testing is planned as part of this research, participating will not serve as a 
substitute for standard medical care by your personal physician. The results of any research might 
be valuable for commercial and/or intellectual property purposes (patenting for example). If you
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decide to  be in this study, you are giving your sample(s) to GlaxoSmithKline (GSK). GSK will be the 
owner of the  study results. GSK plans to  use the results, and may get patents, or sell a drug in the 
future, or make profits other ways. You will not be paid any part of this.
You will not receive any financial benefit tha t might come from the research results.
What am I being asked to consent to?
You are being asked to give consent for your blood to be used by scientists for research purposes. If 
you decide participate in the  study and sign this form, you will be asked at intervals as part of a 
Blood Panel to  give blood samples. This will not exceed more than 450ml (about 2 cups) every 56 
days, nor exceed two sampling visits per week, nor be greater than 300 ml (about 1% cup) per 
sampling visit. There is no scheduled end to  your participation in the study. You may continue to  be 
in the  study until you no longer w ant to  be in the  study or your participation in the  study is stopped 
for any reason (for example, your health prevents you from continuing in the study or GSK stops the 
study).
Why have i been chosen?
You are being asked if you want to  be in this research because you are a salaried GSK employee or a 
contingent /  temporary worker on a site where the  Employee Health and Performance (EHP) is 
situated (RTP, UM, UP). This is because the blood needs to  be very fresh to  be used by researchers 
and cannot easily be obtained from outside these GSK units.
This study will enroll participants who are 18 years old or older.
Do i have to take part?
•  Participation in this research is strictly voluntary. There will be no penalty to  you, and you
won't  lose any benefits, if at any time you decide to  not be in the  study.
• This is not a t rea tm en t study. Your alternative is to  not participate.
•  It is up to you to decide whether or not to  take part.
•  If you do decide to  take part you will be given a copy of this signed and dated informed
consent.
•  If you decide to  take part you are still free to  withdraw at any time without giving a reason.
If you decide to  withdraw, your remaining blood sample(s) will be destroyed. Any 
information and study data collected before your withdrawal from the study will be used by 
GSK.
• If you join the study as part of the blood panel and are asked to  give any particular sample, 
you can say no. You can refuse to  give any sample at any time and still be in the  study.
• Employees do not have to be in this study. No one is allowed to influence or pressure you 
to be in this study. Being in this study is not part of your job. Your involvement in this 
study is as a research participant, not as an employee. A decision to withdraw at any time, 
or a decision not to take part, or a decision to participate will not affect your employment, 
including your employment status, rights, or benefits. Deciding not to participate will not 
be considered negatively with regard to your employment at GSK, and deciding to 
participate will not be considered positively with regard to your employment at GSK.
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You may be withdrawn from the  research at any time by the investigator, or GSK (even if you 
want to  stay in the  study), and the  reason for tha t decision will be given to  you. This could 
happen if:
o The study doctor believes it is best for you to  stop being in the  study, 
o You do not follow directions about the  study, 
o GSK stops the study for any reason.
If you stop being in the  study early, the  study doctor or study staff may ask you some 
questions about being in the  study.
What will happen to me if I take part?
None of the  study procedures are part of your regular medical care. You are being asked to  give 
consent for your blood to be used by scientists for research purposes.
Before you can start the  study, the study doctor or study staff will talk to  you about the  study. Then 
you have to  sign this form before the study doctor or study staff can begin the screening procedures 
below to see if you qualify to  be in the study.
You will be asked to  give blood sample(s) as part of a Blood Panel if you pass a screening medical 
assessment by a study staff member to  help make sure you are healthy enough to  give blood. This 
medical assessment includes taking your height and weight, taking your blood pressure, assessing 
your blood for red and white cell levels, checking that your veins can be accessed for blood draw, 
and the  completion of a medical history questionnaire about w hether or not you have ever given 
blood, not been allowed to give blood, or fainted or passed out from giving blood.
If you do not m eet criteria for participation in the  study, the  study staff will speak to  you about the  
reasons. You may be counseled to  visit your personal physician depending on the  specific reasons, 
for example, if your red blood cell count is low.
If you want to  be in the  study but the study doctor thinks you may not be healthy enough to 
participate, you may be retested in about 2 months to  see if you can be in the study.
If you are added to  the  Blood Panel list, you will give blood at different times during the  study for the  
research described in this form. In addition, certain blood tests (for Hemoglobin and hematocrit 
(hgb/hct)) will be done after every 450 ml (about VA cups) of blood drawn; or if less than 450 ml is 
drawn from an individual cumulatively over the year, levels will be checked annually.
The study doctor or study staff will do the following before each time you give blood:
• ask you questions about your health
• measure your tem perature, blood pressure, and pulse
During the  study, you may be asked to  donate several times over the  course of days or weeks to 
provide consistency for a specific evaluation. Ask the study doctor or study staff about possible 
blood sampling schedules in this study.
Please note tha t genetic analysis (DNA genotyping studies) will NOT be performed using these blood 
samples. Unused samples may be discarded once a specific piece of work has been completed or in 
some instances, processed samples may be stored for future use for the  research described in this 
form. As described later in this form, your blood sample(s) will be not labeled with information tha t  
immediately identifies you. While you are in the study, you must:
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• Follow the instructions you are given.
•  Come to the  study center for all visits with the  study doctor.
•  Tell the  study doctor or study staff about any changes in your health or the way you feel.
• Tell the  study doctor or study staff if you want to  stop being in the study at any time.
Will it cost anything to be in this study?
While you are in the study, you still need to get regular medical care. You (and/or your health care 
payer) will still have to  pay for the  costs of your regular medical care tha t are not a part of this study.
You do not have to  pay for study procedures.
What are the possible benefits of taking part?
Being in this study will not help you. Information from this study might help researchers come up 
with new tests or medications to  help others in the  future.
Will i be paid for being in this study?
You will be reimbursed for your inconvenience and time. The compensation scheme is:
Volume of blood given at a visit Visit pavment 
up to  100 ml $50
1 0 1 -3 0 0  ml $80
The study doctor or study staff can tell you when you will get paid.
What are the possible disadvantages and risks of taking part?
The study staff will take your blood by sticking a needle into a vein in your arm. There is minimal risk 
or discomfort expected from giving blood. Occasional minor bruising, pain, or irritation around the 
site of the puncture may follow a blood sample. In very rare cases, there  may be local infection. You 
may also feel dizzy or faint after giving blood. Please note tha t all the  materials used for collecting 
blood are sterile and used only once.
If the  study doctor learns any new information about the study tha t  might change your mind about 
continuing in the  study, the  study doctor or study staff will tell you about it.
If you think you are pregnant, you cannot be in this study. If you become pregnant, you will be taken 
out of the  study. Tell the study doctor if you think you are pregnant.
If you are pregnant while you are in the study, there  may be risks to  your unborn baby.
The study doctor may ask for information about the  pregnancy and the birth of the  baby. The study 
doctor may share this information with the sponsor and Quorum Review.
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What if I get hurt or sick during the study?
If you have suffered an injury as a result of giving a blood sample for this study, GSK staff would 
provide emergency first aid. If needed, you would be referred to your regular doctor or health care 
practitioner for follow-up care.
GSK is not offering any compensation specifically for study-related injuries, but you are not giving up 
any of your legal rights as a research participant by signing this form.
Wili i receive any information about my health from being in this study?
Your blood will used in investigational and exploratory laboratory research. No diagnostic 
assessments are planned in this research. In the  rare event tha t  exploratory research uncovers 
information which may have clinical significance for you then you will be notified of the  finding. In 
order to  help maintain confidentiality, the  information from the  Principal Investigator will be 
provided to  you through EHP staff. Depending on the  nature of the  finding this may result in EHP 
advising you to  consult with your personal physician about follow-up examinations.
Wili my taking part in this study be kept confidential?
• All personally identifiable information collected about you during the  course of this research 
will be kept strictly confidential.
•  To protect your privacy your sample will be labeled (or "coded") only with a subject number, 
not your name or any other information that would directly identify you. Some basic 
information (e.g. your gender and age) may be supplied with your sample in a similarly 
coded fashion to the  scientists. Only the  EHP staff will have access to  the link between your 
subject number and your name. In this way, your identity will not be divulged to  the  GSK 
scientists who receive your blood sample.
GSK may use your non-personally identified information (age, gender, height etc.)
•  By storing and analyzing it electronically to  find out what this research is telling scientists.
•  By sharing it with regulatory authorities, such as the  U.S. Food and Drug Administration 
(FDA) tha t  approve new medicines or with groups tha t  check tha t  research is done properly
• By publishing the  results of the  research (this will not include any information tha t  directly 
identifies you)
• By sharing it as part of research with other companies or universities for the  purpose of the 
research described in this form and with other GSK offices in this country and in other 
countries. If the  information is sent to  another country, GSK will apply the  same level of 
protection to  your information, to the extent permitted by local law
• By using it to plan new studies or other types of research or other medical purposes related 
to  the development of new medicines
What will happen to the results of this research?
• The results of this research may be published in internal documents for decision making 
within GSK. It may also be published in a scientific journal, although individual participants 
will not be identified in any publication.
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Who is organizing and funding the research?
GlaxoSmithKline is sponsoring this research. GlaxoSmithKline is also paying the study doctor to  do 
this study.
The study doctor and study staff are employees or executives of the  sponsor. If you have concerns 
about this employment, ask the  study doctor or study staff for more information.
The laboratory based research will be carried out at the  GSK R&D sites at RTP, UM, and UP.
Who has reviewed the study?
This research study has been reviewed and approved by the  Quorum Review (described below). 
Contact for Further Information?
If you have any queries or problems, please do not hesitate to  contact any of the  people or groups 
listed below.
What if I wish to complain about the way in which this research has been conducted?
You can ask questions about the study at any time. You can call the  study doctor at any time if you 
have any concerns or complaints. You should call the  study doctor at the phone number listed on 
page 1 of this form if you have questions about the  study procedures, study costs (if any), study 
payment (if any), or if you get hurt or sick during the study.
If you have any cause to  complain about any aspect of the way you have been approached or 
treated  during the  course of this research, including any concerns about your employment status, 
you may contact GSK Integrity Helpline 1-866-GSK-ETHICS (1-866-475-3844) or you may contact the 
Compliance Officer, Global R&D, via the  R&D Compliance Mailbox RD
Compliance/PharmRD/GSK@GSK. You can also contact your personal physician if you have any 
health concerns. If you contact the  Integrity Helpline or the Compliance Officer, Global R&D to  
report a concern, you and your employment will not be compromised in any way because you have 
taken part in a research study.
Quorum Review reviewed this study. Quorum Review is a group of people who review research 
studies to  protect the  rights and welfare of research participants. If you have questions about your 
rights as a research participant, if you are not able to  resolve your concerns with the  study doctor, or 
if you have general questions about what it means to  be in a research study, you can call Quorum 
Review or visit the  Quorum Review website at www.quorumreview.com.
Quorum Review is located in Seattle, Washington.
Office hours are 8:00 AM to  5:00 PM Pacific Time, Monday through Friday.
Ask to  speak with a Research Participant Liaison at 888-776-9115 (toll free).
In the  event of an emergency, dial 911 immediately.
Thank you for your time in reading this form. Please keep this form for future reference.
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Patient Identification Number for this tr ia l:___________
DO YOU WANT TO BE IN THIS STUDY?
Please initial box
1. I confirm tha t I have read this form for the above research study, and the  procedures listed 
in this form have been explained to  me. I have had the opportunity to  consider the 
information and ask the  study doctor or study staff. My questions have been answered 
satisfactorily.
2. I agree to  my blood sample(s) being used by GlaxoSmithKline for a variety of research 
purposes and becoming the  property of GSK. I understand that I will have no further rights 
in respect to  the  sample, other than the ability to  withdraw my consent.
3. I understand tha t  my participation is voluntary and tha t  I am free to  withdraw at any time, 
without giving any reason, without my medical care or legal or employment rights being 
affected. If I withdraw my consent, the  sample will be destroyed but not any research data 
previously derived from it, which will be used by GSK. I have not been influenced by or 
pressured by my employer to  take part in this study.
4. I agree to  take part in the above study.
By signing this form, I do not give up any of my legal rights as a research participant.
I will get a signed copy of this form for my records.
Printed Name of Participant
Signature of Participant Date
I attest tha t  the  participant named above had enough time to  consider this information, had an 
opportunity to  ask questions, and voluntarily agreed to  be in this study.
Printed Name of Person Explaining Consent
Signature of Person Explaining Consent Date
I a ttest tha t  I or my representative discussed this study with the  participant named above.
Signature of Principal Investigator or Sub-Investigator
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